<SEC-DOCUMENT>0001178913-26-000300.txt : 20260204
<SEC-HEADER>0001178913-26-000300.hdr.sgml : 20260204
<ACCEPTANCE-DATETIME>20260204080037
ACCESSION NUMBER:		0001178913-26-000300
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20260129
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260204
DATE AS OF CHANGE:		20260204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entera Bio Ltd.
		CENTRAL INDEX KEY:			0001638097
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38556
		FILM NUMBER:		26596076

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		PROVINCE COUNTRY:   	L3
		ZIP:			9112002
		BUSINESS PHONE:		972-2-532-7151

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		PROVINCE COUNTRY:   	L3
		ZIP:			9112002
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zk2634279.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:entx="http://enterabio.com/20260129" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_e3793fd0246149fc909fd1fcfc95fa89" contextRef="c20260129to20260129" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_2783e5c0c3ef4b5c98066465eeb39ec2" contextRef="c20260129to20260129">0001638097</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_1fc99da374d94b47827b63bc4df1ea69" contextRef="c20260129to20260129">00-0000000</ix:nonNumeric><ix:nonNumeric name="dei:CityAreaCode" id="Fact_845dc47bf7764f37ae6b3ec21fdb1f1c" contextRef="c20260129to20260129">972</ix:nonNumeric><ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_5b00f5ad8e2a42019f08b2e5b15a63bf" contextRef="c20260129to20260129">2-532-7151</ix:nonNumeric><ix:nonNumeric name="dei:Security12bTitle" id="Fact_33337dadb56448e6803d820203d94d6e" contextRef="c20260129to20260129_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember">Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share</ix:nonNumeric><ix:nonNumeric name="dei:TradingSymbol" id="Fact_a700b67d61a142d989acfd1e03ccdf9c" contextRef="c20260129to20260129_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember">ENTXW</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_19ac239564e543ae8bdeb253ce77e391" contextRef="c20260129to20260129_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember">NASDAQ</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_90e9abc973f6425ea56ebe4d147111d6" contextRef="c20260129to20260129_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="entx-20260129.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20260129to20260129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-29</xbrli:startDate><xbrli:endDate>2026-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260129to20260129_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">entx:OrdinarySharesParValueOfNIS00000769Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-29</xbrli:startDate><xbrli:endDate>2026-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260129to20260129_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">entx:WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-29</xbrli:startDate><xbrli:endDate>2026-01-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br/>
    </div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Washington, D.C. 20549</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_854b9d1282cb4016850c835312cb7428" contextRef="c20260129to20260129">8-K</ix:nonNumeric></div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CURRENT REPORT</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_24f7136a7a434d1c8823a066ae74f5f0" contextRef="c20260129to20260129" format="ixt:date-monthname-day-year-en">January 29, 2026</ix:nonNumeric></div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_dc6cd0bdce1a4d91ac30bf2333ad64ce" contextRef="c20260129to20260129">Entera Bio Ltd.</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Exact Name of Registrant as Specified in Its Charter)</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 32.01%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_5ccef13b5de64531b55131310f990d6d" contextRef="c20260129to20260129" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_8531f7f8deb54d378365f039779ae88e" contextRef="c20260129to20260129">001-38556</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_1fc99da374d94b47827b63bc4df1ea69">Not Applicable</span><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 32.01%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(State or other jurisdiction<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br/>
              </span>of incorporation)</div>
          </td>

    <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Commission File Number)</div>
          </td>

    <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(I.R.S. Employer<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br/>
              </span>Identification)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); text-transform: capitalize;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_53e7134a8dee464d8f80218269c94f83" contextRef="c20260129to20260129">Kiryat Hadassah, Minrav Building</ix:nonNumeric> &#8211; <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_2921a3eff99c4dd5bff84c01cafc4be3" contextRef="c20260129to20260129">Fifth Floor</ix:nonNumeric>,
          <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_c317e05c204f4a59a1e4dc8b1f3613c8" contextRef="c20260129to20260129">Jerusalem</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" id="Fact_5dfe71dfd21e4ab8aee3d679ab8f226a" contextRef="c20260129to20260129" format="ixt-sec:countrynameen">Israel</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_70b738c460a04d3c9513ff7984b36624" contextRef="c20260129to20260129">9112002</ix:nonNumeric></span><br/>
      </span>(Address of principal executive offices) (Zip Code)</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;"><br/>
        <span style="-sec-ix-hidden:Fact_845dc47bf7764f37ae6b3ec21fdb1f1c">+972</span><span style="-sec-ix-hidden:Fact_5b00f5ad8e2a42019f08b2e5b15a63bf">-2-532-7151</span> </span></div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Registrant&#8217;s Telephone Number, Including Area Code)</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;&#160;</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>

    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Former name or former address, if changed since last report)</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
      under any of the following provisions (see General Instruction A.2. below):</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_aedbad8e66824d61914f676dc82e5ccb" contextRef="c20260129to20260129" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 96.15%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div style="line-height: 1.25;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_76572359dc7d4cb7bad6d925fd113c86" contextRef="c20260129to20260129" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 96.15%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_25c510ae2a4d49a890418808323caadb" contextRef="c20260129to20260129" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 96.15%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">
            <div style="text-align: left; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_095cdde2305a4992902e14b13d9e8daf" contextRef="c20260129to20260129" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 96.15%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 32.01%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title of each class</div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trading Symbol(s)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 32.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_ed98f41c93304b78938876a12e4df08c" contextRef="c20260129to20260129_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member">Ordinary Shares, par value of NIS 0.0000769</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_8f25ca98f88f4f82bc488b6b84f08e53" contextRef="c20260129to20260129_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member">ENTX</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>

    <td style="width: 32%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_90e9abc973f6425ea56ebe4d147111d6">Nasdaq Capital Market</span><br/>
            </div>
          </td>

  </tr>


</table>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
      (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_93ab7cbcbd0b4c55bd07e713e802587e" contextRef="c20260129to20260129" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br/>
    </div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
      complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744; </div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>

    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;">
          <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>

        </div>

      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 1.01 Entry into a Material Definitive Agreement</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Amended and Restated Collaboration and License Agreement</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As previously reported, on March 16, 2025, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Entera Bio
          Ltd., a company organized under the laws of the State of Israel (the &#8220;<span style="text-decoration: underline;">Company</span>&#8221;), entered into a collaboration and license agreement (the &#8220;<span style="text-decoration: underline;">Original Collaboration Agreement</span>&#8221;) with OPKO Health, Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline;">OPKO
            Health</span>&#8221;), and OPKO Biologics Ltd., a company organized under the laws of the State of Israel (&#8220;<span style="text-decoration: underline;">OPKO Biologics</span>&#8221; and, together with OPKO Health, &#8220;<span style="text-decoration: underline;">OPKO</span>&#8221;).</span></div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On February 3, 2026, the Company and OPKO entered into an
          amended and restated collaboration and license agreement (the &#8220;<span style="text-decoration: underline;">A&amp;R Collaboration Agreement</span>&#8221;), which amends and restates the Original Collaboration Agreement to expand the scope of the agreement to include the collaboration with respect
          to the preclinical and clinical development of a daily long acting PTH tablet (&#8220;<span style="text-decoration: underline;">LA-PTH</span>&#8221;) for the treatment of hypoparathyroidism and other indications in addition to the original oral dual agonist GLP-1/glucagon peptide </span>program<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Development costs incurred by the parties with respect to the development of the LA-PTH program will be shared equally between the Company and OPKO. Except as described
          herein, the material terms of the Original Collaboration Agreement remain unchanged and in full force and effect.</span></div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The foregoing description of the A&amp;R Collaboration Agreement is only a summary and is qualified in its entirety by reference to
        the full text of the A&amp;R Collaboration Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
        Compensatory Arrangements of Certain Officers</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Director Resignation</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On January 29, 2026, Gerald Ostrov notified the Board of Directors of the Company (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Board</span></span>&#8221;) of his resignation as a Director, effective February 1, 2026. Mr. Ostrov&#8217;s resignation was not the result of any disagreement with the Company on any matter relating to the Company&#8217;s
        operations, policies, or practices.</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Appointment of Steven D. Rubin as Director</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Board appointed Steven D. Rubin as a Class III director of the Company, effective February 1, 2026. Mr. Rubin will serve as a
          director until the Company&#8217;s 2026 Annual Meeting of Shareholders and until his successor shall have been elected and qualified, or until his earlier death, resignation, retirement, disqualification or removal. Mr. Rubin has also been appointed to
          serve as a member of the compensation committee of the Board and as Chairman of the audit committee of the Board, in each case, effective February 1, 2026.</div>

      </div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mr. Rubin, 65, has served as OPKO Health&#8217;s Executive Vice President &#8211; Administration since May 2007 and as a director since February
        2007. He has extensive experience as a practicing lawyer, and as general counsel and board member to multiple public companies. Mr. Rubin currently serves on the board of directors of the following companies: Niagen Bioscience, Inc. (Nasdaq: NAGE),
        a bioscience company developing NAD+ products to support cellular health; Cocrystal Pharma, Inc. (NASDAQ:COCP), a biotechnology company developing new treatments for viral diseases&#894; Eloxx Pharmaceuticals (NASDAQ: ELOX), a biotechnology company
        engaged in ribosomal RNA targeted genetic therapies for rare diseases&#894; and Red Violet, Inc., (NASDAQ: RDVT) a leading analytics and information solutions provider. Mr. Rubin previously served as the Senior Vice President, General Counsel and
        Secretary of IVAX from August 2001 until September 2006. Mr. Rubin previously served as a director of the following companies: Neovasc, Inc. (NASDAQ:NVCN), a company developing and marketing medical specialty vascular devices&#894; Non-Invasive
        Monitoring Systems, Inc. (OTCBB:NIMU), a medical device company&#894; Castle Brands, Inc. (NYSE:ROX), a developer and marketer of premium brand spirits&#894; Kidville, Inc. (OTCBB:KVIL), an operator of large, upscale facilities, catering to newborns through
        five-year-old children and their families and offers a wide range of developmental classes for newborns to five-year-olds&#894; VBI Vaccines Inc. (NASDAQ CM: VBIV), a commercial-stage biopharmaceutical company developing a next generation of vaccines&#894;
        Dreams, Inc. (NYSE MKT: DRJ), a vertically integrated sports licensing and products company&#894; Safestitch Medical, Inc. prior to its merger with TransEnterix, Inc.&#894; and, PROLOR Biotech, Inc.&#894; and Cognit, Inc. (NASDAQ:COGT), a data and analytics
        company providing cloud-based mission-critical information and performance marketing solutions. Mr. Rubin holds a B.A. degree from Tulane University and a Juris Doctor from University of Florida.</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">There are no arrangements or understandings between Mr. Rubin and any other person pursuant to which Mr. Rubin was appointed as a
        director of the Company. The Board has determined that Mr. Rubin is independent under the applicable rules of the Securities and Exchange Commission and the Nasdaq Stock Market. In addition, the Board determined that Mr. Rubin qualifies as an
        &#8220;audit committee financial expert&#8221; (as defined in Item 407 of Regulation S-K).</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Since the beginning of Company&#8217;s last fiscal year, the Company has not engaged in any transaction, or any currently proposed
        transaction, in which Mr. Rubin had or will have a direct or indirect material interest that would require disclosure pursuant to Item 404(a) of Regulation S-K.</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mr. Rubin will participate in the Company&#8217;s standard non-employee director compensation arrangements, which were approved by the
        Company&#8217;s shareholders in July 2025, including the right to annual cash payments with respect to Board and applicable committee service and an annual equity grants under the Company&#8217;s 2018 Equity Incentive Plan.</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01 Regulation FD Disclosure.</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On February 4, 2026, the Company issued a press release announcing the A&amp;R Collaboration Agreement and the appointment of Mr.
        Rubin to the Board. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein.</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information disclosed under this Item 7.01, including in Exhibit 99.1 attached hereto, is &#8220;furnished&#8221; and not &#8220;filed&#8221; for purposes
        of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Exchange Act</span></span>&#8221;), or otherwise subject to the liabilities of that section. Such
        information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</span></div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01 Financial Statements and Exhibits.</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits.</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 7.61%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number</div>
            </td>

    <td style="width: 92.39%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.61%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit_10-1.htm">10.1*</a></div>
            </td>

    <td style="width: 92.39%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit_10-1.htm">Amended and Restated
                  Collaboration and License Agreement, dated February 3, 2026, by and among Entera Bio Ltd., OPKO Health, Inc. and OPKO Biologics Ltd.</a></div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.61%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit_99-1.htm">99.1</a></div>
            </td>

    <td style="width: 92.39%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit_99-1.htm">Press release, dated
                  February 4, 2026</a></div>
            </td>

  </tr>

  <tr>

    <td style="width: 7.61%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
            </td>

    <td style="width: 92.39%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
            </td>

  </tr>


</table>
      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">* Pursuant to Item 601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do
        not contain information material to an investment or voting decision and such information is not otherwise disclosed in such exhibit. The Company will supplementally provide a copy of any omitted schedule or similar attachment to the U.S.
        Securities and Exchange Commission or its staff upon request.</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      </div>

      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned thereunto duly authorized.</div>

      <div style="line-height: 1.25;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 3%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 47%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ENTERA BIO LTD.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 3%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 47%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: February 4, 2026</div>
            </td>

    <td style="width: 3%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
            </td>

    <td style="width: 47%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Miranda Toledano</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 3%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 47%; vertical-align: bottom;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name: Miranda Toledano</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title: Chief Executive Officer</div>
            </td>

  </tr>


</table>
      <div style="line-height: 1.25;"><br/>
      </div>

      <div style="line-height: 1.25;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/> </div>

    </div>

  </div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit_10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div class="BRPFPageNumberArea" style="text-align: center;">
    <div class="BRPFPageHeader">
      <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><u><font style="font-style: normal;"> </font></u>
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u><font style="font-style: normal;">Exhibit 10.1</font></u><br>
      </div>
      <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"> <br>
      </div>
      <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Execution Version</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">by and between ENTERA BIO LTD<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">.</font>,</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">OPKO BIOLOGICS LTD<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">.,</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">OPKO HEALTH, INC.</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%LCR%1%%%-->
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">TABLE OF CONTENTS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Page</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="2" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="zf25713f4d63a4335a21270350d03f31c">

          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1"><a href="#DEFINITIONS">1.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#DEFINITIONS">DEFINITIONS</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">1</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1"><a href="#LICENSESEXCLUSIVITY">2.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#LICENSESEXCLUSIVITY">LICENSES; EXCLUSIVITY</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">12</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.1</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licenses</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">12</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sublicensing and Subcontracting</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">12</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.3</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Technology Transfer Activities</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">13</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exclusivity</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">14</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1"><a href="#GOVERNANCE">3.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#GOVERNANCE">GOVERNANCE</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">15</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.1</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Joint Steering Committee</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">15</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subcommittees</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">16</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.3</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Alliance Managers</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">16</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1"><a href="#RESEARCHANDDEVELOPMENTACT">4.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#RESEARCHANDDEVELOPMENTACT">RESEARCH AND DEVELOPMENT ACTIVITIES</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">16</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.1</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">General Overview and Initial Plans</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">16</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Oral Product Research and Development Plans</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">17</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.3</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Regulatory Matters</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">17</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.4</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Development Costs</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">18</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.5</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subcontracting</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">19</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.6</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Recordkeeping</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">19</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.7</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Reporting on Development Activities</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">19</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1"><a href="#COMMERCIALIZATION">5.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#COMMERCIALIZATION">COMMERCIALIZATION</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.1</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercialization Through Sublicensee</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">19</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Direct Commercialization by OPKO</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">20</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1"><a href="#MANUFACTURING">6.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#MANUFACTURING">MANUFACTURING</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.1</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Manufacturing Activities</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">20</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Allocation of Manufacturing Costs</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">20</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.3</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Manufacturing Technology Transfer</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">20</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1"><a href="#FINANCIALTERMS">7.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#FINANCIALTERMS">FINANCIAL TERMS</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.1</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Invoicing and Payment of Development Costs</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">21</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Entera Ordinary Shares</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.3</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proceeds</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">24</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.4</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Recordkeeping and Audit</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">25</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.5</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Withholding Taxes</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">25</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.6</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Payment Method</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">26</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.7</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">No Projections</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">26</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.8</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Right of Set-Off</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">26</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.9</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Third Party Obligations</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">26</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1"><a href="#ENTERAOPT-OUT">8.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#ENTERAOPT-OUT">ENTERA OPT-OUT</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">27</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.1</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Entera Opt-Out</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">27</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effects of the Opt-Out</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">27</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.3</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Development Diligence Post Opt-Out</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">28</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.4</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Reports Post Opt-Out</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">28</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.5</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Additional Financials for OPKO Direct Commercialization Activities</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">28</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">i</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="2" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1"><a href="#INTELLECTUALPROPERTY">9.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#INTELLECTUALPROPERTY">INTELLECTUAL PROPERTY</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">29</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.1</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ownership of Intellectual Property</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">29</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.2</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prosecution, Maintenance, and Defense</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">29</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.3</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Enforcement</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">30</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.4</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Third-Party Infringement</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.5</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patent Extensions</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">32</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.6</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Regulatory Listings</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">32</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1"><a href="#REPRESENTATIONSWARRANTIES">10.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#REPRESENTATIONSWARRANTIES">REPRESENTATIONS, WARRANTIES AND COVENANTS</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">32</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.1</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mutual Representations, Warranties and Covenants</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">32</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.2</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Additional Representations and Warranties of Entera</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">33</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.3</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Entera Covenants</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">36</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.4</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Additional Representations and Warranties of OPKO Health</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">37</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.5</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Anti-Corruption Compliance</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">37</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.6</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">No Other Representations or Warranties</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">38</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1"><a href="#INDEMNIFICATION">11.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#INDEMNIFICATION">INDEMNIFICATION</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">38</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.1</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indemnification by Entera</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">38</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.2</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indemnification by OPKO</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">38</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.3</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indemnification Procedures</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">39</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.4</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certain Third-Party Claims Related to Collaboration Product in the Territory</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">39</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.5</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Limitation of Liability</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">39</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.6</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insurance</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">40</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1"><a href="#CONFIDENTIALITY">12.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#CONFIDENTIALITY">CONFIDENTIALITY</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.1</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Confidential Information</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">40</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.2</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unauthorized Use or Disclosure</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">40</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.3</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exceptions</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">40</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.4</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Disclosures</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">41</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.5</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Existence and Terms of Agreement</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">41</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.6</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Duration</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">42</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.7</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Press Release</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">42</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.8</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Publications</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">42</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1"><a href="#TERMANDTERMINATION">13.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#TERMANDTERMINATION">TERM AND TERMINATION</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13.1</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Term</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">43</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13.2</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Termination</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">43</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13.3</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Special Remedy for OPKO</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">44</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13.4</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effects of Expiration or Termination</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">45</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13.5</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Rights in Bankruptcy</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">46</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1"><a href="#MISCELLANEOUS">14.<br>
              </a> </td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#MISCELLANEOUS">MISCELLANEOUS</a></div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">47</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.1</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Entire Agreement; Amendment</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">47</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.2</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Force Majeure</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">47</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.3</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Notices</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">47</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.4</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Assignment</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">48</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.5</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expenses</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">48</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.6</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Severability</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">48</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.7</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">No Waiver</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">48</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.8</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Independent Contractors; Relationship</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">49</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.9</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Counterparts</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">49</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.1</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Choice of Law; Venue</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">49</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.11</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Use of Names</div>
            </td>
            <td style="width: 5.29%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">49</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.12</div>
            </td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interpretation</div>
            </td>
            <td style="width: 5.29%; vertical-align: top; text-align: right;">49</td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <table align="left" cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="ze8736b5f4dbd4da3b73520377afc33ef">

        <tr>
          <td style="width: 13%;">
            <div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ATTACHMENTS</div>
            </div>
          </td>
          <td style="width: 87%;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13%;" rowspan="1">&#160;</td>
          <td style="width: 87%;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 13%;" rowspan="1"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Schedule 4.1</font></td>
          <td style="width: 87%;" rowspan="1"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Initial Plans</font></td>
        </tr>
        <tr>
          <td style="width: 13%;" rowspan="1">&#160;</td>
          <td style="width: 87%;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 13%;" rowspan="1"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Schedule 5.2</font></td>
          <td style="width: 87%;" rowspan="1">
            <div style="text-align: justify; line-height: 1.25;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Baseball Arbitration for Commercialization Terms</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 13%;" rowspan="1">&#160;</td>
          <td style="width: 87%;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 13%;" rowspan="1"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Schedule 7.2(d)</font></td>
          <td style="width: 87%;" rowspan="1"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Escrow Terms</font></td>
        </tr>
        <tr>
          <td style="width: 13%;" rowspan="1">&#160;</td>
          <td style="width: 87%;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 13%;" rowspan="1"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Schedule 12.6</font></td>
          <td style="width: 87%;" rowspan="1"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Draft Press Release</font></td>
        </tr>

    </table>
    <div style="line-height: 1.25; clear: both;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">ii</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%--> </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AMENDED AND
        RESTATED</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">COLLABORATION AND LICENSE AGREEMENT </font>(this &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Agreement</font>&#8221;) is entered into as of February 3, 2026 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Effective Date</font>&#8221;), by and between (i) <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">OPKO Biologics Ltd</font>., an Israeli company with offices at 16 Ashlegan St., Kiryat Gat 8211804, Israel (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">OPKO</font>&#8221;), (ii) solely for purposes of <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Sections 7.2</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>10.1</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>10.2</u></font> and <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>10.4</u></font> hereof, OPKO
      Health, Inc., a Delaware corporation headquartered at 4400 Biscayne Blvd., Miami, FL 33137 (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">OPKO Health</font>&#8221;); and (iii) <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Entera Bio Ltd.</font>, an Israeli company headquartered at Kiryat Hadassah, Minrav Building, Fifth Floor, Jerusalem, Israel 9112002 (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Entera</font>&#8221;) and amends and restates in its entirety the Collaboration and License Agreement dated March 16, 2025 among OPKO, OPKO Health and Entera (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Prior Agreement</font>&#8221;). OPKO and Entera are referred to herein individually as a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Party</font>&#8221; and collectively as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Parties</font>.&#8221;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">BACKGROUND</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">WHEREAS</font>,
      Entera has focused on the development of oral peptide or protein replacement therapies using Entera&#8217;s proprietary N-Tab&#8482; technology platform (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Entera
        Platform</font>&#8221;);</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">WHEREAS</font>, OPKO
      is interested in developing and commercializing an oral dual agonist GLP-1/glucagon peptide with OPKO&#8217;s proprietary long acting oxyntomodulin analog and an oral daily long-acting PTH tablet using the Entera Platform;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">WHEREAS</font>, OPKO
      and Entera desire to collaborate for preclinical and clinical development and decision making related to oral delivery of a dual agonist GLP-1/glucagon peptide in an oral dosage form (QD) using Entera&#8217;s N-Tab&#8482; technology platform for the treatment of
      obesity, metabolic and fibrotic disorders in humans and a daily long acting PTH tablet (QD) using Entera&#8217;s N-Tab&#8482; technology platform for the treatment of hypoparathyroidism and other indications in humans; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">WHEREAS</font>, in
      accordance with Section 14.1 of the Prior Agreement, the Parties desire to amend and restate the Prior Agreement in its entirety such that it reads as set forth in this Agreement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NOW THEREFORE</font>,
      in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">DEFINITIONS<a name="DEFINITIONS"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As used in this Agreement, the following initially capitalized terms, whether used in the singular or plural form, have the meanings set
      forth in this <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Article 1</u></font>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Accounting Standards</font>&#8221; means U.S. Generally Accepted Accounting Principles (GAAP) or International Financial Reporting Standards (IFRS), or successor standards thereto,
        in each case, as generally and consistently applied for accounting and financial reporting purposes throughout the applicable Party&#8217;s organization.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">1</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Adverse Event</font>&#8221; means any untoward medical occurrence in a patient or Clinical Trial subject administered a pharmaceutical or biologic product and that does not
        necessarily have a causal relationship with the intended treatment.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Affiliate</font>&#8221; means, with respect to an entity, any other corporation, firm, partnership or other entity which directly or indirectly controls or is controlled by, or is
        under common control with such entity, regardless of whether such control exists as of the Effective Date, but only for so long as such control exists. For purposes of this definition, &#8220;control&#8221; shall be presumed to exist if either or both of the
        following conditions is met: (a) direct or indirect ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors of such entity or any direct or indirect parent of such entity; or (b)
        possession, direct or indirect, of the power to direct or cause the direction of the management and policies of any such entity (whether through ownership of securities or other ownership interests, by contract or otherwise).</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Applicable Law</font>&#8221; means the applicable laws, rules, regulations, statutes, guidelines, treaties, orders, injunctions, decrees, judgments or ordinances having the effect of
        law of any national, multinational, federal, state, provincial, county, city, other political subdivision, or other governmental or quasi-governmental authority of any nature, including any Regulatory Authority, in each case, that may be in effect
        from time to time, including: (a) those governing Clinical Trials or the exploitation of any pharmaceutical or biologic drug, product, or therapy, including then-current Good Clinical Practices (GCP), Good Laboratory Practice (GLP), Good
        Manufacturing Practice (GMP), and the U.S. Federal Food, Drug, and Cosmetic Act (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">FD&amp;C Act</font>&#8221;), U.S. Public Health Service Act (42 U.S.C.
        &#167;262) (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PHSA</font>&#8221;), or foreign equivalents; (b) data protection, patient privacy, and electronic transmission or transaction laws and requirements
        in all countries in which information or data that is protected by any applicable privacy laws is received, observed, transmitted, collected, or otherwise possessed, including the U.S. Health Insurance Portability and Accountability Act of 1996,
        the General Data Protection Regulation (EU) 2016/679 (GDPR), or equivalents thereof in any other jurisdiction, including all implementation measures and regulations promulgated and guidance issued by any governmental authority thereunder; and (c)
        anti-bribery or corruption laws such as the U.S. Anti-Kickback Statute, the Foreign Corrupt Practices Act of 1977, or the UK Bribery Act 2010 (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Anti-Corruption Laws</font>&#8221;).</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Biosimilar Version</font>&#8221; means, with respect to a Collaboration Product in a particular country, a pharmaceutical or biologic product that is: (a) approved for use in such
        country pursuant to a regulatory approval process governing approval of a generic, interchangeable, or biosimilar version of such Collaboration Product based on the then-current standards for regulatory approval in such country, whether or not such
        regulatory approval was based upon clinical data generated in support of a prior regulatory approval granted to a Collaboration Product or was obtained using an abbreviated, expedited, or other process; and (b) sold in the same country as such
        Collaboration Product by any Third Party. For clarity, a product may be a Biosimilar Version regardless of whether it is subject to regulation as a biologic or drug product and regardless of the route used to obtain approval (for example, whether
        by abbreviated new drug application (ANDA), BLA, or under 42 U.S.C. &#167; 262).</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">BLA</font>&#8221; means Biologics License Application (as defined by the FDA) or its foreign equivalent (or a supplement, extension, or amendment thereto), or any successor
        application having substantially the same function.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Business Day</font>&#8221; means a day that is not a Saturday, Sunday, or a day on which banking institutions in New York, New York required by Applicable Law to remain closed.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Calendar Quarter</font>&#8221; means each of the three month periods ending on March 31, June 30, September 30, and December 31 of any Calendar Year, except that the first Calendar
        Quarter begins on the Effective Date and the last Calendar Quarter ends on the effective date of termination of this Agreement.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Calendar Year</font>&#8221; means, for the first Calendar Year, the period beginning on the Effective Date and ending on December 31, 2025, and for each Calendar Year thereafter,
        each 12-month period commencing on January 1, and ending on December 31, except that the last Calendar Year ends on the effective date of termination of this Agreement.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Change of Control</font>&#8221; means, with respect to a Person: (a) a merger or consolidation of such Person with a Third Party that results in the voting securities of such Person
        outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent more than 50% of the combined voting power of the surviving entity or the parent of the surviving
        entity immediately after such merger or consolidation; (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the direct or indirect beneficial owner of more than 50% of the combined voting
        power of the outstanding securities of such Person; or (c) the sale or other transfer to a Third Party of all or substantially all of such Person&#8217;s and its controlled Affiliates&#8217; assets (such Third Party in each of (a) through (c), the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Acquiring Entity</font>&#8221;). Notwithstanding the foregoing, any transaction or series of transactions effected for the primary purpose of financing the
        operations of the applicable Person (including the issuance or sale of securities for financing purposes) or changing the form or jurisdiction of organization of such Person will not be deemed a &#8220;Change of Control&#8221; for purposes of this Agreement.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Clinical Trial</font>&#8221; means any clinical study in humans.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Collaboration Product</font>&#8221; means any proprietary Oral Product constituting (i) a long acting, dual agonist GLP-1/glucagon peptide(s) (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Oxyntomodulin Analog</font>&#8221;) or (ii) a long acting PTH peptide but excluding unmodified and non-long acting PTH peptides (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">LA-PTH</font>&#8221;), in either case, that is Controlled by OPKO and combined with the Entera Platform.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.13</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Commercialization Costs</font>&#8221; means, with respect to a Collaboration Product, all internal and external costs and expenses incurred by or on behalf of a Party during the Term
        (whether incurred prior to or following the First Commercial Sale of such Collaboration Product) to the extent directly attributable or reasonably allocable (whether wholly or partially attributable or allocable) to the Commercialization of such
        Collaboration Product, including for medical affairs activities and maintaining regulatory approvals (including any post-marketing Clinical Trial), and Manufacturing Costs for Commercialization purposes; provided that if any of the foregoing costs
        are reimbursed or otherwise offset by a Third Party, including a sublicensee, such costs shall not be included in as Commercialization Costs. Subject to the foregoing, Commercialization Costs include the costs and expenses incurred by OPKO in
        connection with negotiating and executing a sublicense agreement pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 5.1</u></font>, and the costs and expenses incurred by OPKO as part of the
        performance of OPKO&#8217;s obligations under any such sublicense agreement. In all cases, Commercialization Costs exclude Development Costs and Shared Program Damages.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.14</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Commercialize</font>&#8221; means all activities required or directed to market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported or
        otherwise commercialize a pharmaceutical or biologic product or device, including activities to seek and maintain Marketing Approvals and market access and medical affairs activities. When used as a noun, &#8220;Commercialization&#8221; means any and all
        activities involved in Commercializing.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.15</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Commercially Reasonable Efforts</font>&#8221; means, with respect to a Party and an obligation hereunder, the level, caliber, and quality of efforts and resources typically used by
        biopharmaceutical companies of similar size and similarly situated to such Party to perform the obligation at issue, which efforts shall be substantially the same as those efforts made with respect to other products at a similar stage of
        development or in a similar stage of product life, with similar developmental risk profiles, issues of safety and efficacy, and all other scientific and technical factors; provided that with respect to OPKO&#8217;s Commercially Reasonable Efforts, it may
        additionally take into account factors such as the competitiveness of the marketplace, the proprietary position of the products, the regulatory structure involved, Regulatory Authority approved labeling, product profile, the profitability of the
        applicable products, the likely timing of the product&#8217;s entry into the market, the likelihood of receiving regulatory approval, and all other relevant scientific, technical, and commercial factors. For the avoidance of doubt, the level of efforts
        and resources that constitutes Commercially Reasonable Efforts may change over time based on the factors described above.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.16</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Commission</font>&#8221; means the U.S. Securities and Exchange Commission.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.17</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Control</font>&#8221; or &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Controlled</font>&#8221; means, with respect to a Person and any
        Know-How, Patent or materials, the possession of the ability by such Person or its Affiliates (whether by sole or joint ownership, license or otherwise), other than pursuant to this Agreement, to grant, without violating the terms of any agreement
        with a Third Party, a license, access or other right in, to or under such Know-How, Patent or materials, in all cases, in the manner contemplated by this Agreement. Notwithstanding the foregoing, a Person (or an Affiliate of a Person, as
        applicable) will not be deemed to Control any such right that is owned or in-licensed by an Acquiring Entity, except to the extent any such right (a) arises after a Change of Control in the course of the conduct of activities under this Agreement
        by representatives of the Acquiring Entity; or (b) is included in, disclosed, or used in furtherance of a Person&#8217;s activities in connection with this Agreement by the Acquiring Entity or the acquired Person after a Change of Control.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.18</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Develop</font>&#8221; means (a) to research, develop, analyze, test and conduct non-clinical, preclinical, clinical and all other regulatory studies and trials for a product,
        including new indications, new combinations and new formulations; and (b) all other activities related to securing and maintaining Marketing Approval for a product and regulatory activities in connection therewith. &#8220;Developing&#8221; and &#8220;Development&#8221;
        shall have correlative meanings.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.19</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Development Costs</font>&#8221; means, with respect to a Collaboration Product, all internal and external costs and expenses incurred by or on behalf of a Party during the Term to
        the extent directly attributable or reasonably allocable (whether wholly or partially attributable or allocable) to the Development of such Collaboration Product under the Development Plan, including Manufacturing Costs for use in the Development
        of a Collaboration Product in such Development-related activities, and any Shared Program Damages pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 11.4</u></font>. For clarity, Development Costs do
        not include Commercialization Costs, nor do Development Costs include any costs incurred as part of the performance of OPKO&#8217;s obligations under a sublicense agreement (e.g., where a sublicensee collaboration partner requires OPKO to conduct
        additional studies pursuant to the sublicense agreement or to provide support in connection with obtaining regulatory approvals).</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.20</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Development Plans</font>&#8221; means, collectively, the Initial Plans and the Oral Product Research and Development Plans, as the same may be updated from time to time in accordance
        with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 4</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.21</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Effective Date</font>&#8221; has the meaning set forth in the preamble. Notwithstanding the foregoing, for purposes of defining the term "Effective Date" as it relates to the
        Parties&#8217; Background IP and Foreground IP, for the Oxyntomodulin Analog Oral Product Research Collaboration project,&#160; the term "Effective Date" means the Original Effective Date.&#160; For the LA-PTH Oral Product Research Collaboration project, the term
        "Effective Date" means the execution date of this Amended and Restated Collaboration and License Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.22</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Entera Background IP</font>&#8221; means all Patents and Know How that are both (a) Controlled by Entera as of the Effective Date; and (b) necessary or reasonably useful to Develop,
        Manufacture, or Commercialize the Oral Products in the Field.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.23</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Entera Foreground Know-How</font>&#8221; means all Know-How (including Entera Information and Inventions) that during the Term is (a) in the possession and Control of Entera or its
        Affiliates; (b) not generally known; and (c) necessary or reasonably useful to Develop, Manufacture, or Commercialize the Oral Products in the Field; excluding, however, any OPKO Foreground Know-How or any Know-How within the Entera Background IP.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.24</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Entera Foreground Patents</font>&#8221; means each Patent Controlled by Entera during the Term that (a) claims or covers Entera Information and Inventions or (b) otherwise is
        necessary or reasonably useful to Develop, Manufacture, or Commercialize Oral Products in the Field, in each case of (a) or (b) excluding any Patent within the Entera Background IP.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.25</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Entera Information and Inventions</font>&#8221; means all protocols, formulas, data, inventions, know-how and trade secrets, patentable or otherwise, resulting from the Oral Product
        Research Collaborations developed or invented solely by employee(s) of Entera or its Affiliates, or a Third Party acting on behalf of Entera or its Affiliates, and not employed by OPKO or its Affiliates.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.26</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Entera Licensed Technology</font>&#8221; means, collectively, all Entera Background IP, Entera Foreground Know-How, and Entera Foreground Patents.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.27</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Entera Ordinary Shares</font>&#8221; means the ordinary shares, par value NIS 0.0000769 per share, of Entera.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.28</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">European Union</font>&#8221; or &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">EU</font>&#8221; means the European Union and all its
        then-current member countries but including in any case the United Kingdom regardless of whether it is a then-current member country.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.29</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Exclusivity Period</font>&#8221; means, with respect to a Collaboration Product, the period beginning on the Effective Date and ending on the earliest to occur of: (a) the Opt-Out
        Date for such Collaboration Product; or (b) expiration or termination of this Agreement (except with respect to Entera&#8217;s obligations if terminated by OPKO pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section
            13.2(a)</u></font>).</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.30</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Field</font>&#8221; means (i) with respect to the Oxyntomodulin Analog, the treatment of obesity, metabolic, cardiovascular, and fibrotic disorders in humans, including nonalcoholic
        steatohepatitis (NASH), and any other known or indicated use of a dual agonist GLP-1/glucagon peptide and (ii) with respect to LA-PTH, the treatment of chronic hypoparathyroidism and other disorders in humans. As used in this Agreement, each
        reference to &#8220;Field&#8221; shall mean only such subsection of this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 1.29</u></font> as applies to the relevant Collaboration Product.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.31</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">First Commercial Sale</font>&#8221; means, with respect to a Collaboration Product in a country, the first sale to a Third Party following the receipt of Marketing Approval in such
        country; provided that &#8220;First Commercial Sale&#8221; shall not include the transfer of promotional samples of Collaboration Product or the sale, disposal, or use of a Collaboration Product for marketing, regulatory, development or charitable purposes,
        such as Clinical Trials, pre-clinical trials, compassionate use, named patient use, or indigent patient programs.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.32</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Force Majeure</font>&#8221; means conditions beyond the control of the relevant Party and not arising from the fault or negligence of such Party. Subject to the foregoing, a Force
        Majeure event may include an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake,
        storm or like catastrophe, failure of plant or machinery, or regulatory matters (including regulatory holds) (provided in each case the resulting failure to perform could not have been prevented by the exercise of skill, diligence, and prudence
        that would be reasonably and ordinarily expected from a skilled and experienced person engaged in the same type of undertaking under the same or similar circumstances).</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.33</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Good Reason</font>&#8221; means a good faith strategic reason (consistent with maximizing the commercial viability and Patent protection of the Collaboration Products) not to
        Prosecute, enforce or defend, as applicable, a Patent.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.34</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Initial Study</font>&#8221; means the Phase 1 Clinical Trial, including the Single Ascending Dose and Multiple Ascending Dose clinical studies, to be conducted by Entera with respect
        to a Collaboration Product and identified in the applicable Initial Plan.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.35</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Joint Information and Inventions</font>&#8221; means, on a Collaboration Product-by-Collaboration Product basis, all protocols, formulas, data, inventions, know-how and trade
        secrets, patentable or otherwise, resulting from the applicable Oral Product Research Collaboration developed or invented jointly by employee(s) of OPKO or its Affiliates, or a Third Party acting on behalf of OPKO or its Affiliates, and by
        employee(s) of Entera or its Affiliates, or a Third Party acting on behalf of Entera or its Affiliates including those identified in this Agreement.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">6</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.36</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Joint Patents</font>&#8221; means, on a Collaboration Product-by-Collaboration Product basis, each Patent that claims or covers Joint Information and Inventions, excluding any Patent
        within the OPKO Background IP or Entera Background IP.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.37</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Know-How</font>&#8221; means all information and materials, including discoveries, improvements, processes, methods, protocols, formulas, data, inventions (including Entera
        Information and Inventions, OPKO Information and Inventions, and Joint Information and Inventions with respect to a Collaboration Product), know-how, and trade secrets, patentable or otherwise.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.38</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Major Market Country</font>&#8221; means the United States, France, Italy, United Kingdom, Germany, Spain, and Japan.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.39</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Manufacture</font>&#8221; or &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Manufacturing</font>&#8221; means to make, produce, manufacture,
        process, fill, finish, package, label, perform quality assurance testing on, release, ship or store a compound, device or product or any component thereof. When used as a noun, &#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved
        in Manufacturing a compound or product or any component thereof.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.40</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Manufacturing Costs</font>&#8221; means, with respect to a Collaboration Product, all internal and external costs and expenses incurred by or on behalf of a Party during the Term to
        the extent directly attributable or reasonably allocable (whether wholly or partially attributable or allocable) to the Manufacture of such Collaboration Product (including drug substance and drug product and both direct and indirect costs
        (provided that any such indirect costs are reasonably allocable to such product production consistent with the applicable Party&#8217;s Accounting Standards)). To the extent that Collaboration Product is sourced by a Party from one or more Third Party
        contract manufacturing organizations (each a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CMO</font>&#8221;), Manufacturing Costs will equal the out-of-pocket costs incurred by such Party for such
        Manufacturing activity, as evidenced by the invoiced price paid by such Party to such Third Party contract manufacturing organizations for such Manufacturing activities.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.41</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Marketing Approval</font>&#8221; means, with respect to a product in a particular country or jurisdiction, all approvals (including approvals resulting from any priority review,
        breakthrough therapy, accelerated approval or fast track designation, application or submission), licenses, registrations or authorizations by a governmental authority necessary for the manufacture, marketing, sale, or other commercialization of
        such product in such country or jurisdiction, including: (a) with respect to the United States, approval of BLA or NDA for such product by the FDA and with respect to the European Union, approval of a marketing approval application (MAA) for such
        product by the EMA; (b) where required by Applicable Law to market and sell a product, pricing and reimbursement approval in such country or jurisdiction; and (c) where applicable, pre- and post-approval marketing authorizations (including any
        prerequisite manufacturing approval or authorization related thereto), and labeling approval.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.42</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Material Safety Issue</font>&#8221; means OPKO&#8217;s good-faith determination following notice and discussion with Entera that there is an unacceptable risk for harm in humans based upon
        the observation of serious adverse effects in non-clinical toxicity studies with respect to a Collaboration Product or the observation of serious adverse effects in humans after a Collaboration Product has been administered to or taken by humans.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.43</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">NDA</font>&#8221; means a New Drug Application that is submitted to the FDA for Marketing Approval, pursuant to pursuant to 21 USC &#167; 355, or with respect to a jurisdiction other than
        the United States, a similar application for Marketing Approval.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.44</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">OPKO Background IP</font>&#8221; means all Patents and Know How that are both (a) Controlled by OPKO as of the Effective Date; and (b) necessary or reasonably useful to Develop,
        Manufacture, or Commercialize the Oral Products in the Field.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.45</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">OPKO Foreground Know-How</font>&#8221; means all Know-How (including OPKO Information and Inventions) that during the Term is (a) in the possession and Control of OPKO or its
        Affiliates; (b) not generally known; and (c) necessary or reasonably useful to Develop, Manufacture, or Commercialize the Oral Products in the Field; excluding, however, any Entera Foreground Know-How, or any Know-How within the OPKO Background IP.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.46</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">OPKO Foreground Patents</font>&#8221; means all Patents Controlled by OPKO during the Term that claim or cover OPKO Information and Inventions, excluding any Patent within the OPKO
        Background IP.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.47</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">OPKO Information and Inventions</font>&#8221; means all protocols, formulas, data, inventions, know-how and trade secrets, patentable or otherwise, resulting from the Oral Product
        Research Collaboration developed or invented solely by employee(s) of OPKO or its Affiliates, or a Third Party acting on behalf of OPKO or its Affiliates, and not employed by Entera or its Affiliates.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.48</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">OPKO Technology</font>&#8221; means, collectively, all OPKO Background IP, OPKO Foreground Know-How, and OPKO Foreground Patents.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.49</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Oral Product</font>&#8221; means (i) any GLP-1/glucagon dual agonist as an oral treatment form or (ii) any long acting PTH (other than unmodified and non-long acting PTH analogues))
        as an oral treatment form (a) for sale by prescription, over-the-counter or any legal other method; or (b) for administration to human patients in a Clinical Trial, for any and all uses in the Field, including any combination product.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.50</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Oral Product Research Collaboration(s)</font>&#8221; means the Development and Commercialization of a Collaboration Product by the Parties in the Field as contemplated under the
        Development Plans and this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.51</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Original Effective Date</font>&#8221; means March 16, 2025.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.52</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Patents</font>&#8221; means the rights and interests in and to issued patents and pending patent applications in any country, jurisdiction, or region (including inventor&#8217;s
        certificates and utility models), including all provisionals, non-provisionals, substitutions, continuations, continuations-in-part, divisionals, renewals and all patents granted thereon, and all reissues, reexaminations, extensions, confirmations,
        revalidations, registrations and patents of addition thereof, including patent term extensions and supplementary protection certificates, or the equivalents thereof, international patent applications filed under the Patent Cooperation Treaty (PCT)
        and any foreign equivalents to any of the foregoing.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">8</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.53</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Person</font>&#8221; means any natural person, corporation, general partnership, limited partnership, joint venture, proprietorship or other business organization or a governmental
        authority.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.54</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Phase 1 Clinical Trial</font>&#8221; means a Clinical Trial of an investigational product that meets the definition of a Phase 1 study in the Clinical Trial Regulation EU No 536/2014
        and for the United States as described in 21 C.F.R. &#167;312.21(a), or its successor regulation, or the equivalent regulation in any other country.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.55</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Pricing Matters</font>&#8221; means all material issues and decisions regarding price, price terms and other related contract terms with respect to Commercialization of a
        Collaboration Product in each country in the Territory, including discounts, rebates, other price concessions and service fees to payors and purchasers.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.56</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Proceeds</font>&#8221; means for a given Calendar Quarter, the difference (if any) between (a) the sum of (i) Shared Program Recoveries; and (ii) Sublicense Income received by OPKO
        or its Affiliates during such Calendar Quarter, minus (b) the sum of (i) any Commercialization Costs; (ii) Shared Program Damages; and (iii) out-of-pocket costs and expenses incurred by OPKO in connection with (A) obtaining or maintaining Marketing
        Approval or other regulatory approvals with respect to a Collaboration Product (to the extent not included in &#8220;Commercialization Costs&#8221;) or (B) its Prosecution of Patents hereunder, in the case (of (A) and (B)) to the extent directly attributable
        or reasonably allocable to a Collaboration Product. For clarity, Development Costs shall not be subtracted from Proceeds, and net sales of Collaboration Products (whether by OPKO or any of its Affiliates or sublicensees) shall not be included in
        Proceeds (but royalties payable to OPKO or its affiliates based on such net sales would be included, subject to the foregoing).</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.57</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Prosecution</font>&#8221; or &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Prosecute</font>&#8221; means, with respect to a particular
        Patent, all activities associated with the preparation, filing, defense, prosecution, and maintenance of such Patent, as well as supplemental examinations, re-examinations, reissues, supplementary protection certificates and the like with respect
        to such Patent, together with the conduct of interferences, derivation proceedings, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">inter partes </font>review, post-grant review, the defense of
        oppositions, and other similar proceedings with respect to such Patent.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.58</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Regulatory Authority</font>&#8221; means any governmental authority responsible for granting Marketing Approvals for pharmaceutical and biologic products, including: (a) in the
        United States, the U.S. Food and Drug Administration, or any successor entity thereto (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">FDA</font>&#8221;); (b) in the EU, the European Medicines Agency or
        any successor entity thereto (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">EMA</font>&#8221;); and (c) any corresponding national or regional regulatory authorities.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.59</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shared Program Activity</font>&#8221; means any activity with respect to a Collaboration Product conducted by either Party or any of its Affiliates, sublicensees or subcontractors
        consisting of (a) Development Activities; (b) Commercialization activities during the Term with respect to a Collaboration Product; or (c) the Manufacture of the Collaboration Product (including any intermediate thereof or any active therapeutic
        ingredient or other material contained therein) for use in any activities under clause (a) or (b).</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">9</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.60</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shared Program Damages</font>&#8221; means any Damages payable by either Party (or any of its indemnified Persons) to any Third Party claimant, as well as any reasonable attorneys&#8217;
        fees and costs of litigation incurred by either Party (or any of its indemnified Persons) from Third-Party Claims arising from Shared Program Activities, including such losses (and attorneys&#8217; fees and costs) (a) arising from claims of infringement
        of a Third Party&#8217;s Patent and other intellectual property rights pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 9</u></font>; (b) constituting products liability claims; or (c) otherwise arising
        from Shared Program Activities not attributable to either party&#8217;s gross negligence, willful misconduct or breach, provided, however, that &#8220;Shared Program Damages&#8221; shall exclude Damages</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(and attorneys&#8217; fees) for which (i) this Agreement otherwise provides shall be at a Party&#8217;s sole expense; or (ii) a Party has an
      obligation to indemnify the other hereunder.</div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.61</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shared Program Recoveries</font>&#8221; means recoveries or other amounts receivable by either Party (or any of its indemnified Persons) from any Third Party arising from any
        disputes or litigation with such Third Party in connection with the Shared Program Activities, including such recoveries from an enforcement action or settlement pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 9.4</u></font> (Third-Party Infringement); provided, however, that &#8220;Shared Program Recoveries&#8221; shall exclude any and all amounts (a) that this Agreement otherwise provides shall be retained solely by a Party; or
        (b) a Party is entitled to receive from the other Party pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 11.1</u></font> or <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 11.2</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.62</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Sublicense Income</font>&#8221; means all consideration received by OPKO from a sublicensee in consideration of a sublicense of the rights granted to OPKO pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.1(a)</u></font> below with respect to the Entera Licensed Technology, including upfront payments, option, license fees, bonus, development milestones, sales
        milestones payments, royalties, income, equity securities and any and all monetary and non-monetary value whatsoever resulting anywhere in all countries in the Territory, in all cases to the extent directly attributable or reasonably allocable to a
        Collaboration Product. Sublicense Income excludes: (a) consideration from a sublicense as a result of the purchase or sale of debt or equity securities of OPKO (or its Affiliates) by such sublicensee; (b) consideration or any type of funding for
        the Development of Oral Products; and (c) consideration or any type of funding to the extent directly attributable or reasonably allocable to rights to any subcutaneous version of any product.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.63</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Subsidiary</font>&#8221; means any subsidiary of Entera.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.64</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Territory</font>&#8221; means worldwide.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.65</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Third Party</font>&#8221; means any Person other than Entera or OPKO or each of their respective Affiliates.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">10</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.66</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Other Defined Terms</u></font>:</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="2" border="0" id="z1f0691eeddf648a48b8b02e3b5407750" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 55.78%; vertical-align: top; background-color: rgb(208, 206, 206); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Defined Term</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; background-color: rgb(208, 206, 206); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Section</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Acquiring Entity</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Definition of &#8220;Change of Control&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Actions</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Agreement</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preamble</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Alliance Manager</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Anti-Corruption Laws</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Definition of &#8220;Applicable Law&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Bankruptcy Code</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13.2(d)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Board</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CMO</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Definition of &#8220;Manufacturing Costs&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Commercialization Terms</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Company Interests</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2(a)(i)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Confidential Information</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.1(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Damages</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Development Activities</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.2(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Development Budget</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Disclosing Party</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.1(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">EMA</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Definition of &#8220;Regulatory Authority&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Entera</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preamble</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Entera Indemnitees</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Entera Platform</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Escrow Agreement</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2(d)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Escrow Terms</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2(d)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Exchange Act</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2(a)(ii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Exploit</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">FD&amp;C Act</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Definition of &#8220;Applicable Law&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">FDA</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Definition of &#8220;Regulatory Authority&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Finance Leads</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.3(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">GAAP</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.2(m)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Indemnified Party</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Indemnifying Party</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Initial Deposit Account</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2(d)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Initial Plan</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Invoicing Party</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Joint Steering Committee</font>&#8221;
              or &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">JSC</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">LA-PTH</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Definition of &#8220;Collaboration Product&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Lock-Up Period</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Manufacturing Technology Transfer
                Plan</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Non-Publishing Party</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">OPKO</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preamble</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">OPKO Indemnitees</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Opt-Out</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.1(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Opt-Out Date</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.1(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Opt-Out Notice</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.1(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Oral Product Research and
                Development Plan</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Oxyntomodulin Analog</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Definition of &#8220;Collaboration Product&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Party</font>&#8221; or &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Parties</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preamble</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">11</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="2" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 55.78%; vertical-align: top; background-color: rgb(208, 206, 206); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Defined Term</div>
            </td>
            <td style="width: 44.22%; vertical-align: top; background-color: rgb(208, 206, 206); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Section</div>
            </td>
          </tr>

      </table>
    </div>
    <table cellspacing="0" cellpadding="2" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">PHSA</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Definition of &#8220;Applicable Law&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Pre-Existing Product</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Publishing Party</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Purchase Price</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Purchased Shares</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Receiving Party</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.1(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Residual Information</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.2(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Responsible Party</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">SEC Reports</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.2(m)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Securities Act</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.4</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Standstill Period</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Subcontractor</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.5</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Term</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13.1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Third-Party Claims</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.78%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Third-Party Infringement</font>&#8221;</div>
          </td>
          <td style="width: 44.22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.4(a)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">LICENSES; EXCLUSIVITY<a name="LICENSESEXCLUSIVITY"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">2.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Licenses</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Exclusive License Grant to OPKO</u></font>. Subject to the terms and conditions of this Agreement, Entera hereby grants OPKO, on a Collaboration Product-by-Collaboration Product basis, an exclusive
        (even as to Entera and its Affiliates), sublicensable (in accordance with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.2</u></font>), non-transferable (except as set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section</u></font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>14.4</u></font>), worldwide license under the applicable Entera Licensed Technology and
        Entera&#8217;s rights in the applicable Joint Information and Inventions and Joint Patents, to Develop, Manufacture, and Commercialize the applicable Oral Products in the Field.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Non-Exclusive License Grant to Entera</u></font>. Subject to the terms and conditions of this Agreement, OPKO hereby grants Entera, on a Collaboration Product-by-Collaboration Product basis, a
        non-exclusive, non-sublicensable (except as set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.2</u></font>) and non-transferable (except as set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 14.4</u></font>) license under the applicable OPKO Technology and OPKO&#8217;s rights in the applicable Joint Information and Inventions and Joint Patents, to the extent necessary for Entera to perform its
        obligations under the Development Plan, to perform such obligations.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>No Other License</u></font>. Except as expressly set forth in this Agreement, neither Party grants to the other Party by implication, estoppel or otherwise, any right, title, license, or other
        interest in any Know-How or Patents or other intellectual property.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">2.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Sublicensing and Subcontracting</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>OPKO Sublicensing and Subcontracting</u></font>. OPKO may sublicense through multiple tiers the rights granted to it by Entera under this Agreement following consultation and discussion by the JSC
        prior to granting such sublicense. OPKO may exercise its rights and perform its rights and obligations under this Agreement itself or through any of its Affiliates or sublicensees. In addition, OPKO may subcontract to Third Parties the performance
        of tasks and obligations with respect to the Development, Manufacture and Commercialization of a Collaboration Product in the Field as OPKO deems appropriate, subject to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section
            4.5</u></font> in relation to Development Activities. OPKO will remain responsible for the performance of its obligations under this Agreement notwithstanding the use of any Affiliate, sublicensee, or subcontractor.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">12</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Entera Sublicensing and Subcontracting</u></font>. Entera will not sublicense the rights granted to it by OPKO under this Agreement without OPKO&#8217;s consent other than to its Affiliates or
        subcontractors in each case solely to perform tasks on behalf of Entera. Entera may exercise its rights and perform its rights and obligations under this Agreement itself or through any of its Affiliates. Entera may not subcontract to Third Parties
        the performance of tasks and obligations with respect to the Development, Manufacture and Commercialization of a Collaboration Product to any Third Party except for Development Activities under the applicable Initial Plan (including the
        subcontracting of manufacturing for Development to Third-Party CMOs) and subject to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 4.5</u></font> in relation to Development Activities, including to any
        Third-Party CMOs. Entera will remain responsible for the performance of its obligations under this Agreement notwithstanding the use of any Affiliate, sublicensee, or subcontractor.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">2.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Technology Transfer Activities</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Transition Generally</u></font>. Entera will cooperate with and provide timely assistance to OPKO to ensure the smooth transition and to facilitate the transfer to OPKO of the Know-How included in
        the license grant above.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Initial Disclosure and Knowledge Transfer</u></font>. Subject to the remainder of this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.3(b)</u></font>,
        within thirty (30) days following the Effective Date, Entera shall, at its own cost, transfer to OPKO copies of all Know-How included in the Entera Background IP and any Patents embodying the Entera Background IP, by download of digital files to a
        virtual data room or other online filesharing service designated and controlled by OPKO. It is understood and agreed that there may be additional Know-How included in the Entera Background IP that are not identified or not yet existing at the time
        of the initial technology transfer but that are thereafter identified or generated. If after the initial technology transfer, either Party identifies any such additional Know-How included in the Entera Background IP or at OPKO&#8217;s reasonable request,
        Entera shall transfer such additional Know-How included in the Entera Background IP to OPKO promptly after such identification (or notification if identified by OPKO), by download of digital files to a virtual data room or other online filesharing
        service designated and controlled by OPKO. To the extent that any material Know-How does not exist in written form as of the Effective Date or later date of identification, then within ninety (90) days of the Effective Date or as applicable the
        identification date, Entera will, at its own cost, reduce to writing such Know-How in a reasonably organized and complete form, and transfer the same to OPKO. Such Know-How shall include information to assist OPKO to develop processes and
        procedures, including training, to Manufacture a Collaboration Product in the Field in a safe manner and in compliance with Applicable Law.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Technology Transfer following Initial Studies</u></font>. On the timeline to be set forth in the updated Development Plan or as otherwise agreed (but in any event not later than ninety (90) days
        after completion of the Development Activities under an Initial Plan), to the extent not already provided pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.3(b)</u></font>, Entera will disclose and
        make available to OPKO by download of digital files to a virtual data room or other online filesharing service designated and controlled by OPKO, at Entera&#8217;s sole cost and expense, all Clinical Trial data and regulatory filings (e.g., INDs)
        relating to the activities undertaken by Entera under the applicable Development Plan and all Entera Foreground Know-How then in existence (but only to the extent such Know-How is necessary to Develop, Manufacture, or Commercialize the
        Collaboration Products in the Field) that is included in the license granted to OPKO pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.1(a)</u></font>.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">13</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Costs of Technology Transfers</u></font>. Each Party will bear all of its own costs and expenses incurred in connection with conducting any technology transfer activities under this Agreement. To
        the extent directly attributable or reasonably allocable to a Collaboration Product, the costs and expenses incurred in connection with conducting any technology transfer as part of the performance of OPKO&#8217;s obligations under any sublicense
        agreement described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 5.1</u></font> shall constitute a deduction to &#8220;Proceeds&#8221; if incurred by OPKO and shall be added to total &#8220;Proceeds&#8221; if incurred by
        Entera.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">2.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Exclusivity</u></font>.</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: left; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Exclusivity Commitments</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-left: 45pt; text-indent: 63pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the Exclusivity Period, other than in the conduct of an Oral Product Research
        Collaboration (including as contemplated under <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.2(a)</u></font> and <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 5.1</u></font>),
        OPKO will not (and will cause its Affiliates not to), either alone or with Affiliates or Third Parties, research, Develop, Manufacture, or Commercialize (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Exploit</font>&#8221;) any Oral Product or grant any right or license to any Third Party to conduct any of the foregoing activities, other than the rights granted to Entera under this Agreement.</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-left: 45pt; text-indent: 63pt;">
        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
        </div>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">(ii)&#160;&#160;&#160; &#160;&#160;&#160; During the Exclusivity Period, other than in the conduct of an Oral Product Research Collaboration, Entera will not (and
          will cause its Affiliates not to), either alone or with any Affiliates or Third Parties, use the Entera Platform to Exploit any Oral Product, or grant any right or license to any Third Party to conduct any of the foregoing activities, other than
          the rights granted to OPKO under this Agreement.</div>
      </div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-left: 45pt; text-indent: 63pt;"> <br>
      </div>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Exception for Change of Control</u></font>. In the event that OPKO or Entera undergoes a Change of Control with an Acquiring Entity (which for purposes of this paragraph will include such Third
        Party&#8217;s pre-Change of Control affiliates) that is (either directly or through any Third Party) Exploiting an Oral Product (such Oral Product being so Exploited prior to the Change of Control, a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Pre-Existing Product</font>&#8221;), the Acquiring Entity may continue to Exploit such Pre-Existing Product, and neither Party will be deemed to be in breach of <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.4</u></font> as a result thereof following the Change of Control if:</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-left: 45pt; text-indent: 63pt;">(i)&#160;&#160;&#160;&#160; &#160;&#160; &#160; In the case of OPKO, (A) neither the OPKO Technology (excluding intellectual property
        rights Controlled prior to the Change of Control by the Acquiring Entity or its then-affiliates) nor any OPKO Information and Inventions are used by or on behalf of the Acquiring Entity or its Affiliates in connection with the Exploitation of such
        Pre-Existing Products; and (B) OPKO and the Acquiring Entity institute commercially reasonable technical and administrative safeguards to ensure the requirements set forth in the foregoing clause (A) are met, including, in any case, creating
        &#8220;firewalls&#8221; between the personnel working on such Pre-Existing Products and the personnel performing the Development Activities hereunder or having access to data from activities performed under this Agreement or Confidential Information of the
        Parties.</div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">14</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div>
      <div> <br>
      </div>
      <div style="text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the case of Entera, (A) neither the Entera Licensed Technology (excluding intellectual property rights Controlled prior to the Change of Control by the
        Acquiring Entity or its then-affiliates) nor any Entera Information and Inventions are used by or on behalf of the Acquiring Entity or its Affiliates in connection with the Exploitation of such Pre-Existing Products; and (B) Entera and the
        Acquiring Entity institute commercially reasonable technical and administrative safeguards to ensure the requirements set forth in the foregoing clause (A) are met, including, in any case, creating &#8220;firewalls&#8221; between the personnel working on such
        Pre-Existing Products and the personnel performing the Development Activities hereunder or having access to data from activities performed under this Agreement or Confidential Information of the Parties.</div>
      <div> <br>
      </div>
    </div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">GOVERNANCE<a name="GOVERNANCE"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25; text-align: left;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">3.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Joint Steering Committee</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Formation; Composition</u></font>. Promptly following the Effective Date, the Parties shall establish, to the extent not already established, a joint steering committee (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Joint Steering Committee</font>&#8221; or &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">JSC</font>&#8221;) for each of the Oral Product
        Collaboration Programs comprised of two (2) senior representatives from each Party. A Party may replace any of its representatives from time to time by written notice to the other Party</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Specific Responsibilities</u></font>. Prior to expiration of the Term, the JSCs will generally oversee the Oral Product Research Collaborations, for example overseeing the performance of Development
        Activities. The JSCs shall review and guide the implementation and management of, and modifications to, the Development Plans, and shall approve the Development Plans and modifications thereto. The JSCs shall review and discuss any potential
        sublicense, partnership, collaboration, or other strategic relationship with a Third Party involving the sublicensing of the Entera Licensed Technology and where Sublicense Income may be generated, in each case prior to entering into such
        definitive agreement. The JSCs are intended to act as a discussion forum and decision-making body, with the Parties working collaboratively to attempt to mutually agree on any manner referred to the JSCs.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Decision-Making</u></font>. The Parties will attempt to make JSC decisions by consensus vote with escalation for dispute resolution to a senior executive of each Party if there fails to be a
        consensus. In the event that the senior executives cannot after reasonably good faith efforts reach agreement on an issue within the JSC&#8217;s purview within five (5) Business Days of such issue being referred to such senior executive, then: (i) Entera
        shall have final decision making authority with respect to matters relating to the Development of any Collaboration Product through completion of the Initial Study, and (ii) OPKO shall have final decision making authority with respect to all other
        matters (e.g., determination of the lead candidate under the applicable Initial Plan, or Development following completion of the Initial Study) to the extent such decisions are consistent with the Development Plan. For clarity, OPKO shall have
        final decision making authority with respect to the Development Plan (including modifications thereto) and with respect to the Commercialization of the Collaboration Products in the Field (including whether to enter into sublicenses), following
        consultation and discussion by the JSC (it being understood that such consultation and discussion shall not require the approval of the JSC).</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">15</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Limitations on Decision-Making Authority</u></font>. Neither Party may exercise its final decision-making authority in any manner that would (i) materially increase the scope of the other Party&#8217;s
        obligations under the applicable Development Plan without a corresponding increase in the budget for such additional Development Plan activities; (ii) reasonably be expected to violate Applicable Law or infringe any third-party intellectual
        property rights; (iii) modify this Agreement in any other manner in contravention of the terms hereof; or (iv) waive compliance with, or any breach of, this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Clarification</u></font>. OPKO shall have sole decision-making authority with respect to licensing, partnering, or commercialization of a Collaboration Product in the Field following consultation
        and discussion with the relevant JSC. For clarity, OPKO does not have the right to develop, manufacture, commercialize any Oral Product using the Entera Platform other than the Collaboration Product in the Field.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Meetings</u></font>. The JSCs shall meet in person or by teleconference at least once per calendar month until completion of the relevant Initial Study, and thereafter at least once per Calendar
        Quarter (or as otherwise mutually agreed upon). Each Party may invite employees of that Party to attend JSC meetings in a non-participating capacity.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Minutes</u></font>. Promptly following each meeting of a JSC, Entera will prepare and circulate draft meeting minutes to each member of the JSC. The meeting minutes shall set forth, among other
        things, a description, in reasonable detail, of the discussions at the meeting. Such meeting minutes shall be effective only after being approved by both Parties (email is acceptable), and failure to object to proposed draft meeting minutes within
        ten days after receiving the same is deemed acceptance of the same.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">3.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Subcommittees</u></font>. From time to time a JSC may create subcommittees (e.g., joint development committee, joint manufacturing committee, joint commercialization committee) as the JSC sees appropriate. Any
        such subcommittees may be delegated responsibilities that would otherwise fall within the JSC&#8217;s purview.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">3.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Alliance Managers</u></font>. Promptly following the Effective Date, each Party will appoint one or more of its qualified employees to act as its alliance manager hereunder for each of the development programs
        (each, an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Alliance Manager</font>&#8221;). Alliance Managers are intended to act as a point of contact between the Parties, and may attend and participate (but
        not vote) in all JSC meetings.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">RESEARCH AND DEVELOPMENT ACTIVITIES<a name="RESEARCHANDDEVELOPMENTACT"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>General Overview and Initial Plans</u></font>. Entera and OPKO will collaborate with respect to the research and Development of a Collaboration Product in the Field under mutually agreed Development Plans. The
        portion of the Development Plans intending to cover Development Activities with respect to each Collaboration Product through completion of the Initial Study for each such Collaboration Product are attached hereto as <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Schedule 4.1 </font>(each, an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Initial Plan</font>&#8221;). Entera will be principally
        responsible for pre-clinical Development work through the completion of the Initial Studies. OPKO will be principally responsible for the subsequent Development work under the Oral Product Research and Development Plans as described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 4.2</u></font>. Subject to Applicable Law, during the Term, Entera will not (and will cause its Affiliates not to), either alone or with any Affiliates or Third
        Parties, Develop any Collaboration Product other than pursuant to the Development Plans, nor grant any right or license to any Third Party to conduct any of the foregoing activities other than the rights granted to OPKO under this Agreement.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">16</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Oral Product Research and Development Plans</u></font>. The Parties, through the JSC, intend to agree upon an update to the Development Plans as soon as reasonably practical, with this updated portion covering
        the further development of the Collaboration Products in the Field beyond the Initial Studies (such updated portions, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Oral Product Research and
          Development Plans</font>&#8221;). The Oral Product Research and Development Plans are intended to cover Development Activities subsequent to the Initial Studies. After completion of the Initial Studies, OPKO (or its Affiliates or designees) shall be
        responsible for: (i) the Development and (except as otherwise set forth herein) Manufacturing of Collaboration Products for the Field and (ii) the Commercialization activities related to Collaboration Products in the Field.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Performance</u></font>. Each Party will perform the activities allocated to it under the Development Plans (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Development Activities</font>&#8221;) (which includes the activities that Entera is principally responsible for in the &#8220;Initial Plan&#8221; portion of the Development Plans and the activities that OPKO is principally responsible for in the &#8220;Oral
        Product Research and Development Plan&#8221; portion of the Development Plans), in a professional and timely manner, in compliance with Applicable Laws and in accordance with the terms and conditions set forth herein. Each Party will use Commercially
        Reasonable Efforts to achieve the objectives of Development Activities allocated to such Party.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Updates to the Development Plans</u></font>. The Initial Plans and the Oral Product Research and Development Plans may be updated from time to time by the relevant JSC, subject to the limitations on
        final decision-making authority set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 3.1(d)</u></font>. If a JSC is disbanded, then the applicable Oral Product Research and Development Plan may be
        updated by OPKO subject to the same limitations on final decision-making authority as those applicable to the JSC.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Regulatory Matters</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Regulatory Filings</u></font>. The Parties will collaborate on preparing all regulatory filings for the Collaboration Products in the Territory with Entera being responsible for preparing the
        initial drafts of such regulatory documentation and regulatory filings in accordance with the Development Plans. As between the Parties, OPKO (or its Affiliates or designees) shall own the regulatory filings and Marketing Approvals (including
        applications therefore) relating to all Collaboration Products in the Field, and all right, title and interest therein, and shall have the sole right to file any Marketing Approval application or other regulatory filing with respect to
        Collaboration Products in the Field. The Parties will cooperate with and provide to each other Party such assistance as may be requested in connection with the preparation or prosecution of any regulatory filings relating to a Collaboration
        Product, including by executing any required documents, providing access to personnel, and providing the other Party with copies of all reasonably required documentation. All regulatory documentation and regulatory filings for a Collaboration
        Product shall (i) constitute Confidential Information of Entera to the extent relating to the Entera Platform, and (ii) constitute Confidential Information of OPKO to the extent relating to the peptide(s) that are Controlled by OPKO (including any
        subcutaneous version of such peptide(s)).</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">17</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Communication with Regulatory Authorities</u></font>. Entera may provide comments regarding regulatory filings and other correspondence with respect to a Collaboration Product prior to OPKO&#8217;s
        submission, which comments OPKO will consider in good faith prior to submission, provided that such consideration would not unreasonably delay the submission. OPKO will provide Entera with copies of all submissions it makes to, and all material
        correspondence it receives from, a Regulatory Authority pertaining to any regulatory approval or Marketing Approval of a Collaboration Product. To the extent reasonably practicable (including due to timing constraints), appropriate, and permitted
        under Applicable Law, Entera will be provided a reasonable opportunity attend portions of any meeting with a Regulatory Authority pertaining to any regulatory approval or Marketing Approval of a Collaboration Product to the extent the same would
        reasonably be expected to affect Entera&#8217;s own regulatory submission or the Entera Platform. For clarity, if a submission or regulatory approval with respect to a Collaboration Product also relates to a version of OPKO&#8217;s peptide(s) that is not an
        Oral Product, the rights of Entera under this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 4.3</u></font> shall be limited to submissions or regulatory approvals relating to such Oral Product version.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Right of Reference</u></font>. Each Party hereby grants to the other Party a non-exclusive license and right of reference, with the right to grant sublicenses and further rights of reference through
        multiple tiers, under all Marketing Approval and any other regulatory filings Controlled by the other Party with respect to a Collaboration Product as necessary or reasonably useful for a Party for submissions or correspondences with Regulatory
        Authorities with respect to (i) the Collaboration Product in the case of OPKO and (ii) the Entera Platform, in the case of Entera.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Development Costs</u></font>. The Development Plan will include an estimated budget of the Development Costs to be incurred by the Parties for their respective Development Activities (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Development Budget</font>&#8221;). Such budgets are subject to revisions by the relevant JSC and the final decision-making authority of a Party as described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 3.1(c)</u></font> and subject to the limitations contained in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 3.1(d)</u></font>.
        The costs incurred by the Parties under the Development Plan(s) with respect to the Oxyntomodulin Analog will be shared by the Parties 60% by OPKO and 40% by Entera and with respect to LA-PTH will be shared by the Parties equally, and, in each
        case, reconciled on a Calendar Quarterly basis as set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 7</u></font>. Prior to the Opt-Out, a Party may incur Development Costs greater than the
        Development Budget but will not be guaranteed reimbursement or cost-sharing except through an amendment of the Development Budget approved by the applicable JSC subject to the final decision-making authority of a Party as described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 3.1(c)</u></font> and the limitations contained in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 3.1(d)</u></font>.
        Notwithstanding the foregoing from and after the Opt-Out Date, Development Costs pertaining to the Oral Product subject to the Opt-Out (excluding for clarity, Development-related costs or expenses incurred pursuant to the terms of a sublicense
        agreement as set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.2</u></font>) shall be borne 100% by OPKO and 0% by Entera.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">18</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Subcontracting</u></font>. Each Party may engage its Third Party subcontractors (each, a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Subcontractor</font>&#8221;) or
        Affiliates to perform Development Activities hereunder (or in the case of OPKO, Commercialization activities); provided that Entera shall not engage any Subcontractor without the approval of the relevant JSC (and the final decision-making authority
        of a Party as described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 3.1(c)</u></font> and subject to the limitations contained in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 3.1(d)</u></font>). All Subcontractors who are involved in activities contemplated under this Agreement will execute agreements effectively assigning to the subcontracting Party all inventions made during the
        course of and as the result of their association with such Party, free from any lien or encumbrance, and obligating each such individual to maintain as confidential either Party&#8217;s Confidential Information as well as all confidential information of
        other parties that such subcontractor may receive in connection with the activities contemplated under this Agreement. Each Party is responsible for effectively and timely managing and paying its Subcontractors. The engagement of any Affiliate or
        Subcontractor in compliance with this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 4.5</u></font> shall not relieve a Party of its obligations under this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Recordkeeping</u></font>. Entera and OPKO shall maintain, and cause its Affiliates and Subcontractors to maintain, records of its Development Activities in sufficient detail and in good scientific manner
        appropriate for scientific, patent and regulatory purposes, which shall be complete and accurate in all material respects and shall fully and properly reflect all work done, data and developments made, deliverables generated, and other results
        achieved.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Reporting on Development Activities</u></font>. Each Party will provide periodic, high-level progress updates on its Development Activities, which updates will be provided to the applicable JSC members at least
        two (2) days in advance of any JSC meeting, and provide a brief presentation at each JSC meeting regarding Development progress made to date. The agenda for meetings of the JSC will be set by the applicable JSC representatives.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">COMMERCIALIZATION<a name="COMMERCIALIZATION"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Commercialization Through Sublicensee</u></font>. As of the Effective Date, it is the expectation of the Parties that OPKO will not directly Commercialize the Collaboration Product(s) in the Territory, but
        instead will grant to one or more sublicensees the right to Commercialize the Collaboration Product(s) in the Field in the Territory. The grant of such sublicenses by OPKO shall be subject to the provisions of <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.2(a)</u></font>. Without limiting the foregoing, each such sublicense agreement executed by OPKO must be consistent with the terms and conditions of this Agreement and OPKO shall use
        good-faith efforts to include customary commitments from the sublicensee with respect to the Commercialization of the Collaboration Product(s) in the Field in the Territory, including with respect to diligence, reporting of activities, and payment
        terms. Unless otherwise agreed by the Parties, and without limiting the foregoing, each such sublicense will be subject to the terms and conditions of this Agreement concerning prosecution and maintenance of Marketing Approvals, prosecution,
        maintenance and enforcement of intellectual property, and confidentiality, and such sublicensee will be a third-party beneficiary of such terms and conditions of this Agreement. Subject to Applicable Law, during the Term, Entera will not (and will
        cause its Affiliates not to), either alone or with any Affiliates or Third Parties, Commercialize any Collaboration Product nor grant any right or license to any Third Party to conduct any of the foregoing activities other than the rights granted
        to OPKO under this Agreement.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">19</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Direct Commercialization by OPKO</u></font>. In the event that OPKO determines to directly Commercialize a Collaboration Product(s) in one or more jurisdictions in the Territory (excluding, for clarity,
        Commercialization through a sublicensee), then OPKO shall so notify Entera, and OPKO and Entera will promptly negotiate in good faith the terms on which OPKO would directly Commercialize such Collaboration Product(s) in the Territory, including
        with respect to diligence, governance matters, calculation of net sales, royalty reporting, royalty term, royalty reductions, royalty offsets for third-party intellectual property licenses, sales milestones, use of trademarks, responsibility for
        Pricing Matters, and obligations with respect to recalls, suspensions, and product withdrawals (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Commercialization Terms</font>&#8221;). The
        royalties and milestones included in the Commercialization Terms shall be calculated in a manner to reflect the relative contributions of the Parties to the Development and Commercialization of such Collaboration Product as of such date and should
        be based on objective factors as of such date, such as financial terms in transactions involving comparable products at a similar stage of development or in a similar stage of product life, scientific, technical and commercial factors, and the
        competitiveness of the marketplace, and (where applicable) will be consistent with the corresponding provisions and definitions in this Agreement. In the event that the Parties are unable to agree on the Commercialization Terms within one hundred
        twenty (120) days after the date on which OPKO notifies Entera of its determination to directly Commercialize a Collaboration Product(s), the Parties shall resolve such matter by binding, baseball-style arbitration as set forth on <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Schedule 5.2</font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">MANUFACTURING<a name="MANUFACTURING"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">6.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Manufacturing Activities</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Under the Initial Plan</u></font>. OPKO will be responsible for the Manufacture and supply of the active ingredients for Collaboration Products for use in Development Activities under the Initial
        Plans, and Entera will be responsible for the Manufacture and supply of Collaboration Products in drug product form for use in Development Activities under the Initial Plans.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Under the Oral Product Research and Development Plan</u></font>. Unless otherwise agreed by the Parties (e.g., as set forth in the applicable Development Plan), for any quantities of Collaboration
        Product to be used for subsequent Development Activities under an Oral Product Research and Development Plan or for Commercialization, and subject to the successful completion of the Manufacturing technology transfer described below, OPKO will be
        responsible for the Manufacture of Collaboration Product (in both drug substance and drug product form).</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">6.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Allocation of Manufacturing Costs</u></font>. All Manufacturing Costs incurred during the Term in regard to a Collaboration Product in the Field will be included in either Development Costs (and therefore
        allocated between the Parties in accordance with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 4.3</u></font> (Development Costs)) or Commercialization Costs (and therefore allocated between the Parties via
        their inclusion in Proceeds in accordance with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.3</u></font> (Proceeds)), as applicable.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">6.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Manufacturing Technology Transfer</u></font>. The Parties will enter into separate manufacturing technology transfer agreements (each a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Manufacturing Technology Transfer Plan</font>&#8221;) setting forth the terms and conditions under which (a) Entera will transfer, or cause its Third-Party CMOs to transfer, to OPKO all documents and information, and provide
        technical assistance and support, necessary or reasonably useful for OPKO to Manufacture or have manufactured by Third-Party CMOs engaged by OPKO a Collaboration Product and (b) OPKO will transfer, or cause its Third-Party CMOs to transfer, to
        Entera all documents and information, and provide technical assistance and support, to the extent necessary or reasonably useful with respect to the active ingredient for the Collaboration Product for Entera to Manufacture or have manufactured by
        Third-Party CMOs engaged by Entera a Collaboration Product. Following successful completion of the technology transfers as defined in a Manufacturing Technology Transfer Plan and completion of the Initial Studies, unless otherwise agreed by the
        Parties (e.g., as set forth in the Development Plan), OPKO will have the sole right and obligation to supply Collaboration Product for its use under this Agreement.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">20</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">FINANCIAL TERMS<a name="FINANCIALTERMS"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">7.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Invoicing and Payment of Development Costs</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Invoicing of Development Costs</u></font>. Except as otherwise agreed by the Parties with respect to certain Manufacturing Costs owed to a Third-Party CMO as described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.1(c)</u></font>, no later than forty-five (45) days after the end of each Calendar Quarter during which a Party (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Invoicing Party</font>&#8221;) has incurred any Development Costs that are in whole or in part the responsibility of the other Party under this Agreement (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Responsible Party</font>&#8221;), the Invoicing Party shall submit to the Responsible Party an invoice setting forth the amounts (or the portion of such amounts, as applicable) for which the Responsible Party
        is responsible, accompanied with reasonable supporting explanation for such invoiced amounts. The Responsible Party will issue a separate invoice for the Development Costs of each Collaboration Product. The Responsible Party will pay all undisputed
        amounts invoiced within forty-five (45) days of receipt of such invoice. Any adjustments with respect to any previously submitted invoice by the Invoicing Party will be reflected in the next invoice delivered by the Invoicing Party to the
        Responsible Party, such adjustments to be made in a manner consistent with the Invoicing Party&#8217;s Accounting Standards. At the end of each Calendar Quarter, or as otherwise agreed by a JSC, each Party will submit to the JSC a report setting forth
        the status of the Development Costs incurred by the Party in respect of its Development Activities in comparison to the related budget for such Development Activities as set forth in the Development Budget.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Right to Effect an Opt-Out for Failure to Pay Development Costs</u></font>. At any time during the Term, if Entera fails to timely pay the full amount of any undisputed invoice for Development Costs
        with respect to a Collaboration Product delivered by OPKO in accordance with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.1</u></font> and fails to pay such invoice within sixty (60) days from the due
        date of such invoice (including any interest borne in accordance with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.6(c)</u></font>), then at OPKO&#8217;s option and upon OPKO&#8217;s written request, OPKO may cause
        Entera to exercise the Opt-Out with respect to such Collaboration Product. If OPKO elects to cause Entera to exercise the Opt-Out, then OPKO cannot use such failure to pay an invoice for Development Costs and subsequent Opt-Out as the sole basis to
        claim a material breach of this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Pass Through for Manufacturing Costs</u></font>. For Manufacturing Costs that constitute shared Development Costs under <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section
            6.2</u></font>, the Party initially incurring such costs under an agreement with a Third-Party CMO in accordance with the applicable Development Plan (subject to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section
            4.4</u></font>) may elect to have the other Party reimburse the incurring Party&#8217;s applicable share of such Development Costs using the process set forth in this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section
            7.1(c)</u></font> in lieu of utilizing the quarterly invoicing process set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.1(a)</u></font>. With respect to amounts paid by a Party under any
        Third-Party CMO agreement with any Third-Party CMO performing Manufacturing activities for a Collaboration Product (whether in drug product or drug substance form) on behalf of such Party under <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 6.1</u></font> or <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 6.2</u></font>, the Party incurring such costs may invoice the other Party its respective share as
        Development Costs. Notwithstanding anything set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.1(a)</u></font> to the contrary, the payor Party shall pay the portion of such invoice for which it is
        responsible within the time period set forth on the invoice, which payment terms shall be agreed by the Parties prior to the payee Party entering into the applicable Third-Party CMO agreement, and may require payment of such invoices by the payor
        Party before corresponding invoices are due and payable to the Third-Party CMO by the payee Party.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">21</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">7.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Entera Ordinary Shares</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Standstill</u></font>. OPKO Health agrees that, until March 16, 2027 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Standstill Period</font>&#8221;),
        without the prior written consent of the Board of Directors of the Entera (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Board</font>&#8221;) or a duly constituted committee thereof, neither OPKO
        Health nor any of its Affiliates shall, and OPKO Health shall cause its and their respective representatives not to, directly or indirectly, in any manner:</font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt; margin-left: 45pt; text-align: justify;"> (i)&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; acquire, agree to acquire or offer, seek or propose to acquire (by purchase, tender or exchange offer or otherwise) any direct or indirect beneficial, constructive
      or synthetic interest in any Entera Ordinary Shares or other voting equity interests in Entera (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Company Interests</font>&#8221;); </div>
    <div>
      <div> <br>
      </div>
      <div style="margin-left: 45pt; text-indent: 72pt; text-align: justify;"> (ii)&#160;&#160;&#160;&#160;&#160;&#160; &#160; (A) make, engage in, or in any way participate in any &#8220;solicitation&#8221; of &#8220;proxies&#8221; (as such terms are used in the rules of the Securities and Exchange Commission
        promulgated under Section 14 of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Exchange Act</font>&#8221;), including any communication exempt from the
        definition of &#8220;solicitation&#8221; pursuant to Rule 14a-1(l)(2)(iv) promulgated under the Exchange Act and irrespective of whether any such solicitation of proxies or consents constitutes an exempt solicitation pursuant to Rule 14a-2 promulgated under
        the Exchange Act) with respect to any Company Interests or seek the consent of any Person with respect to any Company Interests, (B) call or seek to call a meeting of Entera&#8217;s shareholders or otherwise seek to influence the timing of any meeting of
        Entera&#8217;s shareholders, (C) submit, initiate, participate in or encourage the submission of any proposal for action by the shareholders of Entera, (D) seek the removal of any member of the Board or otherwise seek representation on the Board in any
        manner, (E) seek to advise or influence in any manner whatsoever any Person with respect to the voting of any Company Interests or (F) otherwise seek to control, change or influence the management, Board (or other similar governing body), governing
        documents, policies or affairs of Entera or any of its affiliates;</div>
      <div> <br>
      </div>
      <div style="margin-left: 45pt; text-indent: 72pt; text-align: justify;"> (iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; form, join or in any way participate in a &#8220;group&#8221; (within the meaning of Section 13(d)(3) of the Exchange Act) or otherwise act in concert with any other Person
        with respect to any Company Interests or any of the matters set forth in this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.2(a)</u></font>;</div>
      <div> <br>
      </div>
    </div>
    <div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">22</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div>
      <div> <br>
      </div>
      <div style="margin-left: 45pt;">
        <div style="text-indent: 72pt; text-align: justify;">(iv)&#160;&#160;&#160;&#160; &#160;&#160; &#160; advise, assist, knowingly encourage or knowingly facilitate any other Person to take any actions which, if taken by OPKO Health, would be prohibited by this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.2(a)</u></font>; or</div>
        <div><br>
        </div>
        <div style="text-indent: 72pt; text-align: justify;">(v)&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; publicly disclose any intention, plan or arrangement inconsistent with the foregoing.</div>
        <br>
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Notwithstanding the foregoing, Dr. Phillip Frost, M.D., or any trust controlled by him, may acquire up to two percent (2%) of the
      outstanding Entera Ordinary Shares.</div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Lockup</u></font>. Until March 16, 2026 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Lock-Up Period</font>&#8221;), OPKO Health shall not (and shall
        cause its Affiliates that hold Entera Ordinary Shares), without the prior written consent of Entera, directly or indirectly, (i) offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of, or announce the intention to
        otherwise dispose of, any Entera Ordinary Shares or securities convertible into or exercisable or exchangeable for Entera Ordinary Shares; (ii) enter into any swap, hedge or similar agreement or arrangement that transfers in whole or in part, the
        economic risk of ownership of Entera Ordinary Shares or securities convertible into or exercisable or exchangeable for Entera Ordinary Shares, whether now owned or hereafter acquired by OPKO Health (or its Affiliates) or with respect to which OPKO
        Health (or such Affiliate) has or hereafter acquires the power of disposition, or (iii) engage in any short selling of any Entera Ordinary Shares or securities convertible into or exercisable or exchangeable for Entera Ordinary Shares.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Removal of Restrictive Legend</u></font>. Following the Lock-Up Period, certificates (or evidence of book entry position) evidencing the 3,685,226 Entera Ordinary Shares purchased by OPKO in March
        2025 (the &#8220;Purchased Shares&#8221;) and held by a non-Affiliate of Entera shall not contain any restrictive legend, (i) following any sale of such Purchased Shares pursuant to Rule 144, or (ii) if such Purchased Shares are eligible for sale in accordance
        with Rule 144 without restriction under such rule and the requesting shareholder is not an Affiliate of Entera. Entera shall cause its counsel to issue a legal opinion to Entera&#8217;s transfer agent reasonably promptly if required by such transfer
        agent to effect the removal of the legend hereunder or if requested by OPKO Health (or its Affiliate).</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Purchase Price Escrow</u></font>. OPKO and Entera have entered into that certain Escrow Agreement, dated April 8, 2025, with U.S. Bank National Association, as escrow agent (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Escrow Agreement</font>&#8221;), pursuant to which the $8,000,000 paid to Entera for the Purchased Shares (the &#8220;Purchase Price&#8221;) was placed into the escrow account
        established under the Escrow Agreement. Upon the termination or expiration of this Agreement for any reason, if any funds remain in the escrow established pursuant to the Escrow Agreement, such funds will be released to Entera, and, on or prior to
        the third (3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup>) Business Day immediately following such termination or expiration, OPKO (or its designated Affiliate party to the Escrow Agreement, as applicable) and Entera shall deliver a joint written instruction to the escrow agent
        under the Escrow Agreement, directing such escrow agent to immediately release all such funds to Entera, without any deduction or withholding.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">23</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">7.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Proceeds</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Share of Proceeds</u></font>. Subject to the terms and conditions of this Agreement, during the Term but prior to the Opt-Out Date for a Collaboration Product, OPKO and Entera shall share Proceeds
        for such Collaboration Product, with the following allocation: with respect to an Oxyntomodulin Analog product, 60% for OPKO and 40% for Entera and, with respect to an LA-PTH product, equally. Following the Opt-Out Date and for the remainder of the
        Term (if any), OPKO and Entera shall share Proceeds for such Collaboration Product subject to the Opt-Out, with the following allocation: 85% for OPKO and 15% for Entera.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Calculation and Payment</u></font>.</font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Within forty-five (45) days after the end of each Calendar Quarter beginning with the Calendar Quarter in which Proceeds are first incurred or
      accrued, OPKO will provide Entera a report setting forth the Proceeds (including for example Sublicense Income and Manufacturing Costs for Commercialization, and whether Proceeds for such Calendar Quarter are positive or negative) for such Calendar
      Quarter; provided, that if there are any components of Proceeds in such Calendar Quarter that OPKO is unable to timely include in such quarterly report, then such amount shall be included and reconciled in the financial report in the following
      Calendar Quarter.</div>
    <div>
      <div> <br>
      </div>
      <div style="text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Within forty-five (45) days after receipt of such reports, designated individuals from each Party (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Finance Leads</font>&#8221;) shall confer and agree in writing on whether a reconciliation payment is due from one Party to the other Party, and if so, the amount of such reconciliation payment, so that the
        Parties share Proceeds in accordance with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.3(a)</u></font>. The Party to which a reconciliation payment is due shall send an invoice to the other Party once the
        Finance Leads have agreed on any such amount due, and the Party required to pay such reconciliation payment shall make such payment to the other Party within forty-five (45) days after receipt of such invoice; provided, however, that in the event
        of any disagreement with respect to the calculation of such reconciliation payment, any undisputed portion of such reconciliation payment shall be paid in accordance with the foregoing timetable and the Parties will use good faith efforts to
        resolve the dispute. Any such dispute that has not been resolved within ten (10) Business Days after the initiation of discussions regarding the disputed amounts shall be referred to designated financial officers of each Party to attempt to resolve
        such matter good faith. If such financial officers cannot resolve such matter within ten (10) Business Days after the date on which the matter is referred to them (unless a longer period is agreed to by the Parties), then the dispute shall be
        resolved in accordance with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 14.10</u></font>. For the avoidance of doubt, Proceeds shall be recorded, maintained, and calculated in accordance with Accounting
        Standards. Excluding reconciliation of any Shared Program Damages or Shared Program Recoveries, the final reconciliation of all Proceeds (positive or negative) will occur no later than six (6) months after the expiration of the Term.</div>
      <div> <br>
      </div>
    </div>
    <div>
      <div style="text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the foregoing, and solely in relation to Proceeds incurred or accrued or deemed to be incurred or accrued (e.g., pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 8.1(b)</u></font>) following the Opt-Out Date, and except with respect to the final reconciliation payment, if Proceeds for a Calendar Quarter are less than zero
        dollars ($0), no reconciliation payment will be owed from Entera to OPKO for that Calendar Quarter. Rather, any costs or expenses incurred or accrued in a Calendar Quarter which OPKO is not able to recover due to the application of the previous
        sentence will be carried forward to future Calendar Quarters if not fully taken in such Calendar Quarter until the amount of such reduction has been fully applied against payments due to Entera. If there is a negative Proceed balance at the end of
        the Term, Entera will pay OPKO such balance within ninety (90) days following the effective date of expiration or termination.</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">24</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">7.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Recordkeeping and Audit</u></font>. Upon reasonable prior notice by a Party, the other Party will allow the first Party or a certified public accountant engaged by such Party and reasonably acceptable to the
        other Party (and subject to customary confidentiality obligations) to conduct during normal business hours an audit and inspection of the books and records of such Party to confirm compliance with the reporting and charging of Development Costs and
        Proceeds (as applicable). Any such audit will be reasonable in duration and scope. Each Party will bear its own costs of any such audit unless an audit reveals an overpayment or underpayment in excess of five percent (5%) of the amount that was
        owed, in which case underpaying Party will reimburse the out-of-pocket expenses incurred by the other Party in conducting such audit. If any such audit reveals an underpayment, the applicable Party will promptly correct such underpayment. Following
        the Opt-Out Date as outlined in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 8</u></font> each Party will be relieved of its obligations under this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.4</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">7.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Withholding Taxes</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Where any sum due to be paid
        to either Party hereunder is subject to any withholding or similar tax, the Parties shall use Commercially Reasonable Efforts to conduct all such acts (including the execution of all such documents) to enable them to take advantage of any
        applicable double taxation agreement or treaty. If withholding or similar taxes are paid to a government authority, each Party will provide the other such assistance as is reasonably required to obtain a refund of the withheld or similar taxes, or
        to obtain a credit with respect to such taxes paid.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">If required by Applicable
        Law, OPKO shall be entitled to deduct the amount of any U.S. withholding taxes from any payment due to Entera under this Agreement. OPKO shall pay the amount of such taxes to the appropriate governmental authority and deliver to Entera proof of
        payment of all such taxes. To the extent Entera provides OPKO with a valid withholding certificate issued by the Israel Tax Authority with respect to such payment, OPKO shall not withhold amounts in excess of the rate or amount provided for in such
        withholding certificate.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">If required by Applicable
        Law, Entera shall be entitled to deduct the amount of any Israeli withholding taxes from any payment due to OPKO under this Agreement. Entera shall pay the amount of such taxes to the appropriate governmental authority and deliver to OPKO proof of
        payment of all such taxes. To the extent OPKO provides Entera with a valid withholding certificate issued by the Israel Tax Authority with respect to any such payment, Entera shall not withhold amounts in excess of the rate or amount provided for
        in such withholding certificate.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">All payments under this
        Agreement are exclusive of VAT, which will be added at the applicable rate required by law, against a valid tax invoice, including an allocation number from the Israeli Tax Authority as required by the Israeli Value-Added Tax Law, 1975.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">25</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">7.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Payment Method</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Manner and Currency</u></font>. Unless otherwise stated, undisputed invoiced amounts are due within forty-five (45) days following the paying Party&#8217;s receipt of the applicable invoice. All payments
        due under this Agreement to Entera shall be made by electronic funds transfer in immediately available funds to an account agreed by the Parties. All payments hereunder shall be made in U.S. Dollars. Conversion of sales recorded in local currencies
        to U.S. Dollars shall be performed in a manner consistent with the invoicing Party&#8217;s normal practices in accordance with the Accounting Standards.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Payment Disputes</u></font>. This <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.6(b)</u></font> applies to payment disputes other than those with respect
        to Proceeds, which are instead covered by <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.3</u></font> above. If a Party reasonably and in good faith disputes any invoice (or portion thereof) submitted by
        the other Party, then the disputing Party shall notify the invoicing Party in writing of such dispute on or before the due date for the relevant invoice, and the disputing Party shall only be obligated to pay to the invoicing Party the undisputed
        portion of such invoice. A written notice of dispute may also include a request for any additional information or supporting documentation that the disputing Party reasonably and in good faith believes is necessary to determine whether it is
        responsible for the invoiced amounts. The invoicing Party shall reasonably and in good faith respond to such request in writing within thirty (30) days of receipt thereof with the requested information and documentation or an explanation as to why
        such requested information and documentation is not available. The Parties will use good faith efforts to resolve any such dispute in a timely manner.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Interest on Late Payments</u></font>. Any late payment of an undisputed, invoiced amount hereunder will bear interest, to the extent not prohibited by Applicable Law, at an annual rate of two
        percent (2%) above the prime rate set by the Wall Street Journal on the date payment was due or the highest rate permitted by Applicable Law (whichever is lower), compounded annually and computed from the date such payment was due until the date
        the payment is made.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">7.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>No Projections</u></font>. Entera and OPKO acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of anticipated sales of any product. OPKO MAKES NO
        REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">7.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Right of Set-Off</u></font>. Without limiting any other rights of a Party under this Agreement or otherwise, each Party shall have the right, but not the obligation, to set off, in whole or in part, against any
        obligation or payment it owes to the other Party under this Agreement, any or all damages, liabilities, indemnified amounts, or other payments owed to such offsetting Party by the other Party under this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">7.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Third Party Obligations</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Notwithstanding the other
        provisions of this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 7</u></font> or <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 8</u></font>, Entera shall remain
        responsible for the payment of royalty, milestone and other payment obligations, if any, due to Third Parties with respect to any Patents or Know-How that have been licensed to Entera and are sublicensed to OPKO under this Agreement. All such
        payments shall be made promptly by Entera in accordance with the terms of its agreement with such Third Parties, and shall not be included in Development Costs or Proceeds hereunder.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">26</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Without limitation of <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.9(a)</u></font>, if either Party reasonably determines that rights to any Patent, Know-How, or other intellectual property Controlled by a Third Party are necessary
        or reasonably useful in order to Development, Manufacture, or Commercialize a Collaboration Product in the Field (in addition to the scope of the exclusive license in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section
            2.1</u></font>), the relevant JSC shall determine which Party shall have the right to negotiate and acquire such rights through a license or otherwise (including pursuant to any settlement agreement). The Party obtaining such rights may deduct,
        from amounts owed to the other Party hereunder as part of Proceeds, any amounts payable and actually paid to a Third Party pursuant to any such Third Party license or otherwise. Such amounts payable to such Third Party shall not be included in
        Development Costs or otherwise included in Proceeds hereunder.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">ENTERA OPT-OUT<a name="ENTERAOPT-OUT"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">8.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Entera Opt-Out</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Opt-Out Process</u></font>. At any time following completion of an Initial Study but prior to ninety (90) days before OPKO&#8217;s first patient dosed in a subsequent Clinical Trial with respect to a
        Collaboration Product, Entera may upon written notice to OPKO (an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Opt-Out Notice</font>&#8221;) elect to no longer participate in the sharing of costs with
        respect to further Development, Commercialization, and Manufacture of such Collaboration Product (such election, an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Opt-Out</font>&#8221;). Subject to the
        effects of the Opt-Out below, OPKO will continue the Development, Commercialization, and Manufacture of such Collaboration Product at its sole cost, will control all Development, Commercialization, and Manufacture decisions.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Opt-Out Date</u></font>. The effective date of an Opt-Out (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Opt-Out Date</font>&#8221;) shall be the date of
        OPKO&#8217;s receipt of an Opt-Out Notice, unless otherwise mutually agreed upon by the Parties. Costs and expenses incurred from and after the Opt-Out Date will no longer be subject to the relevant cost-sharing arrangements set forth herein. Following
        the applicable Opt-Out Date, OPKO and Entera shall share Proceeds with respect to the relevant Collaboration Product with the following allocation: 85% for OPKO and 15% for Entera, and revenue received from and after the Opt-Out Date will otherwise
        be retained by OPKO to the extent OPKO elects to directly Commercialize such Collaboration Product(s), subject to its payment obligations as set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 8.5</u></font>.
        Any costs or expenses committed as of the Opt-Out Date and not cancellable by OPKO without penalty will be deemed to have been incurred prior to the Opt-Out Date.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">8.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Effects of the Opt-Out</u></font>. Upon an Opt-Out Date: (a) each Party shall be relieved of its obligations pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.4</u></font>
        with respect to the relevant Collaboration Product, it being understood that the exclusive license granted by Entera to OPKO to research, Develop, Manufacture, and Commercialize Oral Products in the Field shall remain in effect; (b) OPKO will use
        Commercially Reasonable Efforts to Develop such Collaboration Product in the Field as described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 8.3</u></font> and to Commercialize such Collaboration Product
        in the Field in accordance with the terms to be agreed upon pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 5</u></font>; and (c) the reporting obligations of OPKO will be revised as set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 8.4</u></font> below.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">27</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">8.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Development Diligence Post Opt-Out</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Generally</u></font>. From and after the Opt-Out Date, subject to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 8.3(b)</u></font>, OPKO shall use
        Commercially Reasonable Efforts, itself or through its Affiliate(s), (sub)licensee(s) or subcontractor(s), to obtain Marketing Approval for at least one such Collaboration Product in each Major Market Country. For the avoidance of doubt, subject to
        the foregoing, OPKO shall have the sole decision-making authority with respect to such Collaboration Product from and after completion of the relevant Initial Study.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Exception to Diligence Obligation for Safety Concern</u></font>. Notwithstanding any provisions of this Agreement to the contrary, in the event of a Material Safety Issue with respect to a
        Collaboration Product, OPKO shall notify Entera and discuss. OPKO may take any and all actions it deems necessary or appropriate in its sole discretion to appropriately address such Material Safety Issue, including putting on temporary hold or
        ceasing Development of the affected Collaboration Product, or terminating this Agreement in its entirety. In such event, OPKO shall not be in breach of this Agreement or any obligation hereunder as a result of OPKO taking such actions so long as
        OPKO is using Commercially Reasonable Efforts to address and, to the extent practicable, remedy the Material Safety Issue in order to permit continued Development. If a Material Safety Issue is reasonably likely to not be resolved, or is not
        actually resolved, within twelve (12) months following the date on which the Material Safety Issue is identified, then unless otherwise mutually agreed by the Parties, this Agreement shall terminate in accordance with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 13.2(e)</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">8.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Reports Post Opt-Out</u></font>. If Entera exercises an Opt-Out, then this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 8.4</u></font> will apply from and after the
        Opt-Out Date in lieu of the Development Plan and other Development- and Commercialization-related reporting obligations with respect to the relevant Collaboration Product (e.g., in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 4.7</u></font> (Reporting on Development Activities (i.e., providing detailed progress updates on Development Activities and summary of data associated with such Development Activities to the JSC); <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.1</u></font> (Invoicing of Development Costs))). For so long as Development activities are being performed by OPKO (and not by a sublicensee pursuant to a
        sublicense agreement described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 5.1</u></font>) with respect to the Collaboration Products, not required more than once during each Calendar Year, OPKO will
        provide to Entera a high-level written progress report on the status of its material Development activities with respect to the Collaboration Products in Major Market Countries during the applicable Calendar Year, and OPKO&#8217;s high-level plans with
        respect to such Development of the Collaboration Products in Major Market Countries during the following Calendar Year. Any reporting obligations with respect to Commercialization activities from and after the Opt-Out Date:</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">applicable to an OPKO
        sublicensee shall be as set forth in the applicable sublicense agreement (subject to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 5.1</u></font>); and (b) applicable to OPKO (e.g., should OPKO decide to not
        sublicense the Commercialization of the Collaboration Products) shall be as agreed by the Parties as described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 5.2</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">8.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Additional Financials for OPKO Direct Commercialization Activities</u></font>. At least ninety (90) days prior to the First Commercial Sale of a Collaboration Product, OPKO and Entera shall amend this Agreement
        to include additional economic terms as consideration for the exclusive license granted to OPKO in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 2.1(a)</u></font>, as further described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 5.2</u></font>.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">28</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">INTELLECTUAL PROPERTY<a name="INTELLECTUALPROPERTY"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">9.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Ownership of Intellectual Property</u></font>.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Background IP</u></font>. Each Party shall solely own its Background IP (i.e., OPKO Background IP and Entera Background IP) and all right, title and interest therein (subject to any licenses granted
        hereunder).</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Information and Inventions</u></font>. Entera will solely own all Entera Information and Inventions. OPKO will solely own all OPKO Information and Inventions. Entera and OPKO will each own an equal,
        undivided interest in all Joint Information and Inventions. Each Party shall promptly disclose to the other Party in writing, and shall cause its Affiliates, licensees and sublicensees to so disclose, the development, making, conception or
        reduction to practice of any Joint Information and Inventions. Subject to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 2</u></font>, each Party has the right to exploit and grant licenses to any Third Party
        under such Joint Information and Inventions without the consent of, or accounting to, the other Party.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Inventorship</u></font>. Inventorship shall be determined in accordance with the rules of the United States patent law and other Applicable Law in the United States, regardless of where such
        conception, reduction to practice, discovery, development or making occurs.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Cooperation</u></font>. Each Party shall execute such documents and perform such other acts, at its cost and expense, as the other Party may reasonably request to obtain and perfect the assignment
        of the rights set forth in this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 9.1</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">9.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Prosecution, Maintenance, and Defense</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Generally</u></font>. Subject to the provisions of this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 9.2</u></font>, as between the Parties, each Party has
        the sole right (but not the obligation), at its expense, to Prosecute all Patents within such Party&#8217;s Background IP. For clarity, and except as set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section
            9.2(d)</u></font> with respect to Joint Patents or to the extent such costs are included in the calculation of &#8220;Proceeds&#8221; as set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 1</u></font> above,
        each Party is solely responsible for all of its costs incurred in connection with its Prosecution of a Patent, and such costs shall not constitute &#8220;Development Costs,&#8221; &#8220;Manufacturing Costs,&#8221; or &#8220;Commercialization Costs,&#8221; nor be shared between the
        Parties except to the extent the same fall into the deductions contained in the &#8220;Proceeds&#8221; definition in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 1</u></font>. The Parties shall modify <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 9</u></font> as may be reasonably required by a potential sublicensee of the Collaboration Product to allow for such sublicensee to control the Prosecution or
        enforcement of OPKO Technology, Joint Patents, or Entera Licensed Technology on a basis that is different from the Prosecution and enforcement rights under this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>OPKO Patents</u></font>. As between the Parties, OPKO has the sole right (but not the obligation), at its expense, to Prosecute all Patents within the OPKO Technology in its sole discretion,
        provided that OPKO will keep Entera reasonably informed (at OPKO&#8217;s discretion and no more than on a Calendar Quarterly basis and in the form provided by OPKO and approved by the JSC) of all material developments to the extent relating to the
        Collaboration Products or the Entera Platform in connection with any such matters.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">29</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Entera Patents</u></font>. As between the Parties, Entera has the first right (but not the obligation), at its expense, to Prosecute all Patents within the Entera Licensed Technology, provided that
        Entera will: (i) keep OPKO reasonably informed of all material developments in connection with any such matters; and (ii) reasonably and in good faith consider OPKO&#8217;s comments with respect thereto. On a country-by-country basis, Entera will provide
        OPKO written notice of its election to not file patent applications claiming Entera Licensed Technology or to cease Prosecution of Patents within the Entera Licensed Technology at least forty-five (45) days prior to any filing or payment due date,
        or any other due date that requires action. Unless Entera has Good Reason to not make such filings or to not continue such Prosecution of such Patents (or to not allow OPKO to do the same), OPKO may (on a country-by-country basis) file such
        abandoned patent applications or continue Prosecution of such Patents using counsel of its choice and at its own expense.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Joint Patents</u></font>. As between the Parties, OPKO has the first right (but not the obligation) to Prosecute all Joint Patents. Entera will use commercially reasonable efforts to provide OPKO
        with full support in such Prosecution of such Patents. OPKO will (i) keep Entera reasonably informed of all material developments in connection with any such matters;</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; reasonably and in good faith consider Entera&#8217;s comments with respect thereto; and (iii) if using outside counsel, use outside counsel reasonably
      acceptable to Entera. On a country-by-country basis, OPKO will provide Entera written notice of its election to not file patent applications claiming Joint Information and Inventions or to cease Prosecution of Joint Patents at least forty-five (45)
      days prior to any filing or payment due date, or any other due date that requires action. Unless OPKO has Good Reason to not make such filings or to not continue such Prosecution of such Patents (or to not allow Entera to do the same), Entera may (on
      a country-by-country basis) file such abandoned patent applications or continue Prosecution of such Joint Patents using counsel of its choice and at its own expense. Unless stated otherwise, the Parties will share the cost of any such activities of
      the Party having the first right to Prosecute a Joint Patents 50%/50% between OPKO and Entera. Entera will bear all of its own costs and expenses incurred in connection with its exercise of its &#8220;step-in&#8221; rights under this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 9.2(d)</u></font>. Entera may upon written notice elect to cease funding the Prosecution of one or more Joint Patents. From and after the date of such notice, each Patent so identified
      by Entera in such notice will no longer constitute a &#8220;Joint Patent&#8221; hereunder for purposes of determining any payment obligations of OPKO. </div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">9.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Enforcement</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>OPKO Patents</u></font>. As between the Parties, OPKO has the sole right (but not the obligation), at its expense, to enforce all Patents within the OPKO Technology in its sole discretion, provided
        that OPKO will keep Entera reasonably informed (at OPKO&#8217;s discretion and no more than on a Calendar Quarterly basis and in the form provided by OPKO and approved by the JSC) of all material developments to the extent relating to the Oral Products
        or Entera Platform in connection with any such enforcement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Entera Patents</u></font>. As between the Parties, Entera has the first right (but not the obligation), at its expense, to enforce all Patents within the Entera Licensed Technology, provided that
        Entera will: (I) keep OPKO reasonably informed of all material developments in connection with any such enforcement; and (II) reasonably and in good faith consider OPKO&#8217;s comments with respect thereto. On a country-by-country basis, Entera will
        provide OPKO written notice of any desire to not enforce any such Patents. Unless Entera has Good Reason to not enforce (or allow OPKO to enforce) such Patents, OPKO may (on a country-by-country basis) enforce such Patent(s) using counsel of its
        choice and at its own expense.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">30</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Joint Patents</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As between the Parties, OPKO has the first right (but not the obligation), at its expense, to enforce all Joint Patents that claims or covers a
      Collaboration Product or its use in the Field provided, provided that OPKO will (A) keep Entera reasonably informed of all material developments in connection with any such enforcement, and (B) reasonably and in good faith consider Entera&#8217;s comments
      with respect thereto. On a country-by-country basis, OPKO will provide Entera written notice of any desire to not enforce any such Joint Patent. Unless OPKO has Good Reason to not enforce (or allow Entera to enforce) such Patents, Entera may (on a
      country-by-country basis) enforce such Joint Patent using counsel of its choice and at its own expense.</div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As between the Parties, OPKO has the first right (but not the obligation), at its expense, to enforce all other Joint Patents, provided that
      OPKO will (A) keep Entera reasonably informed of all material developments in connection with any such enforcement, and (B) reasonably and in good faith consider Entera&#8217;s comments with respect thereto. On a country-by-country basis, OPKO will provide
      Entera written notice of any desire to not enforce any such other Joint Patents. Unless OPKO has Good Reason to not enforce (or allow Entera to enforce) any such other Joint Patents, Entera may (on a country-by-country basis) enforce such other Joint
      Patent(s) using counsel of its choice and at its own expense.</div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; All of OPKO&#8217;s costs and expenses resulting from such enforcement action shall be shared by the Parties as Shared Program Damages. All of
      Entera&#8217;s costs and expenses resulting from the exercise of any enforcement action pursuant to its &#8220;step-in&#8221; rights in (i) and (ii) above will be shared evenly by the Parties, and not included as Shared Program Damages.</div>
    <br>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">9.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Third-Party Infringement</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Notice</u></font>. Each Party will promptly notify the other of any infringement by a Third Party of any of the Patents that are subject to the licenses hereunder (including any Joint Patents) of
        which it becomes aware, and of any request for declaratory judgment, opposition, nullity action, interference, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">inter-partes </font>reexamination, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">inter-partes </font>review, post-grant review, derivation proceeding, or similar action alleging the invalidity, unenforceability or non-infringement of any
        of such Patents (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Third-Party Infringement</font>&#8221;).</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Control</u></font>. The Party having the right to control the defense or enforcement of the relevant Patents in accordance with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 9.2</u></font> or <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 9.3</u></font> shall keep the other Party informed of the status of the defense or enforcement of the
        relevant Patents in connection with the Third-Party Infringement action, but shall be free to settle or otherwise resolve the Third-Party Infringement as it determines appropriate.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">31</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Recoveries</u></font>. Any recoveries resulting from such an action relating to a claim of Third-Party Infringement shall be first applied against payment of each Party&#8217;s costs and expenses in
        connection therewith. Any remainder will be (i) shared by the Parties 60%/40% (OPKO/Entera) if the recovery is made prior to the Opt-Out Date, and (ii) retained by the enforcing Party if the recovery is made on or after to the Opt-Out Date;
        provided, however, in the case of (ii), that (A) any portion of such remainder in connection with a Third-Party Infringement of a Patent within the Entera Licensed Technology or the Joint Patents that is attributable to lost profits with respect to
        a Collaboration Product in the Field shall be paid to OPKO and shall be subject to the 85%/15% (OPKO/Entera) allocation as if such portion were Proceeds with respect to such Collaboration Product under this Agreement; and (B) notwithstanding (A),
        if Entera is the enforcing Party by virtue of exercising its &#8220;step-in&#8221; rights under <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 9.2</u></font> or <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 9.3</u></font>, such remainder shall be shared evenly (50/50) by the Parties.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">9.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Patent Extensions</u></font>. As between the Parties, the Party with the first right to control the Prosecution of a Patent in accordance with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 9.2</u></font> will in its sole discretion determine whether (and for which Patents) it will apply to seek patent term restoration (including under the Drug Price Competition and Patent Term Restoration Act),
        supplemental protection certificates or their equivalents, and patent term extensions in any jurisdiction.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">9.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Regulatory Listings</u></font>. As between the Parties, OPKO (or its designee) will have the sole right to list, with the applicable Regulatory Authorities, all applicable Patents for a Collaboration Product,
        including all so-called &#8220;Purple Book&#8221; or &#8220;Orange Book&#8221; listings required under the PHSA, and all similar listings in any other relevant countries. For the avoidance of doubt, OPKO will retain final decision-making authority with respect to the
        listing of all applicable Patents for any Collaboration Product, and will retain the right to perform all actions of a reference product sponsor set forth in the U.S. Hatch-Waxman Act or PHSA (and any foreign equivalent of such laws), regardless of
        which Party owns such Patent or controls the Prosecution of such Patent, and Entera will reasonably assist OPKO in connection therewith.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">REPRESENTATIONS,
        WARRANTIES AND COVENANTS<a name="REPRESENTATIONSWARRANTIES"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">10.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Mutual Representations, Warranties and Covenants</u></font>. Each of OPKO, OPKO Health and Entera hereby represents and warrants to each of OPKO, OPKO Health and Entera, as applicable, as of the Effective Date,
        and covenants, as applicable, as follows:</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Corporate Existence and Power</u></font>. It is a company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and
        has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the right to grant the licenses granted
        by it hereunder.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">32</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Authority and Binding
        Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; It has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder.</div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; It has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance
      of its obligations hereunder.</div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party
      that is enforceable against it in accordance with its terms.</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>No Conflicting Agreements</u></font>. It is not a party to and shall not enter into any agreement that would prevent it from granting the rights or exclusivity granted or intended to be granted to
        each of OPKO, OPKO Health and Entera, as applicable, under this Agreement or performing its obligations under this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Compliance</u></font>. It is not debarred, has not been convicted, and is not subject to debarment or conviction pursuant to Section 306 of the FD&amp;C Act. In the course of the performance of the
        Development Activities, such Party shall not use any employee, consultant, agent or independent contractor who has been debarred by any Regulatory Authority, or, to such Party&#8217;s knowledge, is the subject of debarment proceedings by a Regulatory
        Authority or has been convicted pursuant to Section 306 of the FD&amp;C Act. To the actual knowledge of such Party, no person on any of the FDA clinical investigator enforcement lists (including the (i) Disqualified/Totally Restricted List; (ii)
        Restricted List; and (iii) Adequate Assurances List) will participate in the performance of any activities hereunder.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Laws</u></font>. It shall comply with the Applicable Law in the course of performing its obligations pursuant to this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">10.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Additional Representations and Warranties of Entera</u></font>. Entera represents and warrants to OPKO and OPKO Health, as of the Effective Date, that:</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">No officer or employee of
        Entera is subject to any agreement with any Third Party that requires such officer or employee to assign any interest in any Entera Licensed Technology to any Third Party.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Entera solely and exclusively
        owns all of the Entera Licensed Technology in existence as of the Effective Date, free and clear of all encumbrances, and is listed in the records of the appropriate Regulatory Authorities as the sole and exclusive owner of record for each
        registration, grant, and application included in such Entera Licensed Technology.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">To Entera&#8217;s knowledge: (i)
        there are no Patents or Know-How that are Controlled by any Third Party that would be infringed or misappropriated by the development, manufacture, or commercialization of the Entera Platform or Oral Products, and no claim or litigation has been
        brought or asserted alleging that any Patents or other intellectual property rights with respect to the Entera Platform are invalid or unenforceable; and (ii) no person is (or threatens to be) infringing or misappropriating any Patents or Know-How
        Controlled by Entera that claim, cover, or embody the Entera Platform.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Entera has not received
        written notice of any claims, and there are no judgments or settlements against or owed by Entera, or to Entera&#8217;s knowledge, any pending or threatened claims or litigation, in each case relating to the Patents claiming or covering the Entera
        Platform.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">33</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">None of the Entera Licensed
        Technology, nor any provision of this Agreement, are subject to any inbound license or other similar agreement with another person or entity regarding any intellectual property right to be licensed hereunder.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Entera has taken commercially
        reasonable measures consistent with industry practices to protect the secrecy, confidentiality, and value of all Know-How related to the Entera Platform (including requiring all employees, consultants, and independent contractors to execute binding
        and enforceable agreements requiring all such persons to maintain the confidentiality of such Know-How) and such Know-How has not been used, disclosed to, or discovered by any Third Party except pursuant to such confidentiality agreements and there
        has not been a breach by any party to such confidentiality agreements.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Entera has not entered into a
        funding relationship with a Regulatory Authority that would result in rights to any Oral Product residing in the U.S. government, National Institutes of Health, National Institute for Drug Abuse or other Regulatory Authority (including counterparts
        of such agencies in any other countries), and the licenses granted hereunder are not subject to overriding obligations to the U.S. government as set forth in Public Law 96 517 (35 U.S.C. 200 204) or any similar obligations under the Applicable Laws
        of any other country with respect to other Regulatory Authorities.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">To Entera&#8217;s knowledge, the
        Patents included in the Entera Licensed Technology are valid and enforceable.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Entera has: (i) filed and
        prosecuted patent applications within the Entera Background IP in good faith and complied with all duties of disclosure with respect thereto; (ii) not committed any act, or omitted to commit any act, that may cause the Patents constituting Entera
        Background IP to expire prematurely or be declared invalid or unenforceable; (iii) paid all application, registration, maintenance, and renewal fees with respect to the Patents constituting Entera Background IP as of the Effective Date; and (iv)
        filed all necessary documents and certificates with the relevant agencies with respect to the Patents constituting Entera Background IP as of the Effective Date.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Entera has not failed to
        disclose to OPKO any fact or circumstance known to Entera or any of its Affiliates and relating to the Entera Platform that would be reasonably material to OPKO in connection with this Agreement or the transactions contemplated herein, including
        the occurrence of any Adverse Event with respect to the Entera Platform. To Entera&#8217;s knowledge, none of the materials provided to OPKO by Entera or its Affiliates contain any untrue statement of a material fact or fail to state a material fact
        necessary to make the statements therein not misleading.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">[reserved].</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(l)</font>&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">[reserved].</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">34</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Entera has filed all reports,
        schedules, forms, statements and other documents required to be filed by Entera under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two (2) years immediately preceding the Effective Date (or
        such shorter period as Entera was required by Applicable Law to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SEC Reports</font>&#8221;). As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the
        Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the
        light of the circumstances under which they were made, not misleading. Entera has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of Entera included in the SEC Reports complied, at the time of filing
        thereof with the Commission, in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in
        accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">GAAP</font>&#8221;), except
        as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of
        Entera and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
        During the period of engagement of Entera&#8217;s accountants, there have been no disagreements between the accounting firm and Entera on any matters of accounting principles or practices, financial statement disclosure or auditing scope or procedures
        that would require disclosure pursuant to Item 304 of Regulation S-K. Entera has made and kept books and records and accounts which are in reasonable detail and which fairly and accurately reflect the activities of Entera in all material respects,
        subject only to year-end adjustments.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(n)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Entera and the Subsidiaries
        are in compliance in all material respects with all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and all applicable rules and regulations promulgated by the Commission thereunder that are
        effective as of the date hereof. Entera and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific
        authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management&#8217;s general
        or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Entera and the Subsidiaries have established
        disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for Entera and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by Entera in the
        reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(o)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The Entera Ordinary Shares
        are registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and Entera has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Entera Ordinary Shares under the
        Exchange Act nor has Entera received any notification that the Commission is contemplating terminating such registration. Except as disclosed in the SEC Reports, Entera has not, in the twelve (12) months preceding the Effective Date, received
        notice from NASDAQ to the effect that Entera is not in compliance with the listing or maintenance requirements of NASDAQ. The Entera Ordinary Shares are currently eligible for electronic transfer through the Depository Trust Company or another
        established clearing corporation, and Entera is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">35</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">10.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Entera Covenants</u></font>. Entera hereby covenants to OPKO that, except as expressly permitted under this Agreement:</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Entera will not, and will
        cause its Affiliates not to, grant to any Third Party any rights that would be inconsistent or conflict with rights purported to be granted to OPKO under this Agreement, nor shall Entera assign any of its rights, title, or interests in or to the
        Entera Licensed Technology to any Third Party except as permitted in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 14.4</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Neither Entera nor any of its
        Affiliates shall: (i) terminate or modify any existing license or other material agreement to which Entera is a Party relating to the Entera Platform or the subject matter of this Agreement, or exercise, waive, release, or assign any rights or
        claims thereunder, without first obtaining OPKO&#8217;s prior written consent in each case; (ii) breach, or otherwise default under, any such agreement(s); or (iii) commit any act (or failure to act), in each case (of (i)-(iii)) that would result in a
        loss of rights, or otherwise adversely affect the rights, of OPKO, its Affiliates, or its sublicensees hereunder or would permit the counterparty(ies) to any such agreement(s), as applicable, to exercise their respective termination rights under
        such agreements. Without limiting the foregoing, if Entera receives notice of an alleged default by Entera or its Affiliates under any such agreement, where termination of such agreement could be sought by the counterparty or result from such
        default, then Entera will promptly, but in any event within ten (10) Business Days following receipt of notice thereof, provide written notice thereof to OPKO and, to the extent permitted by Applicable Law, grant OPKO the right (but not the
        obligation) to: (x) cure such alleged breach or default (to the extent permitted under the terms of such agreement); and (y) offset any costs or expenses incurred in connection therewith against any payments due or that may become due under this
        Agreement, and such costs and expenses shall be borne 100% by Entera and 0% by OPKO (i.e., shall not be subject to the 60/40% or 85%/15% allocations described herein).</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">All employees, officers, and
        consultants of Entera or any of its Affiliates who are involved in the Development Activities or other activities contemplated under this Agreement have executed or will execute agreements effectively assigning to Entera, or have existing
        obligations under Applicable Laws requiring assignment to Entera of, all inventions made during the course of and as the result of their association with Entera, free from any lien or encumbrance, and obligating each such individual to maintain as
        confidential Entera&#8217;s Confidential Information as well as all confidential information of other parties (including the confidential information of OPKO and its Affiliates and sublicensees) that such individual may receive in connection with the
        activities contemplated under this Agreement.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">36</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Entera will keep OPKO
        apprised, via the JSC at regularly scheduled JSC meetings or otherwise, of all material developments with respect to the Entera Platform, including any and all Adverse Events with respect to the Entera Platform.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">10.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Additional Representations and Warranties of OPKO Health</u></font>. OPKO Health represents and warrants to Entera, as of the Effective Date, that:</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Except for the Purchased
        Shares, neither OPKO Health nor any of its Affiliates owns, beneficially (within the meaning of Rule 13d-3 promulgated under the Exchange Act) or of record, any Entera Ordinary Shares or any or securities convertible into or exercisable or
        exchangeable for Entera Ordinary Shares. OPKO Health is an &#8220;accredited investor&#8221;, as defined in Rule 501(a) promulgated under the Securities Act of 1933, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Securities Act</font>&#8221;), and it acknowledges and agrees that (i) the Entera Ordinary Shares acquired hereunder are &#8220;restricted securities&#8221; as defined by Rule 144 promulgated under the Securities Act, are not registered under
        the Securities Act or any applicable state securities laws and are being offered and sold by Entera to OPKO Health in reliance upon exemptions from registration contained in, or promulgated under, the Securities Act, and (ii) such shares may not be
        sold, transferred, pledged, or otherwise disposed of unless subsequently registered under the Securities Act and any applicable state securities laws or, in the opinion of counsel (reasonably satisfactory to Entera) that, registration under the
        Securities Act or any applicable state securities laws is not required.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">OPKO Health agrees to the
        imprinting, so long as is required by <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.2(c)</u></font>, of a legend on the Purchased Shares in the following form:</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify; margin-right: 36pt; margin-left: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
      SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SECURITIES ACT</font>&#8221;),
      AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
      SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.</div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">10.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Anti-Corruption Compliance</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Each Party represents and
        warrants to the other Party, as of the Effective Date or as applicable covenants to the other Party, that:</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 72pt;"> (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Neither it nor any other of its applicable indemnitees has taken any action, directly or indirectly, that would result in a violation by such
      persons of any Anti-Corruption Laws;</div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 72pt;"> (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; It and its applicable indemnitees will conduct their business in compliance with the Anti-Corruption Laws; and</div>
    <br>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">37</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div> <br>
      </div>
      <div style="margin-left: 45pt; text-indent: 72pt; text-align: justify;"> (iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; It has and shall have all necessary procedures in place to ensure it and its applicable indemnitees do not violate the Anti-Corruption Laws, and has trained or
        will train its applicable indemnitees to comply with these procedures. It shall immediately notify the other Party if it or its applicable indemnitees has any information or suspicion that there may be a violation of the Anti-Corruption Laws,
        including in the event it becomes aware that any of its applicable indemnitees is in violation of the Anti-Corruption Laws.</div>
      <div> <br>
      </div>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Upon written notice, either
        Party may conduct an investigation and audit (the method of which shall be at the sole discretion of such Party) of the other Party&#8217;s policies, books, records, and accounts to verify compliance with this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 10.5</u></font>. Such other Party will cooperate fully with such investigation and audit.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">10.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>No Other Representations or Warranties</u></font>. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY,
        FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES,
        WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">INDEMNIFICATION<a name="INDEMNIFICATION"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">11.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Indemnification by Entera</u></font>. Subject to the remainder of this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 11</u></font>, Entera shall defend, indemnify, and
        hold OPKO, its Affiliates, and its and their respective officers, directors, employees, subcontractors, and agents (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">OPKO Indemnitees</font>&#8221;)
        harmless from and against any and all liabilities, losses, costs, damages, fees, expenses or other amounts payable to a Third Party claimant, as well as any reasonable attorneys&#8217; fees and costs of litigation incurred by such OPKO Indemnitees (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Damages</font>&#8221;), all to the extent resulting from any claims, suits, proceedings or causes of action brought by such Third Party (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Third-Party Claims</font>&#8221;) against such OPKO Indemnitee arising from: (a) a breach of any of Entera&#8217;s representations, warranties or obligations under this Agreement; (b) the
        willful misconduct or negligent acts of any Entera Indemnitee; or (c) violation of Applicable Law by any Entera Indemnitee; provided, however, that Entera&#8217;s obligations pursuant to this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 11.1</u></font> will not apply to the extent such Third-Party Claims or Damages (i) constitute Shared Program Damages or (ii) result from any events or activities described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section</u></font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>11.2</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">11.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Indemnification by OPKO</u></font>. Subject to the remainder of this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 11</u></font>, OPKO shall defend, indemnify, and hold
        Entera, its Affiliates, and its Subcontractors, and its and its Affiliates&#8217; respective officers, directors, employees, and agents (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Entera Indemnitees</font>&#8221;)
        harmless from and against any and all Damages, all to the extent resulting from any Third-Party Claims against such Entera Indemnitee arising from: (a) a breach of any of OPKO&#8217;s representations, warranties or obligations under this Agreement; (b)
        the willful misconduct or negligent acts of any OPKO Indemnitee; or (c) violation of Applicable Law by any OPKO Indemnitee; provided, however, that OPKO&#8217;s obligations pursuant to this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 11.2</u></font> will not apply to the extent such Third-Party Claims or Damages (i) constitute Shared Program Damages or (ii) result from any events or activities described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 11.1</u></font>.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">38</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">11.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Indemnification Procedures</u></font>. The Party claiming indemnity under this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 11</u></font> (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Indemnified Party</font>&#8221;) shall give written notice to the Party from whom indemnity is being sought (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Indemnifying Party</font>&#8221;) promptly after learning of the Third-Party Claim for which indemnity is being sought. The Indemnifying Party&#8217;s obligation to defend, indemnify, and hold harmless pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 11.1</u></font> or <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 11.2</u></font>, as applicable, shall be reduced to the
        extent the Indemnified Party&#8217;s delay in providing notification pursuant to the previous sentence results in material prejudice to the Indemnifying Party. At its option, the Indemnifying Party may assume the defense and have exclusive control, at
        its own expense, of any Third-Party Claim for which indemnity is being sought by giving written notice to the Indemnified Party within thirty (30) days after receipt of the notice of such Third-Party Claim; provided, however, that the Indemnifying
        Party shall not agree to any settlement of such Third-Party Claim under terms that would require the Indemnified Party to pay any money, forego any right, admit any wrongdoing or otherwise be prejudiced, without the Indemnified Party&#8217;s prior
        written consent (not to be unreasonably withheld, conditioned, or delayed). The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party&#8217;s expense, in connection with such defense. The Indemnified
        Party may participate in and monitor such defense with counsel of its own choosing at its sole expense.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">11.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Certain Third-Party Claims Related to Collaboration Product in the Territory</u></font>. During the Term, the Parties shall share in any Shared Program Damages in the same percentages as those applicable to the
        sharing of Development Costs and Proceeds (i.e., 60%/40% (OPKO/Entera) for Oxyntomodulin Analog and 50%/50% for LA-PTH, before the Opt-Out Date and 85%/15% (OPKO/Entera) after the Opt-Out Date with respect to any Collaboration Product for which
        Entera has Opted-Out). With respect to any Shared Program Damages incurred by a Party (or any of its indemnified Persons) during the Term, such Shared Program Damages shall be deemed to constitute (and shall be included in) Development Costs or
        Proceeds, as applicable (and the Parties shall cooperate in good faith to allocate such amount(s) to the appropriate cost category) and shall be shared by the Parties in accordance with <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 7</u></font>. If either Party receives notice of a Third-Party Claim that arises from or is based on any Shared Program Activities, such Party shall inform the other Party in writing as soon as reasonably
        practicable, and the Parties shall discuss a strategy on how to defend against such Third-Party Claim. The foregoing terms shall apply, mutatis mutandis, with respect to the sharing and allocation of any Shared Program Recoveries between the
        Parties.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">11.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Limitation of Liability</u></font>. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, EXEMPLARY OR INDIRECT DAMAGES OF ANY KIND ARISING FROM OR RELATING
        TO ANY BREACH OF THIS AGREEMENT OR ANY CLAIMS ARISING HEREUNDER, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE), REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH
        DAMAGES. NOTWITHSTANDING ANYTHING TO THE CONTRARY, THE FOREGOING LIMITATION OF LIABILITY SHALL NOT APPLY WITH RESPECT TO FRAUD OR WILLFUL MISCONDUCT ON THE PART OF A PARTY, NOR WITH RESPECT TO LIABILITY ARISING OUT OF A BREACH OF <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>SECTION 2.4</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>ARTICLE 9</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>SECTION 10.3</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>ARTICLE 12</u></font>, OR ARISING OUT OF THE INDEMNIFICATION OBLIGATIONS UNDER <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>SECTION 11.1</u></font> OR <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>SECTION 11.2</u></font>.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">39</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">11.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Insurance</u></font>. Each Party shall obtain and maintain at all times during the Term such types and amounts of insurance, as are normal and customary for a similarly situated company, in part to cover its
        indemnification obligations under this Agreement. Upon request by a Party, the other Party shall provide to such Party evidence of such insurance.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CONFIDENTIALITY<a name="CONFIDENTIALITY"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">12.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Confidential Information</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The activities undertaken
        hereunder may involve the exchange of certain confidential and proprietary information of the Parties, including inventions, ideas, processes, trade secrets, research and development activities, information technology systems, specifications,
        designs, Know-How, drawings, business and marketing plans, financial data, policies, procedures, and other information in written, oral or physical/sample form (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Confidential Information</font>&#8221;). The Party disclosing Confidential Information shall be the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Disclosing Party</font>&#8221;
        and the Party receiving such Confidential Information shall be the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Receiving Party</font>.&#8221; The Receiving Party shall maintain in confidence the
        Confidential Information of the Disclosing Party with the same degree of care that it uses to protect its own most sensitive Confidential Information, and shall not disclose, use or grant the use of the Confidential Information of the Disclosing
        Party except on a need-to-know basis to the Receiving Party&#8217;s directors, officers, employees, contractors, advisors and other vendors, in each case solely to the extent such disclosure is reasonably necessary in connection with the Receiving
        Party&#8217;s performance of activities or exercise of rights as authorized by this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">To the extent that disclosure
        to any person is authorized by this Agreement, prior to disclosure, the Receiving Party shall obtain, or shall have obtained, written agreement of such person to hold in confidence and not disclose, use or grant the use of the Confidential
        Information of the Disclosing Party except as expressly permitted under this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">12.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Unauthorized Use or Disclosure</u></font>. Each Party shall notify the other Party promptly upon discovery of any unauthorized use or disclosure of the other Party&#8217;s Confidential Information.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">12.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Exceptions</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The obligations and
        restrictions herein shall not apply to Confidential Information of the Disclosing Party that falls within any of the following exceptions, provided that such information:</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is or becomes part of the public domain through no fault of the Receiving Party;</div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; was known by the Receiving Party prior to the disclosure by the Disclosing Party;</div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; was independently developed by or on behalf of the Receiving Party without use of, reliance upon, or reference to, the Disclosing Party&#8217;s
      Confidential Information; or </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">40</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; has been properly received by the Receiving Party from a Third Party who is not under any obligation to maintain the confidentiality of such
      information, and without breach of this Agreement by the Receiving Party.</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Notwithstanding the
        foregoing, all Know-How constituting:</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Entera Information and Inventions are the Confidential Information of both Parties; and</div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; OPKO Information and Inventions are and shall remain the Confidential Information of OPKO.</div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Nothing in this Agreement
        shall prevent a Party from using any Know-How that is in the public domain. A Party shall also not be restricted under, and shall not be in breach of, this Agreement from using, within or outside this Agreement and for any purpose, any general
        knowledge, skill, and expertise acquired by its employees (or its Affiliates&#8217; employees) in their performance of this Agreement (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Residual Information</font>&#8221;)
        to the extent such Residual Information is retained in the unaided human memory of such employees in intangible form and without use by the Party or such employees of tangible copies of any Confidential Information of the other Party; provided that
        this provision will not be deemed in any event to provide any right to infringe the Patent rights of the other Party or of Third Parties that have licensed or provided materials to the other Party and this section is not intended to grant, and will
        not be deemed to grant the Receiving Party: (i) a right to disclose the Disclosing Party&#8217;s Confidential Information; or (ii) a license under any Patents or other intellectual property right of the Disclosing Party; and provided further that a
        Party&#8217;s use of such Residual Information is on an &#8220;as is, where is&#8221; basis, with all faults and all representations and warranties disclaimed and at such Party&#8217;s sole risk.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">12.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Disclosures</u></font>. If the Receiving Party or its representatives are requested to disclose any Confidential Information (including any notes) in connection with any legal or administrative proceeding or
        investigation, pursuant to rules of a securities exchange, or otherwise pursuant to Applicable Law, the Receiving Party shall notify the Disclosing Party promptly in writing of the existence, terms and circumstances surrounding such a request
        (except where notice is prohibited by law) so that the Disclosing Party may, in its sole discretion and at its sole expense, seek a protective order or other appropriate remedy or take steps to resist or narrow the scope of the disclosure sought by
        such request. The Receiving Party agrees to reasonably assist the Disclosing Party in seeking a protective order or other remedy, if requested by the Disclosing Party. The Receiving Party or its representatives shall furnish only that portion of
        the Confidential Information which is legally required to be disclosed. Confidential Information disclosed pursuant to the foregoing shall remain subject to the obligations of confidentiality and non-use set forth herein.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">12.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Existence and Terms of Agreement</u></font>. The existence of this Agreement, including the terms and conditions contained herein, shall be the Confidential Information of each Party, with each Party treated as
        the Receiving Party, and neither Party shall disclose the existence or any terms or conditions of this Agreement to any Third Party without the prior consent of the other Party, including by virtue of a press release; provided, however, that a
        Party may disclose the existence or terms or conditions of this Agreement: (a) on a need-to-know basis to its legal and financial advisors (provided that such advisors are subject to ethical or other confidentiality obligations) to the extent such
        disclosure is reasonably necessary in connection with such Party&#8217;s performance of activities or exercise of rights under this Agreement; (b) to the extent such disclosure is required to comply with Applicable Law, including the rules and
        regulations promulgated by the Commission or any equivalent governmental authority or securities exchange; provided that in such event, the Party that intends to make a disclosure pursuant to this clause (b) shall provide the other Party a
        reasonable opportunity to review such disclosure and reasonably consider the other Party&#8217;s comments regarding confidential treatment sought for such disclosure; and (c) to a Third Party under customary written confidentiality terms (which may
        include a template confidentiality agreement approved by the JSC) in connection with: (i) an equity investment in such Party by a Third Party; (ii) an actual or potential merger, consolidation, license, collaboration or similar transaction entered
        into by such Party; or (iii) the actual or potential sale of all or substantially all of the assets of such Party.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">41</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">12.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Duration</u></font>. Notwithstanding anything to the contrary in this Agreement, for purposes of this Agreement, the obligations of confidentiality and non-use obligations hereunder shall survive for five (5)
        years after the expiration or termination of this Agreement, except that the obligations with respect to Confidential Information that is a trade secret under Applicable Law shall continue to survive thereafter for so long as such Confidential
        Information remains a trade secret under Applicable Law.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">12.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Press Release</u></font>. The Parties agree that the public announcement of the execution of this Agreement shall be substantially in the form of the press release(s) attached as <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Schedule 12.6</font>. Any other publication, news release or other public announcement relating to this Agreement or to the performance hereunder, shall first be reviewed and
        approved by both Parties.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">12.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Publications</u></font>. During the Term, each Party (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Publishing Party</font>&#8221;) shall submit to the other Party
        (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Non-Publishing Party</font>&#8221;) for review and approval any proposed academic, scientific and medical publication or public presentation that contains
        the Non-Publishing Party&#8217;s Confidential Information or relates to a Collaboration Product. Such review and approval will be conducted for the purposes of preserving the value of the intellectual property licensed hereunder and determining whether
        any portion of the proposed publication or presentation containing the Non-Publishing Party&#8217;s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required to be submitted hereunder
        shall be submitted to the Non-Publishing Party no later than sixty (60) days before submission for publication or presentation. The Non-Publishing Party shall provide its comments with respect to such publications and presentations within thirty
        (30) days of its receipt of such written copy. The sixty (60) day review period may be extended for an additional thirty (30) days if the Non-Publishing Party demonstrates reasonable need for such extension, including for the preparation and filing
        of patent applications. The Publishing Party will comply with standard academic practice regarding authorship of scientific publications and recognition of the contribution of other parties in any publication governed by this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 12.7</u></font>, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For the sake of clarity, (x) where
        Entera is the Publishing Party, Entera shall not include in its academic, scientific and medical publications and public presentations any pre-clinical and clinical data and results relating to a Collaboration Product, including any such data and
        results provided to OPKO under this Agreement, without OPKO&#8217;s prior written consent, such consent not to be unreasonably withheld and (y) in all cases, the Publishing Party&#8217;s obligation to submit any publication to the Non-Publishing Party for
        review and approval under this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 12.7</u></font> shall not apply to any publication that does not contain the Non-Publishing Party&#8217;s Confidential Information or
        relate in any manner to a Collaboration Product.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">42</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">13.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">TERM AND
        TERMINATION<a name="TERMANDTERMINATION"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">13.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Term</u></font>. This Agreement will commence on the Original Effective Date and, unless earlier terminated pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 13.2</u></font>,
        will continue in full force and effect with respect to the Territory either (i) indefinitely; or (ii) in the case of an Opt-Out under <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Article 8</u></font>, for so long
        as Proceeds are being received by OPKO (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Term</font>&#8221;).</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">13.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Termination</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Termination for Breach</u></font>. Either Party may terminate this Agreement, on a Collaboration Product-by-Collaboration Product basis, with written notice to the other Party if such other Party
        materially breaches its obligations under this Agreement with respect to a Collaboration Product and fails to cure such material breach within ninety (90) days from the date of such notice; provided, that if such breach is capable of being cured
        but cannot be cured within such ninety (90) day period and the breaching Party initiates actions to cure such breach within such period and thereafter diligently pursues such actions, the breaching Party shall have such additional period as is
        reasonable in the circumstances to cure such breach. Any dispute regarding: (i) the existence or materiality of a breach specified in a notice provided by a Party in accordance with this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 13.2(a)</u></font>; or (ii) whether a material breach has been cured within the applicable cure period described in this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section
            13.2(a)</u></font> will be resolved in accordance with the dispute resolution procedures (including litigation) described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 14.10</u></font>. No purported
        termination of this Agreement pursuant to this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 13.2(a)</u></font> shall take effect until the resolution of such dispute, and the period for cure of such alleged
        breach shall be tolled during the pendency of any dispute with respect to an alleged breach. If it is ultimately determined that the breaching Party committed such material breach, then the breaching Party will have the right to cure such material
        breach after such determination within the applicable ninety (90) day cure period which will commence as of the date of such determination. Any termination by any Party under this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 13.2(a)</u></font> and the effects of termination provided herein shall be without prejudice to any damages or other legal or equitable remedies to which it may be entitled. For the elimination of doubt, if a Party
        terminates this Agreement with respect to one, but not all Collaboration Products, then this Agreement shall remain in full force and effect with respect to the Collaboration Product that has not been terminated, and all provisions intended to
        survive the termination of this Agreement shall survive in accordance with their respective terms with respect to all Collaboration Products, whether or not terminated.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Termination for Convenience</u></font>. OPKO may terminate this Agreement with respect to either or both Collaboration Products for any reason and without liability upon sixty (60) days written
        notice to Entera; provided, that, for the elimination of doubt, if OPKO terminates this Agreement with respect to one, but not all Collaboration Products, then this Agreement shall remain in full force and effect with respect to the Collaboration
        Product that has not been terminated, and all provisions intended to survive the termination of this Agreement shall survive in accordance with their respective terms with respect to all Collaboration Products, whether or not terminated. Entera
        will not incur any additional Development Costs with respect to the applicable terminated Collaboration Product after receiving notice of termination from OPKO and will use commercially reasonable efforts to reduce any Development Costs for which
        it seeks reimbursement hereunder already committed to the extent cancellable or able to be mitigated.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">43</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Termination for Insolvenc</u></font>y. If, at any time during the Term, either Party makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over
        all or substantially all of its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it that is not discharged within sixty (60) days after the filing thereof, the other Party may terminate this
        Agreement in its entirety by providing written notice of its intent to terminate this Agreement to such Party, in which case, this Agreement shall terminate on the date on which such Party receives such written notice.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Termination for Bankruptcy Code Rejection</u></font>. OPKO may terminate this Agreement in its entirety or on a Collaboration Product-by-Collaboration Product or country-by-country basis in the
        event Entera rejects this Agreement under Section 365 of the U.S. Bankruptcy Code, 11 U.S.C. &#167;&#167; 101 et seq. (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Bankruptcy Code</font>&#8221;) or under any
        similar laws in any other country in the Territory.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Termination for Material Safety Issue</u></font>. In the event a Material Safety Issue is reasonably likely to not be resolved, or is not actually resolved, within twelve (12) months following the
        date on which the Material Safety Issue is identified, then unless otherwise mutually agreed by the Parties, this Agreement shall terminate with respect to the Collaboration Product subject to the Material Safety Issue upon the date that is twelve
        (12) months after the first date of discussion between the Parties of the Material Safety Issue.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">13.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Special Remedy for OPKO</u></font>. In the event that OPKO has the right to terminate this Agreement in whole or in part pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section
            13.2(a)</u></font> (Termination for Breach) (excluding terminations for a material breach due to payment obligations), then OPKO may elect in lieu of termination of this Agreement for the applicable breach, but without limiting any other rights
        or remedies available to OPKO, any or all of the following upon written notice from OPKO: (a) cause Entera to exercise the Opt-Out with respect to such terminated Collaboration Product(s), with the Opt-Out Date deemed to occur as of the date
        indicated in the written notice from OPKO; (b) reduce the amount of any payment obligations of OPKO with respect to such terminated Collaboration Product(s) with respect to Proceeds by fifty percent (50%); (c) OPKO shall have the right to offset
        the full amount of any damages it has suffered as a result of Entera&#8217;s breach against any amounts owed to Entera hereunder; (d) Entera will promptly return to OPKO or destroy any Confidential Information of OPKO in its possession that is not
        necessary for Entera to perform its remaining obligations hereunder (including with respect to other Collaboration Products); and (e) Entera&#8217;s rights (if any) to enforce (including step-in rights) any Joint Patents with respect to such terminated
        Collaboration Product(s) will terminate. The foregoing remedies may be exercised only once within twelve (12) months after the date on which OPKO had the right to terminate this Agreement pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 13.2(a)</u></font> (Termination for Breach), and if so elected by OPKO, be binding on OPKO. For clarity, OPKO shall have the right to seek any remedies available at law or in equity where OPKO elects not
        to invoke the special remedy.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">44</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">13.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Effects of Expiration or Termination</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>General</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon the expiration or termination of this Agreement, each Party shall promptly return to the other Party (or as directed by such other Party
      destroy and certify to such other Party in writing as to such destruction) all of such other Party&#8217;s Confidential Information that is solely applicable to the terminated Collaboration Product and that is in the possession or control of such Party (or
      any of its Affiliates, (sub)licensees or subcontractors), except that such Party shall have the right to retain copies of intangible Confidential Information of such other Party for legal purposes (e.g., monitoring its compliance with obligations
      under this Agreement) or such Confidential Information of the other Party that is necessary or reasonably useful to perform its remaining obligations under this Agreement (including with respect to other Collaboration Products).</div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: justify; margin-left: 45pt; text-indent: 63pt;"> (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If Entera terminates this Agreement pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 13.2(a)</u></font>
      (Termination for Breach) or OPKO terminates this Agreement pursuant to <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 13.2(b) </u></font>(Termination for Convenience), no later than thirty (30) days following
      the effective date of termination, Entera shall provide written notice to OPKO whether it desires to obtain an exclusive (or non-exclusive), worldwide, royalty-bearing license under certain OPKO Technology used and Controlled by OPKO as of the
      effective date of termination in the Development or Commercialization of the terminated Collaboration Products as they exist as of the effective date of termination that (i) cover such Collaboration Products and (ii) were conceived or reduced to
      practice by OPKO or its Affiliates in the course of activities performed under this Agreement, to the extent necessary or reasonably useful to Develop and Commercialize any Collaboration Products in the Field in the Territory. In the event that
      Entera timely elects in writing to receive such license, then the Parties shall negotiate a definitive agreement for such license in good faith for ninety (90) days, which such license shall be on fair market and commercially reasonable terms that
      shall take into account the stage of Development or Commercialization as of the effective date of termination and relative contribution by each Party in such Development and Commercialization. Such definitive agreement shall contain customary terms
      and conditions surrounding (A) an appropriate technology transfer to Entera or its designee of the OPKO Technology to be licensed thereunder, (B) transfer and assignment of appropriate Marketing Approvals and regulatory filings held by OPKO with
      respect to such Collaboration Product(s); provided that if such transfer and assignment is not permitted by the applicable Regulatory Authority, OPKO would agree to permit Entera to cross-reference and rely upon such Marketing Approvals and
      regulatory filings, (C) the sale of the applicable Collaboration Product(s) and all components and in-process inventory with respect thereto existing as of the date of execution of the definitive agreement, at a commercially reasonable price to be
      agreed upon by the Parties, and (D) to the extent OPKO determines, in its sole discretion, that it is practicable and commercially reasonable to do so, assignment or partial assignment to Entera (or its designee) of any agreements with Third Parties
      that relate to the Development or Commercialization of the applicable Collaboration Product(s). With respect to Third Party agreements that OPKO does assign to Entera pursuant to clause (D) above, OPKO would, to the extent OPKO determines, in its
      sole discretion, that it is practicable and commercially reasonable to do so, use reasonable efforts at Entera&#8217;s sole cost and expense, to give Entera the benefit of such contracts for a reasonable transitional period to be agreed upon by the Parties
      (but not to exceed (12) months). If after ninety (90) days, the Parties have not executed a definitive agreement with respect to such license, OPKO shall have no further obligations to Entera with respect to such OPKO Technology.</div>
    <div style="line-height: 1.25; text-align: justify;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">45</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div> <br>
      </div>
      <div style="text-indent: 63pt; margin-left: 45pt; text-align: justify;"> (iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Expiration or termination of this Agreement for any reason shall be without prejudice to any rights or financial compensation that shall have accrued to the
        benefit of a Party prior to such expiration or termination, provided that OPKO shall have no obligation to make any milestone payments for milestones achieved between the date of the notice of termination and the effective date of such termination.
        Such expiration or termination shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement.</div>
      <div> <br>
      </div>
      <div style="margin-left: 45pt; text-indent: 63pt;">
        <div style="text-align: justify;"> (iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If this Agreement expires or is terminated, the applicable JSC(s) shall automatically be dissolved as of the effective date of such termination; provided that such JSC has not been earlier
          disbanded.</div>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <br>
        </div>
      </div>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Other Remedies</u></font>. Termination or expiration of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any
        rights, remedies or claims, whether for damages or otherwise, that a Party may have hereunder or that may arise out of or in connection with such termination or expiration.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Survival</u></font>. The following provisions shall survive and apply after expiration or termination of this Agreement: <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Articles
            1</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>7</u></font> (except for <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 7.2</u></font> and solely with respect
        to payments owing as of the effective date of termination or expiration) and <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>14</u></font>; <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Sections
            2.1(c)</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>4.3(c)</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>7.2</u></font> (solely for the time periods
        prescribed therein), <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>9.1</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>10.3(a)</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>10.3(b)</u></font> (solely with respect to the first sentence), <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>10.3(c)</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>10.4(b)</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>10.5</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>11.1</u></font>-<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>11.3</u></font> (inclusive), <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>11.5</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>12.1</u></font>-<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>12.5</u></font> (inclusive and solely for the time periods prescribed in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 12.5</u></font>) and <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>12.6</u></font>; and this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section
            13.4(c)</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">13.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Rights in Bankruptcy</u></font>.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The Parties agree that this
        Agreement constitutes an executory contract under Section 365 of the Bankruptcy Code for the license of &#8220;intellectual property&#8221; as defined under Section 101 of the Bankruptcy Code and constitutes a license of &#8220;intellectual property&#8221; for purposes of
        any similar laws in any other country in the Territory. The Parties further agree that OPKO, as licensee of such rights under this Agreement, will retain and may fully exercise all of its protections, rights and elections under the Bankruptcy Code,
        including Section 365(n) of the Bankruptcy Code, and any similar laws in any other country in the Territory. In the event of the commencement of a bankruptcy proceeding by or against Entera under the Bankruptcy Code and any similar laws in any
        other country in the Territory, OPKO will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its
        possession, will be promptly delivered to it: (i) upon any such commencement of a bankruptcy proceeding upon its written request therefor, unless Entera elects to continue to perform all of its obligations under this Agreement; or (ii) if not
        delivered under clause (i) above, following the rejection of this Agreement by or on behalf of Entera upon written request therefor by OPKO.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">46</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">All rights, powers and
        remedies of OPKO provided for in this Section are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including under the Bankruptcy Code and any similar laws in
        any other country in the Territory). In the event of an insolvency event (as described in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section</u></font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>13.2(c)</u></font>) in relation to Entera, OPKO, in addition to the rights, power and remedies expressly provided herein, shall be entitled to exercise all other such rights and powers and resort to all other such remedies
        as may now or hereafter exist at law or in equity (including under the Bankruptcy Code). The Parties intend the following OPKO rights to extend to the maximum extent permitted by Applicable Law, including for purposes of the Bankruptcy Code: (i)
        the right of access to any intellectual property (including all embodiments thereof) of Entera, or any Third Party with whom Entera contracts to perform an obligation of Entera under this Agreement that is necessary for the development, manufacture
        or commercialization of a Collaboration Product; (ii) the right to contract directly with any Third Party described in (i) to complete the contracted work; and (iii) the right to cure any breach of or default under any such agreement with a Third
        Party and set off the costs thereof against amounts payable to Entera under this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">14.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">MISCELLANEOUS<a name="MISCELLANEOUS"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Entire Agreement; Amendment</u></font>. This Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties,
        representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings between the Parties existing as of the Effective Date with respect to the
        subject matter hereof. In the event of any inconsistency between the terms contained in the Development Plan and the terms contained in the remainder of this Agreement, the terms contained in the remainder of this Agreement will prevail to the
        extent of such conflict. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration,
        amendment, change or addition to this Agreement will be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Force Majeure</u></font>. Both Parties will be excused from the timely performance of their obligations under this Agreement to the extent that such performance is prevented or delayed by Force Majeure and the
        nonperforming Party promptly provides notice of the prevention to the other Party.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Notices</u></font>. Any notice required or permitted to be given under this Agreement will be in writing, will specifically refer to this Agreement, and will be addressed to the appropriate Party at the address
        specified below or such other address as may be specified by such Party in writing in accordance with this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 14.3</u></font>, and will be deemed to have been given
        for all purposes: (a) when received, if hand-delivered or sent by a reputable international expedited delivery service; or (b) five (5) Business Days after mailing, if mailed by first class certified or registered mail, postage prepaid, return
        receipt requested. This <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 14.3</u></font> is not intended to govern the day-to-day business communications necessary between the Parties in performing their
        obligations under the terms of this Agreement.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">47</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If to OPKO:</div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">OPKO Biologics Ltd.<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>16 Ashlegan St.,<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>Kiryat Gat 8211804, Israel<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>Attention: Gabi Faibish, VP Operations and General Counsel<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>Email: gfaibish@opko.com</div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If to Entera:</div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Entera Bio Ltd.<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>Kiryat Hadassah, PO Box 12117<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>Jerusalem, Israel<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>Attention: Miranda Toledano, Chief Executive Officer<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>Email: miranda@enterabio.com</div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">With a required copy (which shall not constitute notice) to:</div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Goodwin Procter, LLP<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>100 Northern Avenue<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>Boston, MA 02210 USA<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>Attention: Shannyn Henke<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font>Email: SHenke@goodwinlaw.com</div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Assignment</u></font>. Neither Party may assign or transfer its rights or obligations under this Agreement without the prior written consent of the other Party (such consent not to be unreasonably withheld,
        delayed, or conditioned), except a Party may make such an assignment without the other Party&#8217;s consent to an Affiliate or to a Third Party successor to all or substantially all of the business of such Party to which this Agreement relates, whether
        in a merger, sale of stock, sale of assets or other transaction. In addition, OPKO may, without the consent of Entera, assign its rights and obligations under this Agreement with respect to a Collaboration Product to a Third Party in the event that
        OPKO or one of its Affiliates divests rights to such Collaboration Product. This Agreement will be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 14.4</u></font> will be null and void.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Expenses</u></font>. Except as otherwise expressly provided in this Agreement, each Party will pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by
        such Party incidental to the negotiation, preparation, execution, delivery and performance of this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Severability</u></font>. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by an arbitrator or by any court of competent jurisdiction from which no appeal can be or is
        taken, the provision will be considered severed from this Agreement and will not serve to invalidate any remaining provisions hereof.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>No Waiver</u></font>. Any delay in enforcing a Party&#8217;s rights under this Agreement or any waiver as to a particular default or other matter will not constitute a waiver of such Party&#8217;s rights to the future
        enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of time.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">48</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Independent Contractors; Relationship</u></font>. Each Party will act solely as an independent contractor, and nothing in this Agreement will be construed to give either Party the power or authority to act for,
        bind, or commit the other Party in any way. Nothing herein will be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties. Neither Party shall report this Agreement or the relationship
        between the Parties as a partnership for tax purposes unless required by Applicable Law. There are no intended Third-Party beneficiaries to this Agreement.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Counterparts</u></font>. This Agreement may be executed in counterparts and electronically.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Choice of Law; Venue</u></font>. This Agreement will be governed by, and enforced and construed in accordance with, the laws of the State of New York, without regard to its conflicts of law provisions. Each
        Party hereby irrevocably submits to the exclusive jurisdiction of: (a) the courts of the State of New York located in New York, NY; or (b) the U.S. District Court for the Southern District of New York, for the purposes of any actions, suits and
        proceedings (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Actions</font>&#8221;) arising out of or in connection with this Agreement (except for government agency actions to adjudicate
        registered intellectual property rights, e.g., post-grant proceedings at the U.S. Patent and Trademark Office or other foreign equivalent proceedings). Each Party agrees to commence any such Action either in the U.S. District Court for the Southern
        District of New York or if such Action may not be brought in such court for jurisdictional reasons, in the courts of the State of New York located in New York, NY. Each Party irrevocably and unconditionally waives any objection to the laying of
        venue of any Action in such courts. Process may be served upon it in the manner specified in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 14.3</u></font>. Each Party irrevocably waives and covenants not to
        assert or plead any objection which it might otherwise have to such jurisdiction, or to such manner of service of process. Notwithstanding anything to the contrary herein, the interpretation and construction of any Patent will be governed in
        accordance with the laws of the jurisdiction in which such Patent was filed or granted, as the case may be.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Use of Names</u></font>. Except as expressly provided herein, neither Party will use the name, logo, or trademark of the other Party or any of its Affiliates (or any abbreviation or adaptation thereof) in any
        publication, press release, marketing and promotional material, or other form of publicity without the prior written approval of such other Party in each instance. The restrictions imposed by this <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 14.11</u></font> will not prohibit either Party from making any disclosure as permitted under <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 12.3</u></font> or <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Section 12.4</u></font>, identifying the other Party that is required by Applicable Law.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">14.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Interpretation</u></font>. Except where the context expressly requires otherwise: (a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular
        will be deemed to include the plural (and vice versa); (b) the words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; will be deemed to be followed by the phrase &#8220;without limitation;&#8221; (c) the word &#8220;will&#8221; shall be construed to have the same meaning and effect
        as the word &#8220;shall;&#8221; (d) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise
        modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); (e) any reference herein to any person or entity will be construed to include the person&#8217;s or entity&#8217;s successors and assigns; (f) the words
        &#8220;herein,&#8221; &#8220;hereof&#8221; and &#8220;hereunder,&#8221; and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof; (g) all references herein to Articles, Sections, or Exhibits will be construed
        to refer to Articles, Sections, or Exhibits of this Agreement, and references to this Agreement include all attachments hereto; (h) references to &#8220;drugs&#8221; or pharmaceutical products or therapies include biological products or therapies; (i)
        references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof; (j) any action or
        occurrence deemed to be effective as of a particular date will be deemed to be effective as of 11:59 PM ET on such date; and (k) the term &#8220;or&#8221; will be interpreted in the inclusive sense commonly associated with the term &#8220;or&#8221; (and/or). Except as
        otherwise expressly set forth herein, provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like will require that such agreement, consent or approval be specific and in writing, whether
        by written agreement, letter, approved meeting minutes or otherwise (but, except as expressly set forth herein, excluding e-mail and instant messaging). Whenever any payment is to be made or action to be taken under this Agreement is required to be
        made or taken on a day other than a Business Day, such payment will be made or action taken on the next Business Day following such day to make such payment or do such act. The preamble to this Agreement and the descriptive headings of Articles and
        Sections are inserted solely for convenience of reference and are not intended as complete or accurate descriptions of the content of this Agreement or of such Articles or Sections.</font></div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">[Signature Page Follows]</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">49</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; text-align: justify;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 35.95pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">IN WITNESS WHEREOF</font>,
        the Parties have executed this Amended and Restated Collaboration and License Agreement by their duly authorized representatives as of the Effective Date.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zbdf2d1a53199494e8f28372913136966" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">OPKO BIOLOGICS LTD.</div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">ENTERA BIO LTD<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">.</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">By:&#160;<u><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">/s/ Sagit Pinto-Finke</font></u></div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">By:&#160;<u>/<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">s/ Miranda Toledano</font></u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Name: Sagit Pinto-Finkel</div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Name: Miranda Toledano</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Title: Vice President Finance</div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Title: Chief Executive Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">By: <u><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">/s/ Laura Moschcovich</font></u></div>
          </td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Name: Laura Moschcovich</div>
          </td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Title: General Manager</div>
          </td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">For purposes of&#160;<u><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Sections&#160;7.2</font></u>,&#160;<u><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">10.1</font></u>,&#160;<u><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">10.2</font></u>&#160;and&#160;<u><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">10.4</font></u>&#160;only:</div>
          </td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">OPKO HEALTH, INC.</div>
          </td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:&#160;&#160;<u><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">/s/ Steve Rubin</font></u></div>
          </td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name: Steve Rubin</div>
          </td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title: Executive Vice President</div>
          </td>
          <td style="width: 50%; vertical-align: middle; text-align: justify;">&#160;</td>
        </tr>

    </table>
    <div> <br>
    </div>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z224f866d05aa44179314c943a6f6bdfd">

            <tr>
              <td style="width: 50.00%;">
                <div>
                  <div style="text-align: justify; line-height: 1.25;"><img width="103" height="60" src="image1.jpg"></div>
                </div>
              </td>
              <td style="width: 50.00%;">
                <div style="text-align: right;">&#160;
                  <div style="text-align: right; line-height: 1.25;"><img width="144" height="26" src="image0.jpg"></div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">OPKO
      Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">This is the third program that successfully combines Entera&#8217;s oral peptide N-Tab<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> platform with OPKO&#8217;s
      advanced protein chemistry capabilities</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">The companies have accelerated this program and aim to file an investigational new drug (IND) application in late
        2026</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with
        initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; oral OXM to enter clinic thereafter</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Industry veteran Steve Rubin joins Entera&#8217;s board</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MIAMI and TEL AVIV, February 4, 2026 &#8211; OPKO Health, Inc.&#160; (NASDAQ: OPK), through its wholly owned subsidiary, OPKO Biologics (OPKO), and
      Entera Bio Ltd. (NASDAQ: ENTX) (Entera or the Company), a leader in the development of oral peptide and protein replacement therapies, today announced the expansion of their 2025 Collaboration and License Agreement to advance the first oral
      long-acting PTH analog (LA-PTH) as a once-daily tablet for patients with hypoparathyroidism.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The additional program combines OPKO's proprietary long-acting PTH variants with Entera's proprietary N-Tab<sup style="font-style: italic; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>technology. Following favorable pharmacodynamic and pharmacokinetic (PK/PD) data reported in December 2025, the companies have jointly decided to accelerate development and expect to file an IND application with the U.S. Food
        and Drug Administration (FDA) in late 2026.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the expanded collaboration agreement, OPKO and Entera will each hold a 50% pro-rata ownership interest in the LA-PTH
        hypoparathyroidism program and will each be responsible for 50% of the program's development costs. The companies maintain their previously announced 60%/40% (OPKO/Entera) ownership structure and cost-sharing arrangement for the oral OXM program
        for metabolic and fibrotic disorders.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Additionally, the companies announced that Steve Rubin, Executive Vice President of Administration and director at OPKO, has joined the
      board of directors of Entera as Gerry Ostrov steps down from the board. Mr. Rubin joins Entera with three decades of experience in corporate governance and strategic oversight of drug development across multiple public biotechnology companies.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">"The partnership that our team has forged with OPKO since late 2023 has been very synergistic. Oral OXM and oral GLP-2 have both
      demonstrated robust PK profiles and bioavailability. Furthermore, preclinical data of oral LA-PTH suggests that this program holds the potential to transform the hypoparathyroidism landscape,&#8221; said Miranda Toledano, Chief Executive Officer of Entera.
      &#8220;I would also like to take this opportunity to thank Gerry Ostrov for his contributions and service at Entera, and to extend a warm welcome to Steve Rubin to our board of directors."</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health, remarked, "We are pleased to expand our successful
      collaboration with Entera to advance this promising long-acting PTH program for hypoparathyroidism. This program builds on OPKO's expertise in developing differentiated long-acting peptides and Entera's innovative oral peptide platform. Our goal is
      to provide patients with hypoparathyroidism a more convenient treatment option that eliminates the burden of daily injections while maintaining therapeutic efficacy."</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Hypoparathyroidism is a heterogeneous, rare endocrine disorder that leads to abnormally low calcium and high phosphorus levels in the
      blood and requires chronic PTH replacement therapy. Today, the only approved PTH replacement treatment, YORVIPATH<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> developed by Ascendis Pharma, requires patients to administer daily injections, while investigational candidates may require
      weekly injections. Entera previously demonstrated proof-of-concept clinical data for its EB612 program using an unmodified oral PTH(1-34) analog in a 16-week Phase 2 study in patients with hypoparathyroidism (JBMR, 2021). The study showed significant
      reduction in calcium supplement use and maintenance of serum calcium levels above the lower limit for hypoparathyroidism (&gt;7.5 mg/dL) throughout the study. However, the trial required a four-times-daily (QID) regimen with doses of up to 9mg daily.
      The current preclinical data with OPKO's long-acting PTH variant supports a single, once-daily tablet PTH replacement regimen at a significantly lower daily dose.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As part of OPKO&#8217;s and Entera&#8217;s collaboration, the companies are advancing into the clinic the first oral dual agonist GLP-1/glucagon
      peptide for patients with obesity, metabolic and fibrotic disorders. Since March 2025, the companies have completed in vivo PK/PD validation for both the subcutaneous injection and oral tablet formulations of oxyntomodulin. OPKO is planning to
      initiate a single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1 clinical study with the subcutaneous injection formulation, with data expected by the end of 2026. The companies plan to file an IND for the oral OXM tablet formulation
      thereafter. Oxyntomodulin is a naturally occurring GLP-1/glucagon dual agonist peptide hormone found in the small intestine that acts to suppress appetite and induce weight loss, and has additional cardioprotective and anti-fibrotic properties.
      Currently, there are no approved dual GLP-1/glucagon agonists.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Entera Bio</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Entera is a clinical stage company focused on developing
          oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab</font><sup style="font-style: italic; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">) and its pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1 and GLP-2. The Company&#8217;s most advanced product
          candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily&#160;tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo-controlled, dose-ranging Phase 2 study
          of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also
          developing the first oral oxyntomodulin, a dual targeted GLP-1/glucagon peptide, in tablet form for the treatment of obesity and metabolic syndromes; and first oral GLP-2 peptide as an injection-free alternative for patients suffering from rare
          malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit&#160;<u>www.enterabio.com</u>&#160;or follow us on&#160;<u>LinkedIn</u>,&#160;<u>Twitter</u>, and&#160;<u>Facebook</u>.</font></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About OPKO</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">OPKO is a multinational biopharmaceutical and diagnostics
        company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit <u>www.opko.com</u>.</font></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cautionary Statement Regarding Forward Looking Statements</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Various statements in this press release are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform
      Act of 1995. All statements (other than statements of historical facts) in this press release, including those regarding our prospects, plans, financial position, business strategy and expected financial and operational results, may constitute
      forward-looking statements. Words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;design,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;will&#8221;
      and &#8220;would,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and
      uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results
      to differ materially from those reflected in Entera&#8217;s and OPKO&#8217;s forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA&#8217;s interpretation and review of our results from
      and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product
      candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, whether by Entera, OPKO or their respective collaboration and laboratory partners; impacts to research and development or clinical
      activities that Entera or OPKO may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing our product candidates; the
      parties&#8217; reliance on third parties to conduct clinical trials; Entera&#8217;s and OPKO&#8217;s expectations regarding licensing, business transactions, including OPKO&#8217;s development efforts should Entera opt-out, and strategic collaborations; Entera&#8217;s operation
      as a development stage company with limited operating history; Entera&#8217;s ability to continue as a going concern absent access to sources of liquidity; Entera&#8217;s ability to comply with Nasdaq&#8217;s minimum listing standards and other matters related to
      compliance with the requirements of being a public company in the United States; Entera&#8217;s and OPKO&#8217;s intellectual property positions and their ability to protect their respective intellectual property; and other factors that are described in the
      &#8220;Cautionary Statements Regarding Forward-Looking Statements,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of each of Entera&#8217;s and OPKO&#8217;s most recent Annual Reports on Form 10-K
      filed with the SEC, as well as the companies&#8217; respective subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera and OPKO will be
      realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera or OPKO, as applicable. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements
      and estimates will be achieved. Entera and OPKO caution investors not to rely on the forward-looking statements made in this press release. The information in this press release is provided only as of the date of this press release, and neither
      Entera nor OPKO undertakes any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Company Contact:</font><br style="line-height: 1.25;">
      <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Entera Bio</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
        Ms. Miranda Toledano<br>
        Chief Executive Officer<br>
        <u>miranda@enterabio.com</u></font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">OPKO Health</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
        Alliance Advisors IR<br>
        Yvonne Briggs, 310-691-7100<br>
        <u>ybriggs@allianceadvisors.com</u><br>
        <br>
        or</font></div>
    <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
        Bruce Voss, 310-691-7100<br>
        <u>bvoss@allianceadvisors.com</u></font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>entx-20260129.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<xs:schema targetNamespace="http://enterabio.com/20260129" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:entx="http://enterabio.com/20260129" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20260129_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20260129_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20260129_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://enterabio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xs:element name="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" id="entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OrdinarySharesParValueOfNIS00000769Member" id="entx_OrdinarySharesParValueOfNIS00000769Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>entx-20260129_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://enterabio.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="entx-20260129.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://enterabio.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="definition: EntityListingsLineItems to DocumentType" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="definition: EntityListingsLineItems to AmendmentFlag" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="definition: EntityListingsLineItems to DocumentPeriodEndDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalYearFocus" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="definition: EntityListingsLineItems to EntityFileNumber" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="definition: EntityListingsLineItems to EntityRegistrantName" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="definition: EntityListingsLineItems to EntityCentralIndexKey" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="definition: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="definition: EntityListingsLineItems to EntityTaxIdentificationNumber" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine2" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine3" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="definition: EntityListingsLineItems to EntityAddressCityOrTown" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="definition: EntityListingsLineItems to EntityAddressStateOrProvince" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="definition: EntityListingsLineItems to EntityAddressCountry" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="definition: EntityListingsLineItems to EntityAddressPostalZipCode" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="definition: EntityListingsLineItems to CityAreaCode" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="definition: EntityListingsLineItems to LocalPhoneNumber" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="definition: EntityListingsLineItems to Security12bTitle" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="definition: EntityListingsLineItems to TradingSymbol" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="definition: EntityListingsLineItems to NoTradingSymbolFlag" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="definition: EntityListingsLineItems to SecurityExchangeName" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="definition: EntityListingsLineItems to EntityEmergingGrowthCompany" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="definition: EntityListingsLineItems to WrittenCommunications" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="definition: EntityListingsLineItems to SolicitingMaterial" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementTenderOffer" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EntityListingsLineItems" xlink:to="EntityListingsTable" xlink:title="definition: EntityListingsLineItems to EntityListingsTable" order="29.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: EntityListingsTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="entx-20260129.xsd#entx_OrdinarySharesParValueOfNIS00000769Member" xlink:label="OrdinarySharesParValueOfNIS00000769Member" xlink:title="OrdinarySharesParValueOfNIS00000769Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="OrdinarySharesParValueOfNIS00000769Member" xlink:title="definition: ClassOfStockDomain to OrdinarySharesParValueOfNIS00000769Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="entx-20260129.xsd#entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:label="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:title="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:title="definition: ClassOfStockDomain to WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" order="2.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>entx-20260129_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain" xml:lang="en-US" id="us-gaap_ClassOfStockDomain">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsTable" xml:lang="en-US" id="dei_EntityListingsTable">Entity Listings [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsTable" xlink:to="dei_EntityListingsTable" xlink:title="label: EntityListingsTable to dei_EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsLineItems" xml:lang="en-US" id="dei_EntityListingsLineItems">Entity Listings [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems" xlink:title="label: EntityListingsLineItems to dei_EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="entx-20260129.xsd#entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:label="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:title="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" />
    <link:label xlink:type="resource" xlink:label="entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember_lbl1" xml:lang="en-US" id="entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember_lbl1">Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:to="entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember_lbl1" xlink:title="label: WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember to entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="entx-20260129.xsd#entx_OrdinarySharesParValueOfNIS00000769Member" xlink:label="OrdinarySharesParValueOfNIS00000769Member" xlink:title="OrdinarySharesParValueOfNIS00000769Member" />
    <link:label xlink:type="resource" xlink:label="entx_OrdinarySharesParValueOfNIS00000769Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="entx_OrdinarySharesParValueOfNIS00000769Member_lbl1" xml:lang="en-US" id="entx_OrdinarySharesParValueOfNIS00000769Member_lbl1">Ordinary Shares, par value of NIS 0.0000769 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrdinarySharesParValueOfNIS00000769Member" xlink:to="entx_OrdinarySharesParValueOfNIS00000769Member_lbl1" xlink:title="label: OrdinarySharesParValueOfNIS00000769Member to entx_OrdinarySharesParValueOfNIS00000769Member_lbl1" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>entx-20260129_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://enterabio.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="entx-20260129.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://enterabio.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="entx-20260129.xsd#entx_OrdinarySharesParValueOfNIS00000769Member" xlink:label="OrdinarySharesParValueOfNIS00000769Member" xlink:title="OrdinarySharesParValueOfNIS00000769Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="OrdinarySharesParValueOfNIS00000769Member" xlink:title="presentation: ClassOfStockDomain to OrdinarySharesParValueOfNIS00000769Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="entx-20260129.xsd#entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:label="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:title="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" xlink:title="presentation: ClassOfStockDomain to WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: EntityListingsTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="presentation: EntityListingsLineItems to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="presentation: EntityListingsLineItems to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: EntityListingsLineItems to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="presentation: EntityListingsLineItems to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="presentation: EntityListingsLineItems to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="presentation: EntityListingsLineItems to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: EntityListingsLineItems to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: EntityListingsLineItems to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: EntityListingsLineItems to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="presentation: EntityListingsLineItems to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: EntityListingsLineItems to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="presentation: EntityListingsLineItems to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="presentation: EntityListingsLineItems to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="presentation: EntityListingsLineItems to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="presentation: EntityListingsLineItems to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: EntityListingsLineItems to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="presentation: EntityListingsLineItems to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: EntityListingsLineItems to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="presentation: EntityListingsLineItems to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="presentation: EntityListingsLineItems to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="EntityListingsLineItems" xlink:title="presentation: EntityListingsTable to EntityListingsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityListingsTable" xlink:title="presentation: CoverAbstract to EntityListingsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !T E@# 2(  A$! Q$!_\0
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M?/7?XV\2MGZYU,UYU15K+,M6V7X)>F$H+_W&)YUG#WS;,WZX_%/_ -RG=/\
M%'XF29\SXB>.GSR=_B[Q V2!@$[M0.<#CGM51_B#X]D_UGC?Q?)W^?Q+K+<^
MOS7I]37(45:P.!6V#PJ],/17Y0(>;YM+?,\Q?KC<2_SJG02>+?%<O$OB;Q#(
M/236M2?V_BN3VXK&GNKJZ8O<W,]RY)8O/-),Q8YR2TC,23DY.<G)J"BMH4:-
M-WITJ4'WA3C%_?%(YZN,Q==<M;%8BM%[QJUZM1/Y3DT:5KK.KV)!LM5U*S(Q
M@VM]=6Y&.F#%*F,=L5U^G?%OXJZ.5.D?$WX@Z65QM.G>,_$=B5QTVFVU*+&.
MV,8[5Y]16=3"82M_&PV'J_\ 7RC3J?\ I46:TLRS&@DJ&/QM%+94L57II>BA
M45CZ;\*?MJ_MA>!KRUO_  C^U/\ M#:#/9RI+"EA\8_B EFQ0Y$=SIS^('T^
M\MVZ26MY:SVTR$I+"Z$J?TK^ '_!P1^W_P#"&_LX?B'XD\)_M#>%(YXOM>C_
M !&\-Z;H_B!;)5"RPZ3XS\$VOA_4(;R3 =+[Q'9>+$C<L39RH=@_#FBOG,WX
M%X-SVC*AFW#&28R,HN'M)9=AJ>)A%WO['%T*=+%T'=M\U"M3DGJG<^CR?Q!X
MXR"M&ME'%>>X1QFJGLO[1Q%?"5)JR3KX'$SK8/$*T4N6O0J1:7*TUH?Z/W_!
M/O\ X*L_LX_\% M/FT/P?/>?#OXT:/I@U3Q'\&O%]U;/K0L8V$=WK'@[684M
M['QMX?M92JW=W8P6>KZ6LMM+KN@Z1%>V,EU^G5?Y17PF^*GCKX'_ !+\$_%S
MX::[=^&O'?P^\0Z?XF\-:Q9RRQO!?Z?*'-O<I%)$;O2]1MVGTS6--E<VNJZ3
M>7NF7J2VEW/$_P#J%_LX?&;2_P!HCX!?!WXYZ-:M86'Q6^'/A/QP-,=E>32+
MO7M'M;W4M&E=))D:;1]2DN],F9)9%:6T<K(X(8_PSXW^%&%\/,?@,PR2I7J<
M/YS.O3HT,3/VM?+<;04:D\(Z[M*OAZM*?M,)4J7KJ-*M2KSJ2IQK5O[O\#O%
MK$^(^78_ 9U2H4>(LEC0GB*N%@Z6'S+!5^:G3QL:+<E0Q%.K3=/&4H/V/-4H
MU:$:<*KH4/:J_-G]OW_@J'\!_P#@G7?_  OTSXP>$OBEXPOOBO9^+K_1+?X9
MZ7X1U-M+M/!\WARWNYM=_P"$I\9^$O(749O$<2:5]@&H>:=.U+[5]D\JW^T_
MI-7\'W_!QO\ %8>./V^=/\ 6FIBYT_X,?!KP3X9N]-C=&BTWQ-XJN=8^(&IR
MN%&Y+R^\/^)?"(G5FQ]GM+(A%.XO\UX.\&8#CKC?"Y-FL*U3*J6 S#'YA##U
M9T*KI4*'L:'+6A%NG;'8C".3=E*-X7O-)_2^,O&F.X#X%QN=Y5.C3S:>-R[
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M-3+Y2C/EJQRC#0C5S64+.[5;VF$P%56Y70QM9.49<M_F2BBBO] C_.\***]
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MCZ2BGUV/YG:*_IM'_!L-^TCCG]I+X( XZ#1?'A&?K_9(X]\?A4,O_!L1^TR
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M4L1R23A4E@,/AZM2*G_"Q&(PN(@O:4H2CZ;1117\%']]A1110 4444 %%%%
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MZ!_1IR-9;X?2S2<+5N(<VQF+4VK2>$P4EEM"GN[QC7PV,J1;47^_>CCRR?\
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MT6LKA0X"S3,*E.#J9EQ)BN2=VV\-@\#@*%.,D](N.(>+:M=N,HMMZ*/].?\
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MK(@V,?&FM:MXI\365LYY\V%? OA::[P 4CN[49Q*17]B=?YY_20SAYEXDXC
MJ?-2R'*LMRZ,4TX*K7I2S6M)6;7/?,(4JC=I)T5!KW$?Z-?1KR997X8X/&2A
MRU<^S3,\TGS*2G[.E6CE5!/F2:A*GEJK4^6\)1K>TB_WC"BBBOP,_?@HHHH
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M!\:-6\3_ !IUO:2SW-OXIO8])\'74DC*I(N?A_X<\)W2QJ/+B-PZKN<R2/\
ML37^8/C!GBX@\2.*\="?/0HYC++,,T[P='**5/+5*G[TER5IX6==.+2DZKG9
M<S2_U-\'LB?#OAKPEE\X<E>IE<,SQ,6K36(SBI4S2<*FD7[2BL7&@TT^14E!
M.2BF_P"+W_@YW^*$.M?M ?LW?!Z"61V^'WPH\3>/;U 3]GCN?B?XJCT6&(_-
M@W4=I\,(IW!7*07EN58^:P'\Q-?J_P#\%N?BC+\4?^"E?[1,J7D=WI7@&_\
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MHX>G&E2CS2;E+EA"*O)N3M=MO4_RL?VE/$0\7_M%_'WQ8)!,/%'QK^*GB(3
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M\:06-K<3RRPQ1O*GFE?TA_\ !N+^R+=_$O\ :,\4?M6^)-+9_!'P!TN]\/\
M@Z[GC;[/J/Q;\9Z6]B_V9O,$<Y\)^![_ %6\OXI(I#:WWB;PQ>1,DJHR_(\=
M\3T>#N$L\XAJSC&I@,#5^I0E9^VS&NO89?047?F53&5**G92Y:2J5'%QA(^R
M\/N%:W&G&.0\.TJ<YT<=CJ4L?*/,O8Y7AW]8S*LYQ<>1PP=.JJ3<H<]>5*E&
M2G4A?^TGP'X+T'X<>!_!OP]\+6D>G^&? GA7P_X.\/6,,:116>B>&=)M-%TJ
MVCCC"HB06-E!&JH H"X Q70ZA?6NEV%[J=],MO9:=:7-]>3N<)!:VD+W%Q,Y
M[+'#&[L>P4U;KXD_X*1_%%O@U^P9^UAX_AU(:/J-A\%/&>A:%J6^-'L_$WC?
M3V\#^%YH#*"ANE\0^(],^R(RN)+DQ)L?=M/^6N7X2OG&:X' QE*>*S3,,-A(
MSES2E.OCL3"BI2:3E*4JE5-V3DVWHVS_ %8Q^+H93EF-QU2/+A<LP.(Q=2$%
M&*C0P6'G6E&";C!6ITVHIRC%:7:6J_S;/C/\0I_BW\8?BO\ %:YAEM[GXF_$
MKQU\0KBWG*M-!/XT\4:IXDEAF9&=&EBDU)DD*.REU)5F&"?-:**_URP]"EA<
M/0PU"/)1P]&E0HPNWRTJ,(TZ<;O5\L(I7>KMJ?X^8G$5<7B<1BZ[4JV*KU<1
M6DDHJ56M4E4J-16B3G)M):+9!3XXWED2*)'DED=8XXXU+R2.Y"HB(H+,[,0J
MJH)8D  DTROK_P#X)_?"Z;XS?MN?LL?#F."*YMM<^-_@"[UF"92T<GAGPWKU
MKXI\5@H%;>1X:T75F1& 1W"K(R(6=>?-,?2RO+<QS.O;V&78'%X^M=\J]E@\
M/4Q%2\K/E7)3=W9V6MGL=63Y=5S?-LKRFCS>VS3,<%EU+E2E+VN-Q-+#4^6+
M<5*7/55DY13>C:W.YC_X):?\%$Y "O['7QU .,;_  5>Q'D9Z2%".O?IT/(J
MVO\ P2H_X*,/T_8]^-8_WO#&S_T.Y7_/T-?Z6M%?Q(_I3\8].'N&5ZQS1_\
MO11_<Z^BEP-US_BQ^F(R=>O_ #)W_7<_S4E_X)/?\%'7Z?L?_&,?[VB6B?\
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M!7P5J7B#3XU11:^*?%NF1^,?%D;[ %>?_A)=?U5KF49\ZX:64LQ<L?\ -Q^
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M9<;\:3^/B_BB?3WL_P VEIVUQ;+CP;PA#2'"O#<%VCD>61_+"HZ"U_X)*_\
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MXA7],445]!+CWCKE?_&:<6?^)'G'?_L,/#CX>< 7_P"2&X/Z?\TSDO\ ,O\
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M[-/P"\:N6W^;XJ^#WP]U^99!G$B3ZIX>NIDD&YL2(ZN-QPW)SX[?_P#!,O\
MX)[ZD2;C]C3]G:/.<_8/A?X8TH<^@TNQLPOMM QVHHKUL/GV>X2"IX3.LVPM
M..L88?,<91@GW4:=:,5\D>7B<CR3&5'5Q>3Y7BJK2BZF)R_"5ZCBMDYU:,I-
M*[LKV5SC[S_@DG_P3=OBQF_9"^$R;LD_8['5]/'/]T6&KVP7V"X [5S5S_P1
MG_X)DW>?-_9,\%ID$'[-XF^)%EU]/L?C2#:?0K@CMBBBNZ'&7%]/^'Q7Q)#_
M  9[FD?_ $G%(XI<)<*3^/ACAZ?^+)<ME^>&9CR?\$2_^"7DOWOV4M#'?]W\
M1_C/#_Z)^(\?Y=#WIJ_\$2?^"7:]/V4]%/\ O?$KXU/_ .A_$EO3_.3116_^
MO?'%K?ZY<5V6R_UBS>R^7UPQ?!'!;=WPCPPWW>095?[_ *H:,/\ P1=_X)B0
M8"?LG>%&QT\[QE\5+C\S<>.Y2WXY_4UMVW_!'S_@FG:X\K]D?X<OMZ?:;WQC
M>?G]L\33[O\ @6:**REQKQE/X^+>)I?XL^S67YXMFD>#^$H?!PMPY#_#DF61
M_+"HZ.U_X)2_\$Y;/'D_L>_!9\=/M7AQ[[\_MUW<;O\ @6<]ZZBR_P"":G_!
M/NP(,'[&7[-TFW&/MOPD\':B./4:AI5T&]]V<]Z**YY<4\3S^/B//I_XLWS"
M7YXAFRX7X:C\/#N11MM;*< K?=ASTSPO^QO^R)X(8OX-_99_9T\*R,XD:;P]
M\$_AMH\[R *!))/8>&H)I) %4!W=G 50#A1CW71O#'AKP['Y/A_P]H>A1;=O
ME:-I-AI<>W^[LLK>!=OMC'M117EXG'8W&2<\7C,5BIO>>)Q%6O)V5E>56<F[
M+35['JX?"83"4XTL)AL/A:45:-/#T:=&G%=HPIQC%+T2-RBBBN4Z HHHH **
%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %< E@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ!K5Y)<ZSXDUNZ=Y)KW6M<O[_4[N>666>Y=G->U@!0%4!54 *H    P  .
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M8QC%)))>;U"BBBN4Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BHIKB"W :>>&!3T::1(P<$ X+LH."P'U('<5A:AXO\ ">DJ[:IXG\/Z<(T,
MC_;=9TZV*H "6VS7"-CD8P#DD 9)&4VEJVDN[:7YF=2M2HIRJU:=**WE4G&"
M7JY-(Z*BO'=0_:%^!&DL$U/XQ_#.P<XPEWXU\/0-\P++E9+]2-R@E<@;@K%<
MA3C$D_:H_9NC)#?'#X9'!8'R_%VCRC*AF.#%<N&!"G:RDJY*JA9F4&/:TEO4
MI_\ @<?\SQ*W%7"^'FZ>(XDR"A4B[2A6SC+J4XOLXSQ$9)^J/?:*^?D_:M_9
ML<X7XW_#8<@?/XITV,9(9NLDRC&%.3T!*J2&= VC:?M,_L\7\J0VGQM^%TLT
MCE(XO^$V\/I+(P7=A(Y+Y';(Z%002" 2011[:D]JM/\ \#C_ )D0XOX3J2C"
MGQ1P[4E)J,8PSO+9RE)M)**CB6VVVDDDVVTNI[A17'Z/\0? ?B!5?0O&GA75
MU<@(=.U_2[O?D C8(+IRX.1AE!!.0"2#CJX;B"X!:">&=1U:&1) ,D@9*,P&
M2I'U!'8U:E&7PR3]&G^1[E'$8?$14\/7HUX-74Z-6%6+6FJE"4DUJM4^J):*
M**9L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YY\6?BMX
M"^!WPV\:?%OXH>(K+PKX!\ :!?\ B3Q-KM_($AL].T^(R,D2$A[J^NY/+L].
ML( ]UJ%_<6UE:QR7$\:-Z'7\*W_!Q-_P4AO?C9\7)?V*_A3KMS'\(_@OJ\,_
MQ5OM.O)H;/X@?%FU4M_8UPD0C6_\.?#I)5MX(YI)[.]\827]^+=CH&B7[_;^
M'W!6,X\XDPN2X>4J.%BGB\TQJBI+!Y=2E!5JB3TE6JRG##X:#NI5ZL'-*E&I
M*/QG'G&.#X'X=Q6=8F,:U>ZPV6X-R<'C<PK1FZ-'F2;C3A&%2O7FE>-"E4Y;
MU'",ORL_X*8_\%%OB1_P44^/5_\ $#7!J7ACX4^&)+O1O@Y\,);XS6WA3PSY
MS?\ $UU>*WE>PNO&WB,+'>^)=2MQ(D;"VT:RN)M,TJSDD_..BNT^''@#Q/\
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M"^NLUH]C^QBBBBO\X3_0\**** "BBB@ HI"0H+,0JJ"68D   9))/  '))X
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M,JF]ETBXTW3D!(&]]1U06=F$&[)(F8G#!02I ^O/!G_!+[X\:\(IO%6M>"_
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M_J[PAD>75J22AC%@J>)S&R3BN;,\9]8S";M*2;GB9/WI=V( % 50%50 J@
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MAAL;'!8>HHJH\-6C4GAL1B$IPH0KPC*A5TJ58PJ2:HRV/[/?C;^V;\#?@?\
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MDT:2G%N%3 3Z_D!#!K/B/55AMX=3U[6]3N&*10QW6J:KJ-T^YW*QH)[N[N'
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MH2G#%Y[@:N,Y=X9;@:JQ^95$[-)PP&&Q$H.2LY\L7NC]]J***^K/]J HHHH
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M17L']SA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5].T\Q,Q-O=2I=ZE$0KK>JX&/M-55%5$541%"HB@*JJH 554 !54
M8IU:T<#1I/GE>M4W<ZFNN]XQ=TG?6[<I)[2/K^ ?H_\ !/!>)6=9C"OQGQ=4
MJ?6<3Q-Q+_MN(>,<N>6)P>$KSKT<)5<_>CB:D\7F$7>^.DG80 * J@*J@!5
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MFJ7#^.=0FT#P,=0;,DV_PAX?NH9=<MY+AFEGC\5ZUKEO?.6>YLPC^0BQ?!_
MO#K:X@X\I9SBX1;EE?!.#_M).6JC'^VL;4PV7TU>W.O95*L5=^R?N\VF$XKX
MSS_7(^!Z^3X64X*.8\:8M99)0]V51K)L#3QF/J22<E#FJT*4I.+]LK5(PZ>'
M_@N5X;^._B+5? /_  3X_9+_ &@/VQO%UE91R#Q#!I-G\*_A5IE[/YS16WB7
MQAXOD%YX?!A@:9&UK1]*CNU=5LIYY$N$A^K?"7P6_;^^/<\.L_M4?'OPW^SU
MX"N299/V?_V1+>X3Q+?64J0E=,\=?M(>,;2?Q4I8+*E]!\*_#?@*[B,K6]KX
MKN(XOM5S^A/@?P#X%^&7AK3/!GPX\&^%O 7A'1;6"QTCPQX.T#2_#6@:9:6L
M*6]O;6.DZ/:V=C;10P11Q1I% H5$51P!76U\IC\\RBFW2X<R"AEE))Q6.S.N
M\[SBK%I+FE5KTJ65X6=XJI3J8#*L-BJ$VU#%RB?48'*<UDHU<^SNKF%:\9O"
M9=0CE&4TJB;=J=*E4K9GB()2<)T\?FF*PU5*,I86,TK>=?#;X2_#OX1Z,VB?
M#[PQ9:#;W!BDU/4&FO-6\1^(;N&)85U/Q5XKUJYU'Q-XKUAXU"S:QXCU;5-3
MGQF:[<UZ+117S%2I.K.52K.=2I-WE.I)SG)]Y2DW)OS;;/H8QC"*C",8Q2LH
MQ2C%+LDK)+T"N)^)'CC2?AIX"\6^/=;ECBTWPIH6H:Q/YID"SR6T+&TLU\I)
M)#+?WC6]C J1NS37$:JI)KMJ_'7_ (*A?'<0VWA_X"^'K\>;<F#Q5X]-O)DI
M;1LZ^'-"N#Y)&9YEFUF[B2=)$6VTHR1F*YP>7$UE0HSJ?:M:"[S>D?6V[\DS
MX#Q2XYPOAUP-GO%.(E!XC"85X?*L/.S^MYQB[T,NPZAS1E."KR5?$J#YH8.A
MB:UK4V?C[XF\0:EXL\1Z]XIUB9KC5O$>LZGKFI3,<F2^U6\FOKIL\<&:=]H
M 5<*   !;\%^#O$/Q!\5Z%X+\*:>^I^(?$>H0Z;I=DA"^9/+N9I)9#\L-O;0
MI+<W4[?)!;0RS/\ *AKF*_H#_8 _90/PE\-Q_%;QU8/%\1_%^FA=,TV[A,<O
MA#PQ>+#,EM+%(/,BUS5@J3ZGO6.6RMO)TS8DHOC-\]AJ$L354%>WQ5)=HWU>
MOVGLO/79,_RS\)?#7-_%[C2&7N>(CEM*LLSXISC1RPV"JUW.KRU)IQEF.8U/
M:4<'!J;=5U<3.G.AA<1R_77[/WP4\/\ P#^&6A> -#6*>XMHEOO$>KHA237?
M$EU#"-4U1R^91%))&L-C#(2;6PAMK9<+%BO:Z**^FA&,(QA%6C%))=DOZU>[
M>K/]?LKRS 9+EN!RC*\+2P679;A:&"P6$H1Y:6'PV'IQI4J<%O:,(J\I-RE*
M\I-R;;****H[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *IZAJ-AI-C=:GJE[:Z=IUC ]S>WU]<16MI:V\0
MW237%Q,R10Q(.6=V51ZUY1\:?CQ\-_@)X8;Q+\0=;2S\]9DT;0[0+=:_XANX
ME4FTTC3@ZO*59XQ<7D[P:?9+(CWEW K*6^"9?AW^T=^W!J%OJ_Q.EU#X'?L]
M"[CO=&\"6LCKXL\564;J;:ZU6"4*6GFB>22/4-8M(+&V81/IGA^Z4KJ3<]6N
MH/V=.+JUK*U..T4]I5);0CZZNZLM;GY_Q1QY2R?&+A[A_+,1Q9QG6I0JT>'L
MNJ0IPP%"M=4LQXCS.:EA<ARMM-PK8MO%8NSAE^$Q<U)0/C+^W/XM^(7B";X0
M_L?>']2\8>);O[59W?CRWT\306RJ1!)/X;MM0C2SCMHV,@/B;7C:Z9$_DR6<
M-S'+%=U+\$_^"<\$VL-\1?VF_$%Q\0?%^HW0U6Z\,0ZG=W.E-?.R2^9XGUQV
MCU#Q!.C*%DLK62UTHJOV>:34[,^4?T&^%GP<^&_P7\/IX;^'/A?3_#]B=K7E
MS$GGZMJTZ@#[5K&K3[[_ %*XP $:YF=(4 BMXX856-?3JRCA74DJF*DJLU\-
M-75&'DHOXO-RT?5.R9\E@/":MQ%F.'XE\6\SH\8YOAZBKY=PUAX5:/ G#D[6
M4<!E%9N>;XE)RC5S+.?:SQ$7&+PM-4Z;69H^BZ1X>TRST70=+L-&TC3H([:P
MTS2[2"QL;.WB4)'#;VMLD<,4:J  J(!W.3S6G117:DDK)62T26R78_:X0A3A
M"G3A&G3IQC"G3A%0A"$$HQA",4HQC&*2C%))))))(****"@HHHH *^6/VJOV
M*_V9OVT_!0\#?M&?"S0O'EC:C=H6O$3Z/XV\*3_:(+II_"GC32)+/Q'H/GSV
MT/V^TLM033=7MU:QUBRU"PFFM9/J>BNG!XS%Y?B:.-P&*Q&"QF'FJF'Q6%K5
M,/B*%2/PSI5J4H5*<UTE"2?F<^*PF%QV'K83&X:AC,)B(2I5\-BJ-/$8>O3D
MK2IUJ-6,Z=2$EHXSBXOJC^&+]M#_ (-G?C_\,;G4?%G['7C.U^/O@91<7$?@
M#QC<Z5X2^,&D11Q1&&TMM0VV'@;QT9&6Y:6^AD\#WD;/:VMOX<O%\^]3^<GX
MG_"'XI_!3Q/>>"_B[\._&7PU\56,]U;SZ'XU\.ZIX>OV:SG:VGEM8]2MK=;^
MS$JXBO[%KFQN4:.:VN)89(Y&_P!=.O)OB[\!_@M\?O#<_A#XV?"OP%\4_#5P
M(]^D>.?#&D^(K:-X9#-!-:G4;6>:RN+>8F>VN;.6"XMY\302QR@./Z$X4^D;
MQ)E<:.%XFP5#B'"PY8/&4G' 9JH+3FG*G!X/%2A&UE+#T*M5J]7$N<G,_ N*
M?H\\-9HZV)X<Q=?A_%3YIK"S4L=E<INSY8TZE2.+PT9RYKN&(JTZ7-^ZPW)"
M-(_R0**_OC_:/_X-H_V*OBFFI:M\$/%'Q"_9U\470U.XMK?3;Q/'_P /_P"T
M;^=;B*6[\*>)9H=:AT^Q?S([72_#WC#0+2*WE-NB)'%;>1^)'QV_X-GOV[?A
MRVIW_P '_$GPG_:"T2UCB>PL])U^7X=^.M18H#.C>'O&R0>%+7RY,I$5^(=T
MTZC>R0_<'[]D/CAX=YY&G&></)<3/1X;.Z$\'RNZC=XR+K9<HMM--XQ2Y?>E
M"*4N7\'SSP1\0LEE.5/*89SAH:K$Y-B(8IR5N9)8.I[#,'*UTU'"2BI+EC.5
MXN7\Z=%?;/Q4_P"";O[>?P6:;_A8W[)WQMT>"!U234=,\$ZEXMT;+J[[TUOP
M<FOZ/+"@C*RW$5\\$,C0Q32))/"DGQUK&AZWX>O&T[7]'U30]00,SV&L:?=Z
M9>(JRRP,S6M[#!.H6>":%B4 $L,L9^>-P/TW YME6:053+<SR_,8-74\#C<-
MBX-=U+#U:B:\T['YMC\FS?*Y..9Y5F6725DXX_ XK"23>R:Q%*FU?I=:]#+K
MJO"7COQQX!OGU3P+XR\5^"M3D6-9-1\)>(=7\.7TBQ%FB5[O1[RSN&6-G=HP
MTA"%F*X+'/*T5VU*5.M"5*M3A5IS5ITZD(U(22::4H23C)72=FGJDSAI5JM"
MI&K0JU*-6#;A5I3E3J0;3BW&<&I1;3:=FKIM;,_2#X8_\%=O^"CWPF73K?PU
M^UA\4=2TS3+;[)!H_C34[?QSI\D(#[#<?\)3:ZI>33I(XF-TUX+J9HTCN9I[
M8R0/]T>!O^#E7_@HQX9:RC\4?\*2^(MK;H4N6UWX<R:+J5[B%DC=[SPEKNA6
M4+^=Y<LQCTK$JK)$@A,BRQ_S[T5\AC_#O@7,Y2EC>$\AJ3FI<U2GEV'PU63E
M?FDZN&A1J.;NWS\W/>SYKI6^PP'B-QWEJA'"<5YW&$)*4*=?'5<93CR\J4?9
MXQUX>S2BE[)Q]G;F7):4K_U;>'O^#JOXX6T,2^+/V2OA3K4XA59I/#WQ!\7>
M&(9+@;M\L4.I:3XN>&%LIM@>XG=-K9N'W#9[9X?_ .#K70Y3$OBK]BW5K!3$
M&GG\/_&VSU<I/NNU:.*UU+X;:()(MD=C()GO(GW7=W";?&GPW&I_QNT5\OB/
M WPOKJ7_ !C7L)2=^>AFN=4W'_#!YA*DEY>SLNEM3Z2AXW^)E&2<N(88B*5O
M9U\IR=Q>VKE2P%*JVK?\_-;N]S^WFS_X.I/V<6$GV_\ 9?\ C;"1L\HV?B+P
M)<A_E(D\P3:A:^7A@&3:9,JY5MICWRZ$G_!U!^RX-GE?LT_'U\QJ9/,U/X=Q
M[)3G>B;?$,OF1KQMD;RV?)S$F.?X=J*\Y_1^\-6_^1=F*\EFV,M^,V_/?J^E
MK>BO'WQ%_P"@W+'YO*L-^EE^!_;U=_\ !U)^S@H7[#^R]\;IF(?>;OQ'X$M1
M&<+Y958;Z[,H)+;P6A*A5"EMY*>;^(_^#K/P;!(Z^$OV-/$VJ1'SS'+XC^,6
ME:%(NV*[:V5[?3/ 7B)6\V9+&&=UN4^SQ7-W<QI<M8PVFH?QL6-A?:G=16.F
MV5WJ%[/O\FSL;::[NIO*C>:3RK>W2263RXHY)7V(=D:.[856(^B/ ?[&_P"U
MG\4+DVOP^_9J^.?BV81O)_Q)_A?XRN(6$<T5NZ1W)TA+>6<331H+:.5KALLR
MQ%8Y&3"KX)>$F66J9AA71@HN3_M#B#&8:FX[<SDL7AG9/JI)75G?8Z:'C/XL
MYHO9Y=-8B<IJ">7\/T<5/G7+)TXQ6'Q$7)QM>+@Y<LKJUTU_1YK'_!UE\4)U
M?^P/V-_ 6F,?+V'6/B]XAUQ5Q_K=ZV7@?P\7WC_5X9/*_B\WI7@'BW_@Z _;
M?UJVNXO#'PL_9^\&7$C_ .A74.A>+]>^S1><#MN8-7\6NEY+]GW1^;&;./SR
ML_D>4IM7^+_AE_P0?_X*A?$N\LXF_9SF^'NF7<+3'7OB;XW\#^%[.TQ$DJ17
MFD1Z]J7BZ*:4.$6-?#4ACE5XK@PNC*/T9^$W_!K)^T?K86X^-?[1_P (/A]&
M+N!O[/\ A]HGBSXF7LVG&-'G6:\UJV^&]GI^I>;YENJ0QZQ9QIY=V+FY)>S'
MA8O+/HW9"W*O+ARM*'+)PP^:9KG\KI^[%TL+C,QNVU[\)1M;6HN5W/;P>9_2
M-SQ>SHQSVA&HIP<\5E.39$HIKWI>UQ>!P$XV4KPG"7.W_!;DE;X%\;_\%_\
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MQE=*4W3IJWL\+AE.<,+AXPI*52?M*M0HHHK<_0@HHHH **** "BBB@ HHHH
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MH8C!TU&*P& S+V_US _/7PR_94TK2/%;_%?XS:]+\8_C%=;737M:@9?#7A1
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M?OWI^GV.DV-IIFF6EO8:=86\-I965I"D%K:6L"".&""&,+'%%%&JJB*H
MJ6UM;:QMK>RLK>"SL[."&UM+2UACM[:UMK>-8H+>W@B5(H(((D2*&&)%CCC5
M41550!/75AL-##0Y8ZS=N>;WD^R[171??=W9^O>%GA5P[X59!'*<H@L3F.)5
M.KG6=UJ<8XS-<5%.SDDY?5\'0<I1P>"A.5.A!RE.5;$U:^(K%%%%=)^G!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5BZIHL&M[;?5,7&EHXD;3,,MO>NH4H=2^;_2H89 SQ69 MFD$<UPL[
MQPB':HI-)JSU78F<(5(N$XJ4):2C+6,EVDMI1?6+NFM&FM!JJJ*J(JHB*%1%
M 5550 JJH "JH        Q3J**904444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX"_\@NNZ^]&]16#_ ,)5X8_Z&/0?_!QI_P#\D4?\)5X8_P"ACT'_ ,'&G_\
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MKH@RSB&.5P!\J,Q53NP?\&TW_!2.7=YC_L_6VW;CS_BEJ;;\YSM^S>"[C&W
MW;]F=PV[OFV_Z"5%?Q\_I$^(CVED<?3+)>7?%/\ IORM_6Z^C[X>K>EG+]<S
M:_*@MS_.T^(G_!NS_P %,? 6@7FNZ?X#^''Q)>SV$Z%\._B1IU[K]RA*&5[.
MR\3V/A6"X\B-I)7B6[%Q*('AM(;FZEM+>Y_$76M%UCPWK&K>'?$6DZGH/B#0
M=3O]%UW0M:L+K2]8T76-+NI;'4])U;3+Z*"]T[4].O8)[._L+R"&ZL[J&6WN
M(HYHW0?[ M?Y?O[>'@?X[_&O]M#]J/XHZ7\#OBC<:+XN^.?Q'O/#MWI'PO\
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ME/XLUZPT"U?36U&S6TD:TGOQ=W4,\D#_ &*TO)8RQCC67\+Z_K'P6X4X2R/
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MMK>\M)XKFTNX(KFUN8'62&XMYXUEAGAD0E9(I8W62-U)5T8,"00:_BZ^ O\
MP;&?'WPG\6OACXO^+7QK^#>I>"O"WC_PGXC\5^'O#-OXIU&_UGP[HVL6.IZC
MI=K+K7A^RL#=W<5K-:36UW;-92P2!1>YF<V_]I2(D2)'&BQQQJJ1QHH1$1 %
M1$50%554!550 H    K^,^-LGX.R:O@*/"7$M?B6-6G7GC\14PDL)2PTHRI1
MP]&G&=.$JDY+VTZDTY02]G&-I*5_[#X/S7BW-J&-K<5\.4.&YTZE&G@L-3QU
M+'5,1!PG*O7J5*-2<*<%)TZ=.FU&I>-24KQ<+.IKND2/)(ZQQQJSR2.P1$1
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MX=O_  _IEI;MIVIZ>EA%;1:KJ$MS+-'=.XE3R54Q-'/_  J?MX?\$VOVF/\
M@GCXKT'0_CGHNBWWAGQDVICP/\2?!.H7&L^"?$\FDM"U_I\=S>6.F:GI&N6=
MM=65U<Z/K.F64[07/G:?)J-O!<W$7S7AQX=\&<<8;#X;%\9U,LXEK5,3_P (
M<,)!SE1HRFZ<Z%;$>RIXFI.C"5:='#U*M2G33E.,4I6^C\0_$#B_@JO7Q6%X
M-AFG#E&GAV\Z>-<8PJU5"-2%>A0C6K8>G"M.-*->O3I4ZDY1C&3;7-_HNR?\
M%!_V$HO-\W]L?]F2+R?/\[S/C=\.D\K[+_:GVGS=WB$>7]G_ +$UGS]^/*_L
MC5/,V_8+ORB3_@H/^PE%YOF_MC_LR1>3Y_G>9\;OATGE?9?[4^T^;N\0CR_L
M_P#8FL^?OQY7]D:IYFW[!=^5_E3UZW\ OAC+\:_CG\&_@]%)>P'XH_%'P'\/
MY;K3HA->V-MXM\4:7H5YJ$"-#/&&TZTOIKYI)H9((4MVEG0PH]?JV)^C3D.$
MP]?%5^+,SA1PU&KB*T_[/PKY:5&$JE25O;:\L(MV\C\MPOTC\ZQF)P^$H<)Y
M?.OBJ]'#T8?VGB%S5:]2-*G&_P!5TYIR2OTOY:_ZUVE:KINN:9IVM:-?VFJ:
M1JUE:ZEIFI6,\=S97^GWL*7-I>6EQ$S13VUS!)'-#+&S))&ZLI((J_5'2].M
MM(TS3M)LHUBL]+L+33K2)%5$CMK*WCMH(T10%14BB1550%4  # %?RI?\%@_
M^"]LGPDUSQ9^RS^Q-J]C?_$+2?[2\._%#X]6SP7VF^!-90M97WA/X;1E)[36
M/%NE/]IAUSQ3,6TSPQJ<":;I<&JZO%?S:)_,W"G"&=\:9O#*,APKKU6O:5Z]
M67L\+@<*I*,L3C:]G&G3C=)*,95:TVJ="E4J2C!_TCQ1Q7DO!V53S?/<4L/1
MBU3HT:<?:8G&8EQ<HX;!T$U*K5G9N[<:5*"E5KU:5*$ZD?WO_:C_ ."@_P"Q
MW^QI;I_PT-\<_"7@K6IXH9[3P5:/>^*OB#>V]Q)Y4%Y;^!/"MKK/BG^SWE^0
MZI-I<.EP_,\]Y%&DCI^?OA3_ (.(O^";'BOQ?I_A&W\8?%/3WU;5;/1]+UB\
M^$OBFXTZ]O-0E%O9!+728=3UQ5GN7AM0K:1YPGGBQ"T EGB_SS?$'B'7_%NM
MZIXF\5:YK'B;Q)KE[/J6M^(/$&IWNLZWK&HW3F2YU#5-5U&>YO\ 4+VYD)DG
MNKNXFGF<EI)&8DU^L_\ P0V_9<_X:=_X*%?"-=6L9;KP1\$[@_'+Q;*8]02U
M:Y\"W5I=>"=-:]LU\B*ZO/'$N@WJV-]*EOJNEZ3K%M)%<VZW$)_I;'> /!O#
M'"V:9SQ%G6=XW$Y9EV)QE>K@9X/ 8652E2<J5##X>MA<94<ZM?EH0E6Q+525
M2+<*5W;^<LO\>.+N)N*<LR;A_),EPF%S+,,/A*5/'K&8W%1I3JVKXBOB*&*P
M5*,:6'4Z\H4\+)TE"24Z[M?_ $ET=9$5T.5=5=3@C*L 5." 1D$'! ([BG45
M^?7[??\ P4H_9Q_X)Y^ HO$?Q;UN37/'FO6]W_PK_P"$'AF:&?QMXSN[:)G,
MQC820>'/#5O)Y4>I>*M96/3[1IHK:TCU+5+BSTRZ_D_+<MS#.,=A\MRO!XC'
MX_%U%3P^%PU.56M5E9MVC%:1A%2G4J2<84Z<95*DHPC*2_J7,,QP.4X.OF&9
MXO#X'!86'M,1BL34C1HTHW44Y3FTKRG*,(15Y3G*,(*4Y13_ $$)"@LQ"JH)
M9B0  !DDD\  <DG@"OG/XH_M@?LI_!*XCL_B]^T=\$_AM>S,ZQ6/C+XE^$=!
MOI'197:-+*_U6&Z:7;#*5B$)D8QL%4D8K^"[]H7_ (*P_P#!2/\ X*7?$S3?
MA!\)+KQ?X)T;QAKD>G>#/@7^S[/J]CJ=^+F[2*R3Q7XRL#8^(?$"VB2J=8U7
M4;O0/"-M;+-J-]I.EV<4LD7W=\ ?^#6[XV^*_#ND>(?VB/V@_"/PGU6\$-U>
M_#SP1X8G^(FKV-K- '-CJ?C"?7/#V@:=K5M*_E72:1IGB[25:)Q:ZI=HZ3#]
MHJ^$62\+X7#XGQ(XVP7#N)Q,/:4<DRS"U,XS.4+2OSRH.2I.,TH.K3PV)P;E
M>/UM-77X_2\5LWXFQ-?#^'7!N,XBPN'E[.MGF9XJGDN5PJ.44G2CB8*IB(\C
M<Y4I5L-C(Q2E]4DFK_TW?\/6/^";WF^3_P -J?L][_+\S/\ PL+1_*V[MN//
M\WR?,SSY7F>;M^?9L^:MZU_X*;?\$[KS_4_MN?LNI\S+_I7QK\ V/*J')_TW
M7+?Y<'"O]QFRBL7!4?RY?&3_ (-8_COX=T.\U3X&_M+?#OXH:Q#+)+!X3\<>
M#M8^%\TUF#.ZVUIXBL=<\?:?=ZF$6"&(W]AH&GW,TDCS76G0H,_SD?M!_LV_
M'+]E3XB7'PH_:#^'.M_#'Q_;Z9::V- UJ33;O[9HM_<7EI9:SI6JZ+?:IHNL
MZ3=76G:A:P:EI.HWME)<V-W;K.9K:9$^HX<\(?"[B^4Z7#OB%CL=B:<7.>$E
MAL/A<;R*W-4C@L;A\+BJE*#:4ZU.E.E&4HJ4TVK_ "_$?BQXF\)0A5S_ ,/\
M%@L-.2C'&0Q=;%X+F;M&$\9@JV)P]*K4LW3I5JE.K-)N--J,K?Z>7_#?'[$'
MV'^U/^&NOV;_ .S?LGV_^T?^%S> /L/V'R?M'VW[7_;WV?[)]G_?_:?,\GR?
MWN_9\U:?@S]N#]C7XC>--+^''@#]JK]GKQK\0=;OKG3-'\#^%OB_X#U[Q9JF
MHV<%S<W=A8>'],UVYU6[O+6WL[N>YMH;5YH(;:XDE14AD*_Y15?O5_P;A?"R
MV^(/_!270/%-Y93W$7P:^$OQ'^(EI=*+@6UEJ]_!I7PXM#</%-#"TD]EX]U0
M6UO<BX5GC>YCMFDLQ<6W3Q3]'[).&>&\]SZKQ-F6(>5Y=BL70H+ X6E&K7A"
MV%HU).M-\E2NZ=.I*%I*,W*$7)*,N?ACQ[S?B;B/(\AH<,X#"_VGC\-A<17E
MF&)KNG0E+FQ5:E".%IVG"A&I.E";E'GBHU)J+<X_Z%U%%%?RP?TX%%%% !11
M10!YK\9/%<?@;X3_ !&\7R%P/#W@SQ#J2&,A7$T&F7'V<IEXR7\]H]JJZN[8
M2,[V45_)&S,[,[LSNS%F9B69F8Y9F8Y)8DDDDDDG)YK^CG_@HSXP'A?]F/Q'
MIT=TUK>>--<\.^&+4HRJT\9U!-:U&VP<EUGTO1[Q)%"G]T7;<I"D_P XE>%F
MD[UH0Z0IW^<FV_P4?Z1_G!],[/5B^-.%^'X2YH9+P]5Q]1)IJ&)SK'3A.$DI
M-J:PV582I:45[E6#3:D[%?U@_LZ^%1X)^!7PF\,^68I-.\"^'FN8V4)(E[?V
M$6I7PE52RB;[9>3^<5)5I=[+P17\NWPS\-2>,OB-X$\)Q!RWB/Q?X=T9C'PZ
M1:CJUI;3R@]O)ADDE)Y("$@$\'^NR**."**"%%CAAC2**-!A8XXU"(BCLJJ
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MH_AC1M3\1>(-0MM)T/1;*?4=5U.\?R[2PL;5#+<W=S)@^7!!&K22N1A$4L<
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M-X5TS6-,\3?W3Q11011P01QPPPQI%##$BQQ111J$CCCC0!(XXT 5$4!54!5
M  K\/XV\0L%X;Y31\-O#JM&&*R^#IY[Q!",95HX^5EC(T&^>$LRJSB_K>(O.
M&7QY,%A>6M0OA/VO@W@'&>(>;5O$7Q"H2EA\?)3R+AZHVJ/]G1N\'+$Q2A-X
M"G"7^S4'&G+'3Y\;BE.EB%'$_P"=?_P7)_X)R_!W_@GS\9O@_9? F^\1)\/?
MBWX#UG5%\.>*-1?7=2T'Q%X/U>TT_6)X=?F=+B]T_6+76=)G@M)[*)]/NK>]
M"75U#<Q0V7X=U_1-_P ',7Q:D\;_ +?/A[X=6]S%-I7P;^"WA31S"FTO;^(?
M%^I:SXMUCS&5OX],O?#B".1!*C0NQ=XI(53^=FOZ(\+L5FN-X X8QF=8NMCL
MQQ67RQ%;%XB;J5ZU*MB<14P<JM27O5*BP4L/&=2=YSE%RG*<FY/^??%##97@
MN/N)<)DV$HX'+L-C*5&EA</3C2H4:M/!X:.,5&E'W*=.6,6(G&$%&$5)1A&,
M4HK]NO\ @WHTG4]3_P""GOPFETZ39!H_@OXH:MK"&:2+SM,C\(WEEY?EH&%S
MMU&^TZ80N!&IB^TDJ;=2/]%ZOX5_^#7+X8IXA_:[^.'Q4EWM'\-/@>OA^!3&
MK0K?_$?Q9I@BF\PH6CN4L/!VIPP[70/!<7BLKX!7^ZBOY&^D-BX8GQ&KT8-.
M6 R?*\+5LFFJE2%7')-]7[+&4W==&ENF?UAX X6IA_#K"59JT<=FF:8JEK>]
M.%>.";MT_>X2JK/M?9H_E^_X.D/BQ_PCW[+/P(^#UM(/M/Q*^,=SXIU! 9OE
MT;X=^&;Z-0_E31QAI]7\6:>T"W,<\<BV=TT<:S0)-%_#17])'_!SK\6Y?&'[
M;GP[^%<03^SO@]\%=)<NEPTF[7/B%K.HZ[J8>#E('32M/\.H7#;Y0%$B*(49
M_P";>OZ;\#\I_LKPWR+FCRU<S>+S:KMK]<Q,UAY73:=\%2PSZ-?"TFF?S7XW
MYK_:GB+G,8R<J65T\'E5)MO3ZMAXU<1%)QBXJ.,Q&)C;WE)ISC)QDDOTL_X(
M]?":+XR_\%*/V3/"]WIEYJ6EZ+\2X/B/JOV5+HQV,'PMTK4OB#87U]/;/$+:
MR77/#FDVS/<R+:W%S=6UA+'=&\6SN/\ 3LK^&#_@UV^#?_"3_M5_&OXV72W0
MMOA5\)(?"^F$V8:QGUCXDZW")I%OGC81WUAI/A:[C$$,BR-;:M(TI$919?[G
MZ_FWZ1>;+'\>PR^$VZ>29/@L)*%Y.*Q.*=7,:LDG[JE*ABL+";CNJ48R=X67
M]%_1\REX#@-XZ<$JF=9MC<9&3C%3>'PZI9=2@VES.$:N$Q%2"D[+VTI15IW9
M7YU?\%+/^"B?PQ_X)U? :]^(OBA(O$OQ+\4_;=!^#GPSAG,=YXP\6"U>1;S5
M)(PTFE>#?#P,>H>)]:D50L @TG3OM&N:KI=G/]T>/?'/A7X8^"/%WQ&\<ZQ9
M^'O!O@7PYK/BSQ3KM_*D%EI&@:!83ZGJNH74TC)''#:V5M-,[.ZJ O+ <U_E
M_P#_  44_;C\<_M^_M,>,/C9XEFU73_"$<C>'OA-X'U">W:+P+\/=/D8:9IH
M@LLV::OJTIFU[Q)<K-?2S:SJ$]JNIWFG6&F^5X'A!X<OCW/I3QT9QX>R?V5?
M-9QDX2Q52;;PV6TIQ]Z,L2X3G7J0:E2PM.IRSIUJF'<O=\6?$./ F116#<)Y
M_FWM:&54Y14XX:,%'ZSF5:$KQE3PJG"-&G-25;%5*2=.I1AB.3P+]HG]HGXN
M_M4_%SQ7\;OC?XMO?&'CWQ==^;=WEPSQV&DZ= 673/#GAW3M[P:+X;T2V86F
MDZ3:GRK>(-+*]Q>3W5U/_9#_ ,&Z?_!-W0_AA\)++]N/XK:!;7WQ3^+5G-_P
MI>VU*VM;D^ ?A>ZW%H?%.FL1(UMXA^(PEN'-TKB:T\(0:;;VYMWUO68'_CA_
M9G^"^I_M%?M"?!CX&:2FHFX^*?Q(\)^#KJXTF!;F_P!+T75M7MH?$6NPPR))
M&R>'O#_]IZY<-)')%';:?-+(CHC*?]87PAX5T/P+X3\,>"?#-A;Z5X<\(>']
M&\,:!IEI$D%KI^C:#IUOI>F65O#&%CBAMK*UAACC10JH@ &!7[=](3B9</</
MY-P1DBIX"CF=&4\90PBC05#)L"Z='"X*G3IJ*IX?%5^924%%2IX*=!WIU:D9
M?B_@!PX\^SW.>-LY=7'5\OK*E@\1BI2K.MF^-C.MC,;4J3;=3$X;#R@H\SER
MRQWM;1J4Z4UT5?SK?\'-'P_T#Q'^P#X:\<WT%D/$/PX^.O@N70+Z<$7BVGBS
M2?$6@ZYIMC(K(Y%ZO]FWUU YDMY(]'69X&GM;6>V_HIK^3#_ (.A_P!JGP]I
MWPY^#7['FAZC!>^+?$OB./XR^/+&":.1] \,Z!;:EH7@R*_2"]2:"Z\1:OJ&
MMW=G;W=G-"UGH,MU^[DDL93_ #WX2X3&XSQ%X4C@%4=2AFM'%UY0NN3!852K
M8USDOAISPL:M*5VE-U%3U<TG^_\ BGB\%@_#[BN>.E!4ZV48G"45-)\^-Q<?
M88&,(O>:Q<Z,XM*\.1U-%!M?Q;5^S?\ P0"TKQ3J?_!4;X"/X<E>.QTK2?B;
MJOC%$D*>?X6@^'GB& Q/B-RZ+XCNO#LYC#1!C"-TA4&*7\9*_M._X-FOV&-<
M\%>%O'7[</Q!TDV$_P 2]'D^'GP5M-0TV:"_/@ZTU87'C+QE;W%Q(C?V?XCU
MC3-.T72C%:".XM=#O[R.\GM[V%(_[6\7\]P>1>'W$4\5.G[7,\#6R; T)I2E
M7Q>94YX=*G%[RP]&5;%N5UR1P[DGSJ*?\9>$.1XS.^/\@6&C55'*\73SC'5Z
M<N14,-E\XUE[22:?+B<0J&#Y%S.I]8Y9+V?M)1_K*K^.7_@ZK^*<S:G^R3\$
MH))A!#8_$+XIZG$&=+=YKFXTCPEH4DB&(QW,T:6OB)862='LDDG$D4JW\3Q?
MV-5_G;?\'$GQ7A^)'_!2SQYX>L[^[NK#X/\ @'X>?#<6TWG);66J#2'\9ZPM
MI$Y\K]Y=>+U6>XA!\YX521B8%2/^3/ '*_[1\1\OKN#G3RC 9EF<]&TFJ'U"
MC)M?#RU\=2G%MV<HI:WL_P"JO';,_P"SO#K,Z2FH5,UQ>7Y93?-%-\^)CC*\
M5&5^?FPN#KQ:BN:,9.::Y+K\,*_87_@@W\*[OXH_\%/?V?'2UMKK2OAN/&WQ
M1U];E2_E67AGP?K%GI,\"&VN(6GB\7:SX:9//:V5$\R2&X%VEM%+^/5?N;_P
M1H^-W@G]B[P[^VM^W-XPABN?$/PL^#6B_"SX,^'[^XGL[3Q]\3/BKX@-W;^&
MK,QVMR]T=-D\(:'JGB6YM$EE\/\ AJXN+RZ2.*_MV?\ LGQ&JXJ'!/$5# TI
MU\=F6!>2X*A32E4K8O/*U+**%."<HI-U,:FYMI4XJ51Z09_'_AQ1PU3C;AZM
MC:L*&"RW&O.\;7J.4:=#"Y%1JYQ6JU'&,GRQA@FN6W[R3C3NG-,_=_\ X+[_
M /!5]_V=_!VI_L;?L^^*K[3OCS\0="MI/B7XS\.70MKWX3^ =8.XZ/9:HJ2/
M8^./&^F+/;1&P:'5_#/AJ^;7K>]TG5;_ ,.7;_QC? +]F;X^_M2^,X_A_P#L
M^?"CQC\5?%+>4UU:>&--,NGZ-#/'=207GB7Q#>/:>'/"NGSBRN4@U+Q)JVE6
M$T\1MXKE[@K$WZ&_L&_L$_M&_P#!83]IKQQ\0_&WB37-/\!7'C"?Q9^T+\>M
M5A>^E34=<N&U$^#_  9%?,]OJOC34[4K;Z/I2L^C>"_#Z6NHZI$EA#H6B:Y_
MH+_LT_LN_ []D7X7:)\(?@+X%TOP5X1T:%//:WC2?7?$>I>5''=>(/%>NR(-
M0\0:]?F-7N]1OI'; 2WMH[:SAM[:'\*Q?%O#_@1D-'A/(\/AL]XRQ%.GC,]Q
M$IM83#XVI2BXO'5*?+7G3IQ?)@,LIU*,X89O%5ZM"IB>?%?N.&X3SWQRSRKQ
M5GF(Q61\&X:=3"9%AH03Q>*P=.JU-X.%7FH4IUI+GQN9U:5>$\0HX2A2KTL*
MEA?X2O$O_!N/_P %+?#W@FY\76OAGX1^*=2MK.*[/@#PU\38IO&TS2,H>SME
MUC1-&\)S7D"G?+&OBORV56$$LT@"']^?^#=#]AKQW^S%\$_C1\5OC1X%UKP!
M\6OBIX_D\&1>&O$]CK.D>(M%\#?#-[BR@74M(U2VM(+;^VO%FH>(=0L+VP6\
MM=8T*#1-4M]2N;2ZMHX?Z/:X3XH?$OP7\&OASXW^*_Q%UJW\.^!?AWX8UCQ?
MXJUJYYCL-%T.RFO[V5(Q\]Q<O%"8;.SA#7%[=R06ENDD\T:-^0\1^,G&7&>1
M8GAC,:.7SIYCC,'/VF7X:O0Q-2-&JJE/ ^SC7JPK4ZF)CAZD5[/VOM*2CS34
MDH_K7#OA#P?P?GE#B3+9XZ%; X/%TU#'8FE7PU.5>G[.IC%.=&%2E5IX9XBE
M)JHJ?LZTFXQLW+X._P""H'_!1WX=_P#!.?X#3>-M5;3?$?Q@\:B^T;X+?#&:
MZ>*Z\5:Y:K;#4M<U)+=7N+/P=X1BOK6^\0ZFPBC>:XTS0[:8:IK5@C?YN'QT
M^._Q7_:4^*'B?XQ_&KQEJ?CGX@^+;O[3JVM:DT:+'#&"EGIFEV%ND-CI&C:=
M#BWT[2=.M[>RM(01%"'>1W]^_P""@W[:WCG]O;]IKQO\=O%C7NG:!<SG0/AC
MX-N9DDA\#?#K2YYQH.AJL,DL)U*Y\V?6O$5S'-.MUK^I:@UO,-/CL;>W]^_X
M(O?LJV?[67[?GPB\*^(M-DU'P%\/)[KXN>.HFAN7L9]-\#&&^T;3+V>!T2%-
M6\42:):>3.9(;V'[3:S6\UL]QL_I7@'@S*_"3@S'\2YS1A5SY975S'.*_N2J
MX>G3I^VI9)@JEFJ:4U3I5I1;6*QSYY5)T*>&C2_G+CKC#,_%CC+ <+Y+B)4\
MAEFE+ 952M*-+$U)3]E6SO&PYE*JHT_;5\/":C+#X%<L:<,15Q#J?UP_\$,O
M^"9FD?L8? #3/C'\3/#<*?M.?&W1;75_$T]Y*]Y/\//!-U)+>>&? >E)-:VL
M>EZC+IT]KJ?C>2W2XEN=>GDTI=6U'1]'TQS^[U( % 50%50 J@   #   X
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MV:?A29)99? WP4^'>AW,L\:Q3O>P^&M/FOFGC5459S>33^=M1 9-Q"+G:/\
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M@LJL8Y%(&T[F_+RLL?4=3$U%TA:$5V45K]\G)^ECY#Z47%%;B+Q:SG!^UE/
M\,4,)D."IMODA.E0AB\QDHV24Y9CBL12E+5SA0I>\XQBEZ'\)? \_P 2OB;X
M$\!0?>\5>*-(TB9MS*4L[B[C^WRAD^93#8K<2ALJ 4!9XU!=?ZV--T^TTG3K
M#2K")8+'3+*UT^SA4 +#:6<$=M;Q*%  6.&-$    '  XK^=#_@G)X?M]<_:
MB\,W-Q%%*GAKP[XJ\01K)SMN(],.D6\L8_YZPS:NDJ\C&PGG&#_1Y7?E4$J=
M6IUE-0^4(I_BY_@?TY]#3(*.#X&XBXB<(_6\ZXA>!]I9<SP.38.@Z$;VNE];
MS#'-J]G:+M=!1117JG]B'XM_\%9==5M6^#/AF.1=\&G>+M=O(MV6VW5SHNGZ
M=(5XVKFSU158EMQW ;=AW_CW7VI^W]\1HOB%^TGXMBLY%ETSP/;V7@6R=65U
M>;1O-FUAU=<Y4:W>ZC"H!V[80P&YF9OBNOE\7-5,36DK-<_*FMFH)03^:C<_
MQU\>L^H\2>+O&^8X:I[7#4\UAE5":=X2CD>#PN33E3>SIU*V!JU8M:253FN^
M:[^DOV0/"A\9?M+?!_2-C-':^+K3Q%,RARL2>%(9_$R22E%.(_/TJ*/:Y6.9
MY$@=U$N:*^X/^"5OPLEO?$OCOXPWT$BV>B:>G@KP_*VSRIM2U1H-1UV159"^
M^RL+?384EC=1MU.XB8GYEHKU\MI\M!S:UJ3;5_Y8V2_\F3?W']R_1*X6J9-X
M7/-L714:_%.=8W-:'/#EJ?V=AJ='+,(I7]YPG5P>+Q-)O25+$PG%<LE*7[;5
M\6?\%&/C#<? ;]AG]J7XI6%]::?K7ASX->,XO#4]\Q6V;Q1K>E3:#X<@<+/:
MR.;C6=3LXDBM[F"ZE9A':2I<M$P^TZ_FT_X.;_CS;> ?V+? OP/M+^S77/CY
M\4M+-YI4DI6]G\%?#%8O%NK:G:QK_K(K'Q<W@2SN-W[M?[3C8D2"(-]YP-DT
MN(.,.&\H4/:0QF;X)8B/+SKZG1K1Q&-DXW2E&&$I5IM-I-1:NC]^XTSB.0<)
M\0YNY^SG@LIQE2A+F<6\7.E*C@X*24G&53%U*-.,N5\LI)V:1_!E117:?#;P
M==_$3XB^ ?A_IZ/)?^.?&GA;P=91QRQP2/=^)M<L=%MDCGFCFBA=IKY LLL4
ML<;$.\;J"I_TYK584*56O5ERTJ-.=6I)[1A3BYSD_2*;^1_FG0HU,37HX>DN
M:K7JTZ---V3J59J$$WTO*25S_3Q_X)??#*3X0_\ !/C]D?P/<VL-I?VOP4\(
M:]JD<$30J^J^,K,^,-0E=9(X9S))=:[(6:XBBN",":**0&)/O.L'PKX?LO"7
MA?PWX5TU=FG>&=!T?P_8)_<LM&T^WTVU7H/NP6T8Z#IT'2MZO\J,RQD\QS''
MYA4_B8[&XK&5/\>)KU*TM_.;/]2<#A:>!P6#P-+2E@\+A\+33U:IX>C"C"[Z
M^[!!117PU_P4L^/$O[-?["/[3_Q>L=7CT/Q!H7PKU_1O!VI.S*]MXY\:)'X+
M\&26^QD=KF/Q+K^FRPA'5@\>[<H4L%E^"KYGC\#EV&7-B<PQF&P6'C9OFK8J
MM"A25DFW>=2*LDWV08[&4<OP6+Q^)ERX?!87$8NO+3W:.&I3K57[S2TA"3U:
M7=I:GV[]KM/^?FW_ ._T?_Q56*_RE?@?\0?VAOBY\8?A!\'M/^/?QCTZ7XG?
M$OP!\-;*>#XE^,@+!_&GBC2?"]M-#$=;$0%JVI(\<9 C'EA2 O%?ZK>E:=;Z
M1IFFZ3: K::786>G6P9F9A;V5O';0AF=F9B(XE!9F9B>68DDU^A>)/AM5\.:
M^4X;$9S0S6MFE+%UE"A@ZN%^KTL-.A3A*;J5JJFZ\ZM11C&W)[&3D_>B? ^'
M7B+0\0J&:8G#93B,LHY;6PU!RQ&)I5W7JXB%6I*,8TX0<%2C3@VY74_:I1UC
M(_C_ /\ @ZL^*]R)/V1_@=:7,!LG'Q'^*FOVFV4W"WD/]@>$O"<ZNLXA$1@N
MO&22QRVTDV[R'@F@C,Z7'\>U?O!_P<9_%2/XB?\ !2?Q3X=M+]KNP^$'PP^'
M?PZ2%;Q+BWM-2DM-0\<:PB6T;$65P+OQB+>ZCE5;F;[)#,Y:W:U"_@_7]G>#
MN6?V5X;\+4'%1J8G!5,RJ/EY7-YGB:^.IRDGNXT*]&FGUC")_'7C!F3S/Q&X
MFJJ3=/#8JCEU)<RDH++L)0PE11:V4L12K5&MU*I)/4_77_@A=\([GXN?\%./
MV=(3817^C?#J]\4?%?Q$9461;*S\&>&-4DT2^6-E;,L?C:^\*PQ2+L>UDG6\
MC=)+=37^E'7\2W_!K#\(H-9^./[3/QOO-/NA)X#^'/A/X>:%J<EM>?89)OB%
MKM]K7B"SMKD@:<]];6_@30Y;E!OU&UMKZW$9AM-1N5N?[::_E?Z0V:_7_$.K
M@XN\,ERG+LOLMO:5H5,TF[J33E;,(0D[1:=-0<?<YG_4'@!ECP'A]0Q4E:6<
MYIF.8:M\W)3G3RR":<8\J?\ 9[G%)SBXS4U+WW&)7XZ_\%Y_BQ<_"G_@F+^T
M!_9US#;ZO\1O^$.^%EDLR3.MQ9^,?%VD6WB>!3#- R3-X/M_$!@9I&C$P3SX
M+FW\V"3]BJ_DU_X.I_BK#9?"C]E7X(1LAN/$OQ"\8_%6\4^=YD</@CPVGA'3
MF7$!@*2O\0=4#[[J.8-#'Y<$R&62#XCPORK^V?$'A/!.//!9QA\;5CR\ZE1R
MSFS*M&<;KW)T\)*$W?2,F[2MRO[7Q*S/^Q^ ^*L<I\DUE&)PE&?.J;A7S%++
MZ$XR:?OPJXJ$H1M><DH)KFNOXL:]%^#_ ,/[GXL?%OX7?"RRE:"\^)?Q%\$_
M#^TG4J&AN?&7B;3/#L$JEDD4-'+J2."T<B@J,HX^4^=5^HO_  1<^'=I\3/^
M"G'[)VB:EHHUK2=%\<:KXZOTDLVN[339? /@_P 1>+="UB[/ER0VOV#Q3I.@
MOI]U<;(EUE],A1C<30(_^B7$>8_V/P_GF;7L\MRC,L?%IQ3YL)@ZU>"CS>ZY
M.5-**>CDTNI_GSPWEW]K\0Y%E32E',LXRW R4E)QY,5C*-&;FH^]R*$Y2FUJ
MHIO2US_3 T32;30=&TC0]/A2WL-&TRPTFRMX\^7!::=:16=M#'D [(H841<@
M':HX%?D5_P %YOB7>?#3_@F#^T)+IDT,6I>-_P#A"?AO"DX+1S6'C+QIHFG>
M(8]B3P2&0>&O[8>V=&=8KQ;:2>&>V6:&3]B*_FQ_X.A]7U33_P!A/X2V%E<3
M06.O?M0>$]/UE(W41WEI;?#3XJ:Q;6D\;*2Z#4M-L[U'0JT<MDBEMLC*W^<W
MAO@HYCQ]PCAJG+*$\_RZO552[C4AA<1#%U(2W;=2-&4-=W)7:5V?Z&>(>-EE
MW O%F*@YQG#(<QI4I4[<].KB<//"TJBNU94ZE:,V]U&+:3=D_P"#6NY^&'@F
M\^)7Q+^'GPYT_<;_ ,?^.?"7@FQ".8V-YXJU_3]"MML@M[LHWG7Z8<6MR5/S
M"WF(\MN&KZ\_X)_7WAW3?VZ?V.;[Q6%_L"U_:<^!TM_(\ABAML?$CPX+2^NI
M!/;[;.PO3;7MZ3(5^R6\P:&X4FWE_P!(LWQ-3!Y3F>+HQE*KA<NQN)I1@E*<
MJE##5:L(Q3:3DY12BFTF[)M'^=>38:GC,XRK"5G"-'%9E@<-5E4;5-4Z^*I4
MJCFTI-049-R:BVHW:3>A_JB>'M&M?#N@:'X>LD6.RT+1],T:T1=VU+72[*"Q
MMT7<2VU8H$ W$M@<DFMBBBO\J&VVVW=MMMO=MZMOU/\ 49*RLMEHC_-3_P""
MY]GJMI_P5)_:E.I>:(+K6O!%YHRR7*3HNE2_#;P@O^CHDLOV2)]1349&MF6%
M_/>:X:+_ $CS)/R3K^E?_@YQ^ &O^"?VP_ 7Q^CM;N;P;\;/AGI6BC45M9#8
M6/C/X<22Z5J6DR7:LT4=S=Z!>Z!J=M;R)"UP#J$UNUR;>\^S?S45_I9X89A1
MS/P^X1Q%"4)1IY'@<%-4[VC7RZBL!7A)/53C6PT^>^\KR7NM,_SC\3\OK9;X
M@<68>LJBE5SG%8Z#J--RHYE+Z_1E%K1T_9XF*II:PBE"7OQDC^Q#_@U1\<VC
M1?M??#1B$OHI/ACXYA!$:M<6DZ^)= N2A,S2R"SFMK7S MO%'";Z(O-.T\<=
MM_817^7#_P $UOVX]=_X)^_M4>#OCI:Z;?\ B3P7)!=>$?BIX0TV:VAO_$?P
M_P!<DM_[4723?%;$>(=%N;:SU[0?M,UE%=7VG#2+C4]-L-4O;R+_ $K_ -G[
M]H_X)_M2?#?0OBQ\"/B#H/Q!\%Z_9PW4%[I-SMU#3)I$!ETKQ%HMP(=6\.ZY
M8R;[?4-'UFSL[^SN(Y(I8 5R?Y,^D!PGF.5<9XKB+ZM4ED^?QPM2EC(1E*C1
MQU#"4<+B<'7FKJG7F\/]:I*?*JM*JU1<W0K*G_57@/Q5EV;<'X3(/K%..<9#
M]8I5\'*2C6JX*IBJM;"XRC!V]I1C"O'#590<G2K4KUE!5Z#J>WT45QOC?XB_
M#_X9Z--XB^(WCCPCX#T&W5FFUGQCXBTCPWIB!5+$&]UB[L[<OA3MC60NY&U5
M9L"OP>$)U)1A",ISDU&,(1<I2D]E&*3;;Z))MG[C*48IRDU&*5W*3222W;;T
M2\V=E17X#_M;?\'$O[#_ , ;/4]'^#U_J7[3_P 08H&&GV7P_D73?AXEW):7
M$ML=7^(NHPO:&Q%U%#:WDGAG2O$UY!]H6:.SFC1J\<_X(P_MX?M8_P#!2;]I
MWX^?&/XQ:B?"_P '?A%X!TOPQX#^&'@:WOM)^&]CXC\>^([R^%QK4UU//=^-
M_&FG^&_#:Q3:OJES*FE0W GTC1_#=OKTUM>?<OPWXLH<.YAQ3F66U,GR?+Z5
M&I[7,U+"XG&3Q%>CAJ%+!X*:6)J.I5KTW[6I3I4%3YY1J3E'D?Q2\0N%JW$.
M X7R_,J6:YQCIUH^RRUK%8?"0P^'JXJM4QF,IMX:ERTJ,XQI0J5*[JNG"5.$
M9<Z^H?\ @X2^+ ^&/_!,[XI:5;:N-)UKXL>*_ /PQT?$MDLFI1:EX@@U_P 3
MZ5%!=K(UU]M\%^'?$B3):QFZM[<37T4D!M/.3_.AK^S/_@ZK^*\UKX+_ &2O
M@=;Q0R6^O>*?B%\5=5G%VXGM+CPAI&C>$M"@:R53')'?1>.?$$JW,CI) UAY
M<22+<RM%_&97]=?1YROZAX=T<8X)3SK-LQS#FM#FE2HSAED(MQ][DC++ZDHQ
MGJG.<HI1FF_Y,^D#FGU[Q J8-3;ADV59?@7"\^6-6O">9SERRM#GG3QU&,YT
M[J4:=.,I.5-J/J/P/^'[_%CXU?"#X61$"3XE_%'X?_#^,LD\BA_&7BS2?#J$
MQVLL%S( VI E+>:&=A\L,L<A5Q_K=:9IUKI&FZ?I-C&(;'3+&TTZSA4*JQ6M
ME!';6\:JBHBA(8D4!$50!A548 _S9_\ @A?\)IOBU_P4Y_9R@:R@O='^'U_X
MH^*FO^>J.+6U\%^%=6GT2[BB=6WSQ>,KOPND3IMDM6D^W1NC6H8?Z4M?D7TF
MLT5?B/A[*(SYHY=E%;&SBI)J%7,\6Z;C**5XS]EEU&;NW>%2#22UE^M_1MRQ
MT.&L]S:4%&68YQ3PD).%I3HY;A(3C)3O>5/VV/KPC&R49PJ:MR:11117\SG]
M''P-_P %2OB?<_![_@GE^UWX[L-1GTG5;3X*^*M T34K4,;JRU[QO%%X(T2Z
MM=D4S)<6^J>(K2:*;R]ENR?:)7ABB>:/_+@K_3%_X+:Z'JFO_P#!+S]K.WTF
M%[B>P\&>']<N8$=$+Z7H7COPKJFK3$R21H4L=-M;G4I$)9W2S9(8Y)VB0_YG
M5?VE]&2C1CPOQ#B(J/UBKGT*-5KEYO8T,OPTZ"EIS<JGB,0XW;C=RY4GSW_C
MKZ2M6J^(>'*,G+V-/)J]6G%N7(JM;&SC6E%7Y5*4:-%2:2DU"',VE&Q7^MA^
MSAX0TOX?_L]_ WP-HEM;6>C^$/A%\.?#>EVEG&\=K:Z?HWA'2+"TM[=)'DD$
M,,$"1Q^9(\C*H:1V<L3_ ))]?W(_LG_\''/[(GAS]EKX9:/^T$GQ1L_CIX(\
M%:/X3\5:-X>\&MK]CXNU;PYIL>F1>)-)UU;VSTRSM?$*VD-[<6>I2VUSI-S=
M2VJB_AMUNINGZ0_#'$?$6 X7ED.68W-88+&9E#&8; 4JF(K0GBZ6"^JUYT*2
ME)TH+#XF$JS7+1=2*DTJESF^CYQ)P]D&,XHAGF9X#*JF-PN5SP>(S#$4<+1G
M#"5,<L51A7KSA#VLGB<-.-%2YZL:<I1B_9.W].>MZWH_AO1]4\0>(-4L-$T+
M1+"ZU36-8U2ZAL=-TS3;&%[B\OKZ\N'C@MK6V@C>:>>9TCCC1F9@!7^?W_P5
M_P#^"F'C_P#X*4?'[1OV9?V;H=7U?X ^&/&EKX9^'F@^'EFDU;X\?$6YNDTN
M/QIJ%NJ1,VBB]D:P\!:),\EM;Z<LGBS4Y8[_ %=+'P]Q'_!3?_@N%\<?V\;3
M4_A1X TNX^"/[-L[HEWX.M-0^U^-?B"D,_G1R_$/7[5TM/[-W1P/#X2T2*/3
M(I$D_M34-?#PFV_9C_@@3_P2&U[X0/I/[;_[3GAAM(^(6K:29/@'\-=;LI(=
M:\"Z+K-G)#=?$CQ3:3LK:;XH\0Z5=R6/AO0;BVCOO#VAW-WJ.J%-6UB"QT/X
M/AKA#!>#^2UN/N.(86KQ*Z4Z7"O#DJD*TZ6/G!<E>LZ<G&6)I*7-6G2<Z678
M9SJ*I/'5L/3H_=\1<68KQ:SBEP)P54Q5/AR-6%7BOB.G"=&%3 0E)3PN'<X<
MRH5W%QHJI%3S#$*$/9QR^CBJE;\7?^"M'[/?AK]A/X2?L6?L3:->6-Y\0=/\
M"^*/C_\ M%:K:6]B)/%'Q-^(&IPZ#X?N'NT@2^DTGP;I>@>)O"'AA7:.&72(
M?M5REQJ$L\Z_B!7[%_\ !>GXL7OQ4_X*>?'V"6]L[[2/AA!X(^%7AM[,'$&G
M^'?"6EZKK%I<R>;*DUU;^-/$/BI)7C6%479 T1EADEE_'2OZ4\.H8S_4O(,7
MF-5U\QS;!_V[CZ\E%3JXK/*M3-9N2C&*7LXXN-"$$K4:5*G1C[E.*7\X>(U7
M"2XTSW"Y?2]AE^4XJ.18'#IR<*&&R.C2RJ,(<TI.TYX2I6G*[=6K5J5I7G4D
MW^VW_!OE\)D^)O\ P4O^%>KWE@;O3/A1X9\<_$JXN'BF>WL]1T[09]$T)V=)
MH81=-JNNP2VJ3^?Q;SW,5LSVGG6_^C%7\7O_  :K?"V>[^(G[6'QHNM/D%IH
M7@[P!\--$U.3?Y$U[XEUG5_$WB.TM1O\I[FQMO#'AJ2ZD:,S00:K;I#(L=W<
MI)_:%7\<_2!S-X_Q'QN&4^>&49=EN7PM+FC&4\/_ &C52LVDU4Q\HSBK-3BT
MUS)G]>^ V7+ ^'67U^3DJ9KCLRS"I>')*5L5+ 4I.Z3DI4,#2G"3OS4Y0<6X
M<H4445^)'[*%%%% !7PI_P %%_&!\+?LR^(["&Z%O>>,=:T+PS#%@,US:RWG
M]I:E'@]$^PZ=*&<<J[1XY85]UU^.'_!6'Q<P@^$?@.(Q-')/XB\67H##S8Y;
M:.RTC3@RAB=DD=YJ3#*I@H"#*'(BY<;/DPM9]7%0_P# VHO\&S\C\>,]?#WA
M'QUCXS=.K6R6IE-&47)357/*U')XN#A[RE!8YU$UI'D<I6BFS\9J[;X;>&I/
M&7Q#\#>$XX/M)\1^+?#VC- 3M$D.H:K:VTX9L@J@@DD9V!R$#$<@5Q->V_LY
M^//"GPO^-'@7X@>-+34[_0/">HW6KS6ND16\]]+>P:;>KI7E174T$+>7J3VL
MI+31;=@?>H4FOFX).45)VBY)2?9-J[Z[+R9_D?PQ0P&)XDX?P^:XFC@\KKYW
ME=+,L7B&HT,+@*F.H1QF(K-J25*CAW4J3O&2Y8NZ:T/ZM+:WAM+:WM+=!'!:
MP16\,:@!4AAC6.- % 4!455    &  .*GK\R9O\ @J?\#$0M#X/^),SC)\MK
M#P_$6 !.%8Z^Z[R0%4/L3G+.H'/!>)_^"L'A2*SE'@SX3>(;V_+*('\3ZWIN
MEV:J3\SRQZ5'K$SLHY6-)4#'Y3*@^:OHWCL(E_&7HHS?X*)_K1B_I >#>!HR
MJ5./,GJ1IP<E3P=/'8VHU%:1ITL'@ZTY2=K1A&-V[)(_4'X@^.O#_P ,_!?B
M3QWXHO([+1/#.E7>IW<DCA7G-O$S06-LN&::]OY_+L[."-'DGN9HHT1F8"OY
M,_'/BJ\\<^,_%?C+4,B]\4^(=7UZX1BI,3ZI?SWGDY144B!95A4JBC:@P!TK
MV;X]_M4?%K]H>Z@3QIJT%CX;L)FGTSP?H,<MCH%K-ND\N\NHGFFGU74DAD\D
M7U_-+Y2^8+*&S2::-_F^O'QN*6)E%035.%[7WDW:\FEHMDDKM[OK9?P;](?Q
MMPGBKF65Y;P_0Q6'X8R&6(JT*N,@J.*S3,,3&%.IC9X=2G]7P]&C3]E@Z<Y>
MW<:N(JUE3E5C0HE?L1_P2<\-7WV_XP>,7C9=,%GX:\-6\VY-LM\9M0U2\CV?
MZS=;VXL6W#"8NL'+8Q^1FA:%K'B;6=,\/>'].NM7UO6;VWT[2],L8C-=7M[=
M2"*""&->K.[#+,51%#22,D:LP_J/_9?^"=O\ _@]X<\"LT<^N%9-9\57D>UD
MN?$6IA)+U(G4MNMK%%AT^V(=E>.U\Y2/.(JLNI.I74[>[23DWTYFFHKUUYO2
M+\CUOHE\%8_//$:GQ6Z56&3\(8;%UJN*<6J-;-,QP6(R_"8&,VK3J*ABL3C:
MB@VZ4,/253E5>ES\'^WAXL_X1+]EWXE2JI:77[73O"<04J"/^$@U*VL[ALMQ
MA;+[4S !F*@A=I(=?YEZ_<K_ (*L^+X[+X>_#7P1%</'=:_XJO\ 7[B!6PL^
MG^']-:TQ(!RRK?:U:R*#@;XE8;B#M_#6C,I\V):_DA&/WWG_ .W?ULI^EYG:
MS+Q4AED)J5/A[A[+,#."<6H8K&2Q&;56^752EA\=A$XRU7(FDDU?K_A_X<F\
M7^.O!WA:WA\^7Q#XFT32!%QADO\ 4;>WEW9XV+%([/P?D4\'H?Z[["RM]-L;
M/3K52EK86EO96R$[BEO:PI!"I/&2L<:@G'.,U_-/^P5X//C#]J'X=*\)EM?#
M,FI^,+MOEVP#0=/FEL)G5@2P&L3:;&FS#++)')G:C _TQ5V95"U.K4_FFH+_
M +=5W\GSK[O(_=?H7Y']5X/XKX@G3Y9YOG]#+J<VDG+#Y/@85;Q=KN#KYK7@
M[-Q<Z32M*,C^=#_@I,MTO[3NK"Y9F0^$/"S6A8DC[*\-VZJA.#M69IE(Z*X=
M5RH!KX&K]:_^"JOPWN;+Q?\ #[XK6L$SZ?KNCS^"]6N-\7D6VJ:+/<:II$?E
M[A-YFH6%_J9#!'CVZ4X9T8QH_P"2E>9BXN&)K)]:DI*_:;YE^#/Y$\?<LQ>5
M>,''='%TY0EBLYGF="4E+EJX3-*-''8:I3DTE.*IUU3DXW4*M.I2;YJ<DOT.
M_P""9.JP6/[21L)G16UOP)XFM+0,2'DN[633M3\M.<'_ $*SO967&<1;@P"D
M-_0U7\B/PT^(.N_"OQYX7^('AN0)J_A?5;?4K>-V98+N.,E+JPN=N2UK?VKS
M6EPN&_=3,0"0*_I'^$G[9'P&^+/A^RU2V\;Z)X2UEXH!JGA;Q?JEEHFJ:7>R
M!%DMUFOI;>SU.V$S%;>_L)9(IX\/)';2B6WB]'+:].-.5*<HQESN<>9I*2:2
M:3>C::VW:>BLG;^L?HB^(?#M/A+'<$9EF>#R[.L#F^+S' T,;B*6&689?CZ=
M"4G@Y5I0C6KX;$TJ_P!8H0DZL:52C547!U'#ZGKP+]I?XV:1\!?A+XC\:WUQ
M"NLRVMQH_@^P>5$FU3Q5?6EQ_9<$2%)7>*U>-[^]989%BL[69Y J_,/._BM^
MW+^SU\+]-NIH_&FG^.M=CW):^&_!-S#K-U/<!-ZI<ZC SZ5IT7(#S75V&&<1
MPRO\E?@U^T1^T=XZ_:.\71^(O%9@TW2=,%S;^&/"VGR2R:;H%E<R(TBB64+)
M?:C<K#;C4-2DC@-T\$?E6UI D=M'OBL=3I0<:<E.K)-+E::A?[3:TNNBU=]U
M8_1?&GZ0/#/ N18_+>'<WP.<\:8S#U<-E^&RZO2QM'**E5>SEF&9UZ$JE"A/
M"QDZN'P4YO$XFO&E&5&&&=6M#PB_OKO5+Z]U._G:YOM1N[F^O;EPH>XN[N9[
MBYG<(JH&EFD>1@JJH+':H&!6GX7\,ZWXS\1Z)X4\-V$^IZ]XAU.TTG2K"W1G
MDN+V]F6&%<*K%(E+>9/,P\N"!))I66.-V&+##-<316]O%)///(D,$$*-+---
M*P2.**- SR22.RHB(I9V(5020*_?#]@S]CF;X2V2?%GXEZ<B?$76K 1>'M#N
M ';P7HUXBM/)=1D%$\2:G'L2<C=)I-EOL5=9[N_0>-A\//$5%".D5K.72,>_
MFWM%=7Y)M?Y_^$WAAG?BQQ91RS#1Q$,JH5J>+XDSN2E*G@,%.HY5+UIJ4:F8
MX[EJ4L#0;E.K6<J]1+#4,35I_:?P$^$FF? _X4^$OASIK)/+H]@)M9OT! U/
MQ!?'[3K.H '!$<UZ\B6RD QVD5O&V60L2O8:*^GC&,(QA%6C%**79)67_#]3
M_87+<NP63Y=@<JR[#PPN7Y;A,/@<%AJ:M"AA<)2A0H4HWN[0I0C&[;;M=MMM
MG\HG[;W_  <=^.?V;?VD?C=^SW\.?V<?!'BVW^$WC2^\%VOCSQ#X^UN+^UKW
M2;>T35)+CPSIWA^-;0V6KM?Z:T2Z_*\J6@E8VLTC00_R]?MR?M_?M"?\%!OB
M+H/Q'^/FH>&X[GPGH,GASPGX4\$:5?Z'X-\-6%S=F^U*32],U/6->O\ [?J]
MR+=]4U"]U:\NKM+'3X&D6"RMXH_]'CQ%_P $[_V#O%_B#7?%GBK]CO\ 9M\1
M^*/%&LZIXB\2>(=;^#O@74]9U[7M;O9]2UC6=7U*\T66[U#4]4U"YN+Z_OKJ
M66XN[J>6>>1Y9&8XW_#LW_@GA_T9%^RU_P"&/^'O_P H:_HS@_Q.\,>#HX+%
M9?P%F"SNA@:.&Q.;RQL*]>M7^KQHXS$4(XK$UX83ZW)U93AAHTH\E1TK*G[J
M_#.+_#;Q*XOECL)CN.L"LCQ&-K5\/E$<"Z-&CAOK/M\)AJ\\+AL//&_5%&DH
M5,5*K)U*2JW]I)R/\LBMSPQXEU[P9XE\/>,/"VIW.B>)_">N:3XE\.:S9,JW
MFD:]H5_;ZII&IVC.KHMS8:A:V]W SHZB6)"RL,@_ZC?_  [-_P"">'_1D7[+
M7_AC_A[_ /*&C_AV;_P3P_Z,B_9:_P##'_#W_P"4-?H,_I-<.5(2IU.%\WG"
M<7"<)XC RA.$ERRC*,FU*,DVG%IIK1JS=OS^'T;.(*<X5*?%&5TZE.49PJ0P
M^-C.$XM2C.$HVE&49*\9)III--/;^/+P3_P<W?\ !07PUI^D:9XD\'_LX^/U
MTZS6TO=9UKP)XSTGQ)K4D<'EI?7MUX;^(VDZ!#>/*$EN39>&;:UE7S4CM8'D
M2:+V/_B*<_:@_P"C;_@A_P"#CQM_\GU_55_P[-_X)X?]&1?LM?\ AC_A[_\
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M4EM<Z%XWTRUF>)Y;?3?&OAVYTKQ/9P2-#&6ABU00Y4,(PX5A^+'Q*_X-P_\
M@GU-XNT:^T'6_P!HGP;I5[K5MIUQX6T#XC^%[W0V@6_9I&6Z\7?#KQ1XG66X
MAF6TE9?$058((G@2&Z,US-_5O"7C[DG$-*.'S#)<TP>90P\ZF)AA%A,7@)^R
M@G4E1JU\5A<1%5-7&C4P\O9I\DJ]2WM)?RUQ3X"YUD-5XG+<[RW%Y=/$PIX:
M6+>+PF/INK/]TJL,/A<30DZ>TZ].M3YW'VD:%/F]G#\5O@#_ ,'(G[=/P;\
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MEC^V?!/B76/#.H2QQ/YB6]S<Z/>6CW=H6)$EG=&:UF1GCEA>-W5O]%?XB?\
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MZ?3M-\<>#[N:9O#/CGP^LLES%-H_B&PC$P%M>WZ:;J46I:%=7;:GI-_'%_K
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M^8PQ,Z=7"8.AB^6A2CAH3E[66+JX:K>:4%"C)?$XM?RC45_52_[*G[-KC#?
M_P"&@X(^3PII49P2K=8X%.<J,'J 64$*[ALRX_8__9DN58/\%O \98.-UOIA
MMF4R#!*^1+&H*]4X(0_= &0?->5UNE2D_5S7_MK/Y(E]"SC)+W.,.&9/M*AF
ML%]ZPT_R/Y::*_I\D_8B_9=E8,WPET$$#;B.;4H5P"3RL-XBD\GYB"Q& 3@
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?&XFHY5\7BJJA%3KUZDZCC&%.+C2ITX1****T/I3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 29, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 29,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Entera Bio Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat Hadassah, Minrav Building<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Fifth Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jerusalem<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">9112002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">2-532-7151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=entx_OrdinarySharesParValueOfNIS00000769Member', window );">Ordinary Shares, par value of NIS 0.0000769 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value of NIS 0.0000769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember', window );">Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENTXW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=entx_OrdinarySharesParValueOfNIS00000769Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=entx_OrdinarySharesParValueOfNIS00000769Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="zk2634279.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enterabio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>entx-20260129.xsd</File>
    <File>entx-20260129_def.xml</File>
    <File>entx-20260129_lab.xml</File>
    <File>entx-20260129_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="zk2634279.htm">zk2634279.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zk2634279.htm": {
   "nsprefix": "entx",
   "nsuri": "http://enterabio.com/20260129",
   "dts": {
    "schema": {
     "local": [
      "entx-20260129.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "entx-20260129_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "entx-20260129_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "entx-20260129_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2634279.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/dei/2025": 9
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 35,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 26
   },
   "report": {
    "R1": {
     "role": "http://enterabio.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20260129to20260129",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634279.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260129to20260129",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634279.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "entx_OrdinarySharesParValueOfNIS00000769Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enterabio.com/20260129",
     "localname": "OrdinarySharesParValueOfNIS00000769Member",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares, par value of NIS 0.0000769 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "entx_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enterabio.com/20260129",
     "localname": "WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://enterabio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001178913-26-000300-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-26-000300-xbrl.zip
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M*7_*?.]EL/#Y\S?Q/UUV^\4O\3]0/OP/4$L#!!0    ( !% 1%Q]0BX@E@H
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MSQ8,VJ8Y>^M[Q^X9_1[&%;A<I!#7%6E3<!O&T!CA5?].F.O=*JQO+L](28>
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M?@0'\ GZ#O__KZ=A[MF])D<T(Q@_@!D,6)?)Z?%F"6]K%(7+ ,IC"P)]?9R
MD%T87IT>KT[[FE?GUY?(S6/2FW,W37$,@M/DF<3+YIKIYOBD'T]56E/*CZ>L
M,KO*X1FJO-?-\4F/(4'8NXN\UT]<[>I4R4]B0,Y@E6QGQQ-X_:PKI JCF$T^
M,X0;+@ZWL3]B=Q6RX_V(Z1:C>#.,?$S"9&(H3IN=N&9I=:Y;[4XO2<H<;S_)
M)8&4 9.6!W8@U1E<QS#RH">[X[D>3"/I5'8;8#?54\!G04RR<E#64Z(%A6YC
MCK\W/8B8OITK_H&3ODH(LU^^#C";__LS&A/@QC)2P'6YK6G;6(:<C]+6?/5$
MM[5Y0#1FJQ,Z!;,7046Z!H1(6HLX-G4?T%EB>K9@F@.PW.8/@YC*(R]$Q(&O
M[$*-(1=]$ !*1_XDQNZW_AI1A5(A3A SX'X$O?TL/N(0H$AU5BY VDL#.(!)
M]B+G1[Z."%OB K*9+ "[DL> _ V"%1SYC\-)B_][<]W[#,,9)$K:E<\3;"J<
MER:Y/]#T29HP(*[LAGU,C3+9U:1 -)<L@2BNNPL4[ 8HG^#0* D^G/D^@1LG
MVX<38Z=";$P\2&YK+7ZGPD+[D! QBQBX)\2#_:GF%![Z @@!44SO@+L0G^_6
MD+B(\F'E'I,_0."/_'Z4HM=GP[R P3%!+J-Y]?:*S=XIE-9\Y^M0:'>.#BVU
M^]EK7>8Z.4=2X@)KG^@".Z.@Q5,E+C'OI'7(C<GET,4Z\?ATQO*9%D^X_$(D
M73]-4%XY0[ ?,< ?M1!ERW\X9&S4E5L!2KL@W4.]/@UYVS%E$97<=4TBX723
M)6[-5A<;29A,NHO%C9J.<0'>[+-L/9[Q?0#FBJK:-E$1I<UF74TT2@NK!#GQ
MK/>:E^MNG^HC&T-SKELM1KF %8S-BI>A5?F25H()!W0NP 'WB+H@^!<"<L^.
MJ/-. 4IQ009U"3XP4ZOLA$PXX87NQ7AAZ^5B-VAP6C^D<)?CB'QZ!WHB%5"X
MXC>+7;$E=H\"^+C2;"#D-:?6HOO--DM?0*:TXMDX0N@KZX5^@G/$]]^C^!&$
M^LUP/20EN JQ7W0CJ8K"J[&$^-?6BS]@) D(AI$'UW_"C5;]'$Q*_@S&?OW-
MM"H:(!-,.."-]0X81BXF2TP2ILF6R@"O&)G- 'OZT:#4&2EW%)QAOU>J4*[H
MG(+0PD=OK??1%*R''N.-?+1]J,JP>"C IKR3B[7?->5H5O1+;E#AE)[U3NE[
M'J-,Q7^<8EOK$@,NY1 MSGYW%-.KZ QM0+DG9?-V8U[ZG9*VZ)2T1><R;:'2
M.]H6G1=;V+Q7F9=^MZ0MNB5MT;U,6ZCTCK9%]\46-F]@IM(?L(\C,L7/ZJ-!
M!2B=)?91%V.(7&J'V6$_G#2#S3N8J>23U?.(C G^CK9/^N<Z(@>JLT4&>C'>
M,),\S""9F-(E]N]H2HMO;Z^,XT4:HATL).1BW* G=> P(6-)]>W?YA29CS&-
M0? ?6N9N;YB .B<HP(OQ@XG@8:Y0(DIOV+P+RN>[/H% XP9=DRA/NLEFQ0TD
M2FN<CB%5M7EGD[_7%XP7.-+_!2NO610FVVRSP@5D2JN<C2.5MGGO<0+=%6&4
MVIW9E!-6E,YK%L7)-MNL= &9TDIGXTBE;=X[G!+ 7RB>;,(9#A29M6VB+$J;
MS0*;:)165PDBGTBR>?_O$:>2UCQT:$"(^F@1-HM=3*FTY-I04GB;=_CD2'2W
M=A<@FD/- P@FB#**IR$V:U^"5.71/!U+JF__1MY=",F<L?I$\'.\&.!P"2+]
MS;D1F;HSRT':;(GR%"O>F^6$E :Q>7/O"_-U#".6<[B*Q%\[U4<3C1A1L1R,
MS78H0ZNT$7*"20O8O',WP0%R$:?T&<20(* N_?(!<G;0 &Q6OI!0^9E!$TEJ
M;O-^W9A ;E48N<G;75/^-0ADY/N9^_ABH"B9"6BS%TH3+.T)4T3I#9OWZY3\
MAY2N("GMD%RXWB<:^ 6YI8CLH9[1Q)7..=6>H#TOK!:5O<+KJKFA+O=E:?TW
MNV3*IOL.%>5-]?U V6*) "=Z<_)=,U,GIL8W_O5RVQ;^@W\=V_O_ 5!+ P04
M    "  10$1<E,KQ 9;N  "*5 < $    &5X:&EB:71?,3 M,2YH=&WLO7MS
MVTB2+_K_C;C? :N-WB-%4!J];'>WNQU!2W*W9FQ)*\FS=\]_1:!(H@T"'#PD
M<S[]S4=5H0H/2K))68(P<<ZV!>)1C\RL?/PR\[=I/HO>_;__C^?]-I4BH'_!
MO_,PC^2[W_[&_U47_V-[V_L8^C+.9.#ER:_>__W''_P3_>\X\8N9C'//3Z7(
MX98B"^.)]SY-1)"&P41Z%Y?GXS"2WOZKG;W=G;V=5P<'!]8+CI+Y(@TGT]S;
M^^675]ZVM[^[_]I^?GN;1_HW-=3?1DFP\$83/XF2]/>-_QS3_S:\+%]$\O>-
M<1+GVV,Q"Z/%K][_N0YG,O/.Y*UWF<Q$_'\&'ET9>)E,P_%;C^[.PG_+7[V]
MW7G^ULOEUWQ;1.$D_M6+Y!BNT'=^]?YSE_[W=H-'$X0WGA^)+/M]X_WEQ8<+
M,9%GQ6PDTR&L@QF,_398PERFZOGF-_P),Y2IOD/=T_ J6J^W7A3&<GLJ\0\8
M_L[^*S6?;Y\]7\ /_NJ%.7S-5]=NU5=&213 %'XKWOV&UYU%5\_%23H3$=P$
M6X;7@:"*=^6&_S9-/9K&[QN\(F:Q1DD*L\<7Q/*MQW]MCY(\3V8POOE7+TNB
M,/!&D?"_F-_S9/ZK=UC]T2S*[OQKN8-,*? HW#-)DR(.MJL_-6R8-Q/I)(RW
MD1I^]421)^92RE^A:_=<E).OTW 4 K$#*UCK\]LH+7?];[#M3Y\&O&<XYI.O
MTB_R,(F]?\HT@__:XW;^W3(#31-KFD+[$C^]P0T_G9P=GQQ[P[-C[_+DZGIX
M#7\<G7_\.'Q_?CF\/CT_HY\^GAZ=G%V=>,,_+D].X)'KMIG41KWQ[K_^<^_U
M[MNG-_71PA,Q"!N9WTH9>S"ID\NA]_[TW/MX?=P@ ZJO>^!H'+K>>+>CY,:@
M RMY?O&/<URXC^=_G!Y=/<[R#8S<??;+!U38@5D0$?QY,OQX_>? .ST[VGEZ
M0[R')/8C*5)\()\:!8&T$WZKNF+T&;RX454 WX/R^(4TR,:S= ZW;(_PGFTQ
MSE%7$M&M6&0M+]JHJ%UQDDU!P?Q]0_VCHGEMWX9!/OW58YVI/AO6L^A7=>?>
M[NY/I;*U;^M:2EMNTK6,(MUZ^(+-H:R&4J^^E)G,?_IX=/G3WD\__:2,@H>K
MT75RV4#E:]G/33K.TZ/0Z^'[CR?>^0<X@N$X.KN^6HM@6*\&5YD2[N7*9K%T
M9W,Q @O5EU&4S84/!NSO&[L;]/=<! ']O;^A3 [ZZ7[&)L^Y;<H.$[7:G>ED
MM+D[\/#_;0&?A\'O&_\>[[]ZLW<P/@Q>'XC#@X-78G]O_\WNP:O=8/=@?+#G
MVXQOF=HPS_2=_3=>"?1<U' .8# W,LU#7T1Z0"#&4,0DN#I@M^T!RPAOFLHQ
MF-_')Q].STY1W;O:>+>W8QL%YB-_$V@,YD'[QYN_F":W^HOEU_<WZA]HH59>
MR)43:^OTK3]PSJY1I-=BV3*H/7BUL_]+VS;<>_+?S*I+J1;V^%[3@@LN(:R#
M]I1M<77R_QU]_'QU^L_3Z__=>+?_XFBP<1GTQ;>>=;G#5+G_H\E2'S_W6,G6
M%_YXJMK?N1]_-TWKY^\GC[7-2[FPLY[Z>^I?1OWW6\CG1OU7Q2@B!L#8#+JN
MX((/=Z7"S^%2SQ0]4RQCBH-.,L6U]*<Q&%F3A7>=BC@;R]0; C_<A'G8V8/B
M?EO9\\2=/''829XX^>I'188LL.@H ]QOWQ[%?/WC_)\GEV?#LZ.3C7<'+\YJ
MM6=?_KO#%NJK'TUYW1"]!QVU4/^>A''N7>42;@ M_2B9S<(<_NJYH>>&9=S0
M68O5UQS055W\=<\"JV&!;MJGPR@*1>Q+[Y.(Q42F/1NL72._/+DZ&5X>_3D\
M.SX^^>?)Q_,+1*P-CZXWWAV^. 5]R6+HGPCA9_WHP:\8:#H]Z7( ](<3;#?D
M]F%'%?D_9"Q3$7GG,+Z;$!Y$A_MI'.8A7+R(1-P+\IXOEO)%-U7Z<V2*BS0)
M"C_W$,XG4G]*S'$L;V24S"F/J,L,\J9GD-4P2#<5_DLY*2*1)^D"5'XP?#NK
M\?=\L"(^Z&80RCX.CI(L[RH;_-RSP6K8X'Z^Y.?&!B\"H_-+SP.KX8'[&5_/
MC0<NI9^DP1<IYST+]"QP!PO<3ZU\?BPP3U(\ ;PD=BSESF/5?CACE+[PH_-/
MGTXNCTZ''T__+^6V;[Q[]>(" @V+4+OTC-W^=Z[$CR?(;DCJ5QUU_"-D1Z9^
M"-_YMZ J(]?3-"DF4\_@[SL+Y^E98T6LT4W?_W&82C_WZAPR6GA8_J&;7+&_
M^Z.YHCR\/PW//G\8'EU_OCP]^V/CW>L7I[U4%L#YL\M:RX\GPFZ(YM<=U5H^
MB;@8"S\O"';<=:.RYX95<4,W%95A%"4^JR;)V'-YH\.QJ)XM5L46W80FN(S0
MD#G;L\6Z%?@/IY@@=SK\>'UR^>EJX]V;%Z?!5U? _.W1A4XK\3^\ZE(WY/.;
MCBKQI_%-$OJZNL>%6%"$"#28%X*EZ?EC5?S13;7^!$MQ"N\\#<)8I OO:BK2
MSIJX?=V;%?%"-W7YBS3QI0RZ2OT_O,!'5ZB_F^!B!U%&VM*P",*\H\S05UE8
M$3-T$V+\/V$^G2910$X=\;6S&E'/!BMB@VZBC+6]_$GFTR3H* _TV;DKXH%N
MPHS/$LS-_4OZ&/OJZCG0\\"*>.!^J6O/C0<N\67H-;V2^?;Y>-QS0<\%R[C@
M?J#7Y\8%U],PQ1A"FB^\\Q%\3*SM2/#J],[T^2,"K-S&[_SB>OO\\_7&NY]?
M7'RUL@"JK:'ZN]/1U;X@P4K6\>>.1E=U]&@.6D'155=ASP,KXH&.1E#'8[ -
M,]2.\ZE<)R\T*P5O>E)\."EV,X!I8UJ.0_B8Q"JI%TF6=UQ$]P5C5L0770UM
M8J6 K.>$GA/NS0G=C&L.@R!$IX6(O ]A+&+,.,W@OI223;W6;-3U9C\U*S8_
MWT6V^E]P&=L4FU]P5=_9/@IWS(_0F[Q]9U7OZ]I+N)<WO^4WW#?]\/?M>*WM
M.-V@VTG'23H3D7X*OV>N;;P+?_L;7J_Y-E;4=]U[\IW7F^AF&5D]FU[9#2S$
M$[C[##A\H.OP].SZY./'DZ/KS\./%Y?G%R>7V(+WEQ?G06Q>!_NJIR]WVI^X
MQFH8]R/-!Z@GK2_\\83UR_?X$]\\W7F=W\8RS:;A'+TIIW!21A'H(P67QY[#
MF#O:?*_GBU7QQ7?X&)\P7P#U9](O4!4?>)]$")R!RKL<J"KQ8ZR@U+-&SQK+
M6.,[?)Y/F#5.8K!>?8D^SVXRP,$:4ZU?%@-\AW/S"3, H5*V&95R&H^Q#D&7
MN6&-^:POBQN^P\'YA+GA0N08_3KY"O_)N@O8/5AC*NO+8H/O2-QXPFQ@=<SY
M&&98)+MGA#4Q@MT7\@+[/YY=4\'GJ_\97EX.S[#EX\:[O=T7Y_)<LAJ5GP9>
M^2,USCPZ_^?)&?S=Z<HU/YYRNR'"@;6ZZ0S]5)#G\U+.4YF!4L-H<V 6D:8B
MQE@L>7^.DAMT!G6U@$W/)BMCDV[Z1BU(0X55B#TL;DG&'@.6.\HI]W/P]9QR
M-Z=TU55*:/VN'QAKS.)[86S038?I@PX,@L7]*4643SO*+FM,;WEA[-)-C^H0
M>&'[*$G38DY0T*-D-H]"C#X_&A3T8$4Y+B^,'KOIVCQ+O/-\*M.:\$Y22W9W
M5%BO$=[_<&CG\<FGL],/IT>JY=W>WHOS<=;6H'*AT_[+'TZ+'1'4>QWU7Y[&
M@9S%X3CT34>S3KM?>GY8%3]TTU'9P _=[?#7<\/*N*&;SL@J-U#Q[:#H;/'Y
M@Q['O"J&Z*9;\@B&)4)LC5SB.8\B$<XRL'0CD<L 1NH=)5$D1DEJF"8H_-R#
MQ[#VR+5,TQ!!/ST+]2RTE(6ZZ:K\&,["W/0H_!B*41B%7<T9Z[EA9=S034?I
M:9P5Z;K\]#^>_@]_>%Y,Z0<\.C_[<'I\<G9].OQXBIG=>_LOSA=:6X/*A2[[
M0G\\+79$%N]WU!=ZE,3C,)!Q'HH(L[2PR KJ*<^4(9Z\:.X,.W33%?HY%D4^
M35*X%GB?,XFQV^,P\Z,$5)9>7^F98CE3=-,C>O+5E_,.-QGI&6!E#-!-#VAY
M CQ>E<'#O9X OX$ N^D_//D:9CG53$8@\+5,9X0!'DY2V>&2"H=]2855L44W
M'8G'1=IE8[5/,%P5^7]' \ G3/X7H(]0#%:*KA99ZWE@93SP'0T GS(/%*-(
M(76Z:IW^<!8H0RG7)Y>?AF?'^)_3,XVN/WAQ$:6F9< _J$:(=;73D:4^J7LU
MDOF@HY$EM%*?*?'?)9%[TE\5Z7<SBH2D'\9=-DU[#E@5!W0S9'0UE]BE!XS3
MF0P6GN[C\WC>\\.>&+^!&+L9OK$:89Y\G8<*H@XDV7TY?;]P2,\:=[-&-P-+
ME_BR#-,TWHOX"U;2\->"2F\6TBMJ&_]0+\:GTZNCDX\?AV<GYY^Q!.KABW-@
M5%; ^;/33HN^IM!JY.%A1YT6)W$>IK(,K+_UAO"?H,,Q]IXC5L41W?1E?, F
M-MXG\9=<$P"V637H"VM]"PEVTYEPEL"H'A-ZUQ/?MQ!?-YT'PRR##ZQ+ 6BF
MOSL;3/?TUT!_W;303[[.L8?B(TJ_GOJ^A?JZB;"\DC"P-58KZ"EP=13839#C
M6>+]CPAA<#WY/6WRZR:^$*N!P0&,&=+>$?R:"C]/TNPMESY"U.$TG'?4-=37
M<5D5;]QO)9\;;QPE!99-G8NTJRT[>A;HXP7+66":A+ZDHE[B]JWW3QD77<W$
MZ%EA9:S035Z@<AEC[TS,NEHJM>>!U?% -Z-EIZ00I3)?&ZBLV63]Y2XBU/^"
MRV(42?6+/4!<JW<E$,;YB9[QZ*._;^#B 57*",G2#^/)[QN[_/=<!('^>Y2D
M@4SIGVINW[>VR 9)^JOWG[OTO[>>6JJ]W=V?@$G"X/>-?\N?WQR\'KT:'P:C
MX# 0!Z,W!Z_V=P_>O!%C_^! CDL"*1>FRIOUS=@[^*E&6K_5-[:=VOXJLCP<
M+]9 <'SA5KUQE$0!1BRNKX='?WXZH3;%3018O5:GG4:>:UP#+9#N>&>%&N^Y
MZ#:4JDWTM8SU[D=7,*3?</D=\J[MS<.VMK*35_Y4!@5P'JG/>,>[;YK_"L>)
M(BZD8G$7D<"4RZ91];O]7;O]"J$DW[[;=2Y]H%!:,<&\%YD<B2CRANDHS!7Z
M&C,"CI+93*:8)Q#^FZ]291,S]UZFK)/*WNSL;P9;3T:LG&0^O+M" ?U^KVZ_
MN0K,$]GMXU2,<Z]2P.+.3=>:J:/"6O*M0;_RX=TI+D8^M128Y0]MH!J\[.=2
MF;9%E/U2^[/>3*23,-X&[5VOEKH"/^?)3!L/,%:19;]OO+^\^' A)O)]*L67
M(?P?6Z2WB7-?HN51?\E9,1O)E-]2W\'5:>,.Z<5813;23^'WS+6-=V'8(N#M
MJ<UAZ-LC7(!M(!0)7Q+1K5AD+:OD'GJ_35/X7#85 ;Q)_<-8(6R7;"LRWYU_
M=6E$;0V8S_.O_*MM9WB:$/;IN<H:C(3_99(F11QL5W[:J$RV\M=_;&]?7)Z/
MPTB66W8I,YG_!/_^:>^GGW[:WGY7,]:>@*G18BXNI]'',H/  CH^.:::#)<G
M5]?#:_CCZ/SCQ^'[\TLJST _?3P].CF[.O&&?UR>G*#1U#:3VJ@W&HR?._>%
M+H843_S5.W@]7U,"\C3,O'6?+-8"E]RG5UKQN%JA-8_D'KOJJ0%MYK@T__6?
M/^_OKW]<5GT^M1KPV;VW6QX,@7A!!EX8YXDG*#GQ@QREA4@7WL' V]_=?^UM
M8N^<1QHK)TF&-]([%KFL#'B />&P].!(YK=2QMYFN+5V^J(.Y^]#D*23T,^\
MCWF@1K4S@+%XIUDJ9!2"%)Z!BK( .9U/817'"!7V1.[MO?:&V322$[CW*H=G
M_A&F"[C^!_S_G_?W]G[>/1RHEWB;C[3(G -=6=K-$!8S2R(9<:+TO$CG2<9=
MWE>J=/U6O+O"/<:>Q&_0QBS>J<$,5OZAO5UT6:SW _8,B#K7\(U#^QM3X-AD
M/*!4=BWR_I0BRJ= 2;&/=.D=RTC<BE0"7<(V*FMW*D7P+V!M9GD@P,/#W5V@
M[<P7BUAZ[Z.; ![^%,+@!MZ'C][!P=[!FT>E2C6/"G&^I64% GT$=N<6K,CP
MR.H[AG :6+VVG(JU_Q0!Z(9BBDL9I^+&>U^$$7JD85'#,8B'#U&2I /O[S(M
M,A')F1$ O^SM[>_N[C_:DNM^L^ZQ@(LM,-\LHW^"=92#+*;TW#"G(R-,9;Z@
MEFINOS6\_2-(OCBSDM>\@)JS?1*I/P5Q2(?**_A $D^(A)F0U<[3*]0>/.:Y
M<Y&&(//:3LH='J(U-F2M5(YEFG+?.>1)7)\8-*\P*$0$4A2.4_%HX\=^>.ZH
M:;A@ 41\H/* 'G-)84C4:9Y/2S6JM>BUCZO2OQ\>_>./R_//9\==4-+730;_
M\^?)Y<GP2@M2?6 I/IH"38X3O\B C1+NTAA((-9D3J(#= ^0+9$WQ\K_ ?7!
MF*=)CJR6RGDD?)8P\%@JYD!L7I&!G%4O1XK;>_,VPT?F:2AS5&K/MJ_%"'XY
M_'D?5]B?QJC9+3QX68YM9QY7VZ5QEF;+A1I$]?SKZ>S!=.9H1R$>7GA,9SG9
M.IK&D%982I8A +[&9(>"W!.3) XST-@_7FSO_6T2%3Y>,21)"C]^K)'<(CSE
M! A@^$_R=0%6UBP)"EA>^(8 PN/#5G].P/3ID6WUR,7UGQZY&7-%V4B<BG4T
ML?34\9W481WK@<PP\1X.=-\H-I+-H53Z,&_$03#)Z#]L<84_!-(/,U2&9N(+
M[EA:-J?E3085\D8":8!L$_>B,"(6]7"2B0D-" 35?Q]O-<N[.V4<3@@I*4^E
MR)6@U:N1C& -\L7 FP$%P^J%/DUK'(Y23(#U@C CWR7I@],"-H#51&&1KU<G
MWQ6/UILNYLE<P/9,%VD2PJ!F-(H$CP)2PU0UWG*4I!#UO/)P7@ECPRD^F),!
M]LQDL:?L> ^15+@IN$L537K %UD7M/B+# S;OFAZN&9R9 78$/D4C*PPAP<%
MFB@9S"5'(H$!4:-GD/;F#3O]AM^]X6?G_^-=XZ9_.+\\J2IJL*0^\!$((EVQ
MC/<9%EQ.$N1G$(VS$#U%N)OXTZS(4:S!.4C7!_""&QF+.,_4:0OLR<P)_\2F
MWGPHNSOG$H[ RQXIBU&4W&:_KF5?"9#WG>M=!V]65GMOQ_%*?]O_7>\0CT\^
MG)Z=HAO[ZC?AQ<"KOV]8UV"%_F-[>QC[TR3=WG['I9IH2NOEMK7DU7MD>[20
M'U,;$GG(>",XX'RP-'+4%/%01YS P+N=2CIWRE=)#X^Z(A(IV2Q1@:<WGF8#
M,'EN6-C-I(CA)I)?FMM<,;9J3^(0@9P8A+?<B2N6D*XP;-K&%?(7,M/>4^*F
MC7>KL!SOY,\AG,-%3"K650XB5:1!5G'^('%EWN>=JQWO#QF#[$;2A>= IP0:
MM5X 1V[LA_,(AK#YQW!XL84$2P!B+DD)=/LA!.&M"JG.@4"=[WJ;IQ\NK[8&
M^!@<S[[,,OR7^1D90^;)H+1R@;JE@'/<%YD<H$R?F &JXR&C/E,Y7IC/HQ &
MC#J@* ?-&JD>56I&98(6^31-BLDT*<@YP*_Q"3Y,GC*C?";I!)B0<5\[;4*L
M%1'Q/3@+%[#1CI=8!K-X(EB*O48H1>O2F2FUPRML/,83AU$\<_&Y_Q+%9P &
M>":]DYN:JU_)30SO@*A);D&$P:6 +/W$]XLTI?YW:))[<Y :9(VFWI'V!ERG
M*)"R8O07F$:>"&8A6O8<(/+F4P$<X\LBY_>EWDC%E5%7#@H_5RHTV#=! I.*
MD[QDA%BB;!4I&MFD0PB0H!A 8A>#2@)GPPQE'GJ\@)J"TFYN%7#/BV0/7B+)
MCL=A%-8@$4RN ]YT,*3G2'5H7<=D,Z,;!TF9O2)6*'@ IR?JHI@T#6<O$0Z0
M(]_'3X)2&\(A'8#A[>-)G+!;1?V%AEN:1!E=SO2?$5#;:#'@BR7E@@RES\]F
M2:QOY2&3/:]'"O8DL%N$8$RP,;5.3;?HAR1VH,P44(5\H0Y>9."-X,!/8@5A
MR!+EC<J:WK+C?:C '$CG#N28='U<)+6UZCF]YG $19$WDFCX9L6,?7OT3B\<
M>S*D82-S)P0%P7&6:U%:%)89#)^=2=CL3;&E%MQ>;B^Y-7LT]F8).E"FL,/C
M< S;-)<IJ@/>YJO=G[;TLF1YXG\AC0Q$#DP.Y(7V'E.R%H[X)E&N3;PJ(^7*
M@1?P5Y.4UL3:(7P?4E/#"(&.E%_.NO\MWK(YVBHG#RL-2YW1VM;?,M"CGR>W
ML((PQ/(>E'1L-?$URQ$!# 1ZA/&_SM%E&?*&XFCM"6QJHE+JH;NRF03Y'I*[
MP?!">8,.(&2$0B*2$#PVNO,VS.161P3LX4L4L*6%\%'<-BH%%4,B$K= "VD1
MH5(-LJM0A_  C9^\R/'RI C1WQ_CO^D8#O%?[#]'Q^I?1>RKAP+IIQ)__:L(
M)DC-3(5I0&:.R\.2I)[EM/=P-)KBM=TV\&9%E(?EGV.)3KR(!PC"$I2.FY!,
M*'31@;X#0M@G4<S$CZS$J@HH- AL8,XUS#%)0(^BHH2LS?RK$%FX[5P513Y-
M4A(>9G!%*G'N?E0$;,LMP*ZDY4M2L%'U$X.*H4AJT4PL4/+B+[0&EF!-DYF7
MPS:CX,#_6M]@R0KO!1G"P\,/NTH;+3<M[M=YE(2Y<7;B^)9H;D%:3 9:?QNH
MEZ1BOK#G")?B;=8><^^/) G*CU^@&"&TX.8?1Q=@1]//'SGVA NB;X#?/^K?
MRVE_$G$QAAM <I$Q;^[]A/=JCRSY 3[P]L.QEP0#[YC&C3<<)1F</C"5(=#4
MRL+?=W+<A^/_$K/YVR/\; V-2 /FKHH:&70ETQN<&HWR<)]N.=HI5P+ESINW
M^Z_WMQYQ$A=_7@UK@P<:0.\XB&A/_JL(;T2$[/P6ST($0PG&,/BL8V@K8I["
MC?Z"MX2.XS0!"@&Q ;)G%M*I2=2%?PL^ 5$$J1@*?">E0S!S'"VHJ1!KIR$C
MN%BK"V/T19H.)#0H#JMD>G"DRA'Q6S)/#9(_#/?"42Q!^0)R2D:P2O0O-> \
MQS\4_HCNL$Y*K0G@=8=+>./5CI_&69%2M.DB27-5_X_FJ_Q7^M*0A*&W]\LO
MKRT_$[Y.^;Y0.Q3 '7K9M<#!?VZ>?-[R]G?W7O_M]9M?@'&.+RYY#ZV]8R\6
M?()BL5JA_@N8+@/;D#?2DFBPZ.%L'M%^\$?@!(&Y2+U;YK"@($D132A$C+_A
MB4%3AATORCUH$:HT+%*O%4;2M[0M 4K/]B@-1Q1M)OT?6VL8PB'-2&'":-F'
M^, _0O\+^C[0PX>G&#O"/RAZ/N)W6%++K/V;-UKZ>9__X;U7W\6?87%W86@6
M%&WP.-Q)$SHJIPTG>U:%]G5#97OU E6V]V&2A?"T2+U_@CY%E2[N91Q74*L7
MRO>BG#H8(Z' #<M-E,CW\=PH\<FJ!HA,T*V4WQHM%W@WLEO)G.KE:']FA8C5
MP-)2#^)7<!@5'3^6XF)^(@@)><]#?\ 6B@^6X42BL!ZH8>HUNN$U,D9:\R*,
MA 7%<]26TJ6/DVH:J9IDN7#:W$K0A9M75J#I#;<@CG@$Q1Q]!09D@^*;PP0*
MP945<W3Z\Q+,"3;0],()G!\*?=.V[? D?C89J4@T@U3 OA:C42IOT.D"IQ1H
MA1+,=?L@TSNC1.^(TB?*^)^82;/+R@-13KYE\5G87T_#-.! !3LI?-@_=N88
M<E.*,"'5*US0XD@)Z737KDE8D/(88JBR(6G4"$ [=)R2[CO)D9# Z< A3\0V
MT?*5"[^)1"*_"CP&#2&4\\>9ELOKQ<#V]$FE:_#!/#P['L)1_/[CD!:=W4A&
M\U,*GX<:7Q^Z^<;0S7X?NGFV9_[KEWCF?QPV^F:L!#V=?V)+$J'\NJQ0DT(+
MHH6<CWG68*QYF^CKI$,F4G 0V$]XKW: "-V/2<>WV610#D<.@EN:N#46Y<8!
M.8P'JL*4F -CK!Q"'5%+W[Q$$D4% L_)8U'-R%'!15!G%L;<1L5(>%?H%H/+
M ^\*Q);@& K?F&BC?23B+PQ%@KT"TTS#6W%P_YND7P;F7]H?0-3N>C;YX)_A
M6>U'"1S>':&TGU\@I1VAK *5W/MOSD)LI#;RH"J5+9\BBG(&-TTQ;A0F 6)K
MR6<!5,89>@=[ ^_O12R]@UT@1H0+H3Y#?Z$>>"Q]=6%/.T?-,/X7CF\4E @R
M8OHF#%V89KFYJ12*:M"@Q<(YGVF3PPWH&0<FZ"+E.\RCE*.H'I3F0<PWI!F7
M?75-=,\&!G>![']YR62/]-9L\NNPIDM[BD IQ$C4S[07*_IO(;^202S:YRQ6
M9@FR=)#+G.^P8D#*L>63I/OV]K=M'N3TH]A77_F[B*G\PMY@V>>K7.8R" V@
MYXZ]W9?('N0!PCT]8MS"?;UB%S+-DE@YL."V=,*N&P1D)E$8&%HA)P_?S:\1
MMLN":1*A$1'W=$;ZNTD(GVF'V)WWE!R2%#EYFDC3F2'V"@@65&3V\6@TJ5&V
MRQ=2"1/6E.C%]4\2:FJ$A4-@2EC5%CU=Z*5@IQF&*Z3@-#M4DA#>@1I^B;AX
MM?N3/DJ!9T=D3ZC/,&9!PR^*]"8D-;]$3I#4,3 )YRY+//#M]KQ)@O",6K:$
M TO"B0PA]$.F:IU-"EIY@Q4+<C8/I&,R87\1[2R:1P9[A- '"1.7F87$<' @
M(QF#F46@7$).N("5]N6S(2+6.MJTT$HZ##/QMY01%<G204<3'C.6Q*515%VB
MB#'+MB%&%YW7&Z@P"F-<#@OK5*Z,NLL362;AGDUZ@?U!'<N&EW,LF@$H,.[!
MRI+R[X$;1[- Y>"%U8(!6SO>69+CMIM%=Q)]&$O62F4.=?%YHQS@1/II.!/L
M[T:\%3Z@ -S\&4L S%6FD?$TVNAMECJ;;M 08V44-,,!$04X:!X<0_DQC?@B
M\Y\XWYKI#"_:<3U.02]!XG7Y!Q2#-MP(,]?EC(">:C-KDEB+X&I]G6X>OB\Q
M,\/%E+1BBTU@(\N+8%'FJ#YXZ]MV\DD2Q$O$FC<&>EKIPBX=<)X2.HA#,'C@
ML],'9!66/1-VHO7@/GGDFR#Q5E)8Z,XYGSN%#H94Z*!:9 C/[+ Z#TH8UVGO
M".4%U4R)^2*&]X7C4,$DXB3>;GDP>Z19?AQNPU=KX!\\Z!D";,'60+P?)19$
MNJPG9!0A@]NOE'?HMDAXB5C^>L'QHR3+&Q/X[@U>&##HB-/VN$(%!BSH#S_)
M5.:U5%U\$:M4I,H_C-IR#.K+5$1C#J>SQAHPI!!)$LMAEPJ:05&;MRC;+&'D
MFP:X4YB%'3!FQMZ55L]:(0A;!. D(&9.Y<-TSH'(\S0$J4"*(,7[!6A@\!>I
M[0DKB&9PM],DXK0%@G2P=E]Y@WG,?+.^-VJL=X3N;?@7:G<Z9TB,QP*6@,34
M#6NCN!'H?\=X.1<(J<$6,EO!I7,!MG ;].<O,J\C5Q7.TT6"$DEYS?7MM>KY
MEA' E"-$4HK]N;4$?R(@*YI%M<_"V:A(,[:@2UQ?,AYC-08,[[MFI34?-+DB
MCM*!?%2($1PM)U8H99H?8+"'R!IF03/<\:Y*0$/%6FEY1+]9V:%+>8/$=&AY
M)^ <CA6$D#@SAH\!<9FD5/D5S(Z\.DTN7T#A0AOOLT+!51;5]%Y52EYJ%_I]
MI@H+C=Q2RUH!DXP HS%WF7/*'24PRXDRV!BB8=(NFE9@QSM5L%1!M2':=HF/
M?ND=6_5UCLP4KC"O)4#NFZ1BYAV+F9C(=O6YAX$LAX$<]#"0YVMGO\1T'5MJ
M-.9$DHBQ3ET3$4=P&VD4C%OC0Y42.&8)HIT#L*!(24  Y1B=AV/E54+&BR)5
MP .A?@-$>2=IKB[Q'PHL6%[F/^C+EI/+G)AV[3EY/Z@I3D%B+H1SK)9SA6G!
MT?K%T30PNJNTAZ'1,O@&O([%%1"S0%=:=9<=[W^F,F;,'T$&8^ N@^6N2?*Z
M?4N%PJ+(TB7*48?Q31+=\(%_Y!;DZ[8-]!*QV^4&1YC]I11YBK\FZ?UM(;94
M= U%HXAX)BV"G>L1ZA #T#@B3$I@E>A?A8A47IKDC^IJ9$F18F)#OI@C&\#X
MB-Y'"PN]&B85-N6:T#HXH?"X&7$TO%1=@%=E85[H<H#L1N:06:)5+(Y[E#,A
MYT%6$(86HS5ZK"8)N05(1GD=Z&C7#\R$+E9IK:#!,:-<H7KUHAQ]+LAY74[;
MJ<R:,EZ^>K<14E$XEFK+]#W6\UBU(,R^X-W8< 23(7&6O'QB+-6N2BRD;[*B
M*#C#2>$^YDR%8U6<D*H&TCZ@ 92D-<NF.F]'@;V#%@>(G)X):_NQOR3G5.**
MBR]2M4_@I"0]!B>_!ND#I"]&X&,+0\W"EPK9*ER"Y0 $&RVT$YWU-O&=EMD(
M!U:!=I\T,G30F%%9IB6  8MIJ67BHMX(,XIQ:+*KJL: DP]F#RD*OV#$,H?M
M1L2",VJSVI( \;1@Y0I8SX=3S'^DJ"7FEK58R%6"2"7P.)I5)64,2K(85*J\
MZBUB=#V%F&X2E7>%"?!),<HMR6')"#N[RA$62&7&22OO)"K"[_LJ/G2#$4K,
M7'62+S09!3+S,9D*ICN"6[M]%KY$3#.2"N=WMJ:=4WK>51G1I)*U"K;@E<]W
MFS9>(IBX&<(#0NLQOQ[)X&$8(J6164?F/^+D=OO/Y'8 "D^N](<9_(LR[]6A
M8XJ#F+B_.H!&"R?DKE#[)?BB=/KBG0G[=O]*PM@JG3+PM"?*J=BA2QT0/L7V
MS=6J02:<2\:3QKIR-V"6L>./H+58"5(C8HVSJUR .DX*L[G4F ;:_#+(%:[2
M$L8#Y55GQQJMPAU+&3K>-06_@NV.J01/G,O9G-% E CAX [NA'\8^ 6AK\H=
M4&$#^A$K^C7I"EM-4 F8G**QTFFH"M2HL!EN8,#:YK9:+944[571+"4HTHD?
M5%Y,Z+:4Z]42M$IX-9R&7C;0YU+&JO!?,9O?8]MLY9UQ5]+)<S- ,H':GU']
MJJ/7U7*X6+WQ?9-#@I'ZG 2G2HR.BY3J3"B51=302K9A77-;N\/5.3'5(6G8
MFO"5[T1S=]NZ=06Y\A*3"92?O5$%(<0:0B(SB3D" VW)#:B+P>+?:#;(+#?5
MG9%+,$*O82X#NWS^P',*Z=LZO&71%('6<W*NSD(50$V=%;O(A?: 81*I5?E]
M0!<XOJ["$X0<@(MH:.L*#&7V;CD2QV]HRO<SHDP%>NP(7MVUYH[6+OI 1DP;
M;Q*Z%1ET1Y_OQZ91A=W5Q_T165C]6BX+^P?( 8EU'ZA"X$U9<[B/E'QCI.2P
MCY0\7[G^$K-E:O'3)XXS@8^[)7Q^! SDV.U!M:1>AE;_W&<N(N%4!&K#9JC2
M()7'K3#1>%FU$AJ6]=RV/JS* V:@3;&6B/DCX!'V]ISVE96*%O7P?F#M/UH+
M&J[1 A08H&R&AQK>I)\DQ*V^PO3H AT>BF]HAG9LRIW)#M6Z2*6+<K&Z"1'^
MAJNNZIADQM@+:CI$NE.3I]FH1*Z1*IN'PF@LY0,WM5(:# $NV]$&0^I*=:3]
MEY@'5I5'+8+?+<N%%'7*K2[X(0,?<N#(E\H24"G!E0\-=-2#(E&J4DTQYSZ@
MM3J-Y+$PC84J'I/5BB3=_^+0[7_179_I_DO,P5C60YP:3N9E\Y5J[R@JZBQF
MH O<Z0VK)O%PX6C+'>AMN"/90+:@OE41>2U9@%O='[G7D4XE>V^4<N_T@A@-
MB_"9*V62<Q/<OH5=754"I#Q")P>\S4O&708BSM,0C QXM7O+CGJ%#J<Q-OY!
M@S"?+Q=DR3@4SA*>-_G,Y-*:<<E[7*U+[BL6W*='<;>%P$O,N]%]O&TF:L6)
ML2.=SSITKWM_PO\G#S1BG:F..[K W!0.W0FZI19]Z5?2C1L6%6L%E/]Q$:$8
M4">HY=4J#0:NX^?@W6KGL4FS_A#*Z.$579X5,;_$C!%%:I;\UT&@5I+6-]B9
M!.HUIU;Q7Z31TQC[H*!]L\5$7[7(0_8 ZP.RC--Q]6@.F0 3J/=S?*ZDY3)0
MQYGJ:-25+9^^P$!C4[WV <SR73SRMDPM&WC3Y!;>F7)^,]EB#2NM*PZ8OU$W
M4*]L$C;=YL*7B#FN<Z$Z-]KK+JD(;>/!4?-[(>LAG_F1"&<9EWG HJUW\ZT.
M'9:H8KO]RLI8JIV=W%K]NLB!&E69Q(G\HY;D17//2T3\WDG$K4<9%J1/_"3B
MNDX8N,-V&2(72'7ZZ0$=)-L@RE70$.&N&?;40!?AG(A.^WL-FPQ4F1K*VB._
M1.70*)FHV7K)="148Q1P./!O!*%$!%Q!N$6RD)1]73TBG<HJ%#"T*X;HKO&V
MS[S]<4Z*SO7WRI2NVKW=9JV7""!45/%1PV.N31/U^[C\D,6:1/# :U<[F=Y:
M#\0^NOR-T>57?73Y^0897B(^58F <VI3E:HH8_-13HDM^C[N2T<-"+T;$172
M.SN]\G9WD"S>O/X% W)\SZ \]KI]<+U$S-E)D8+J)&+O<UQ'OS\6R/GD<RNY
MNN,S<#7'NY';/3)F7*"S[+B$16Q*!XSJ'D0V$L'Z8^PHX?T#?@M ^US6MT$L
M^="BVYSQ$E$[)V@S9PCB6"#J-DSNC<!O@>U\<]%;BK:(- H1X(E@=.R"#/2I
M>^J!P33/M\\+RU:BMU#6="MNYFWI')B'J6E$MK0HK;>I\-W52?/QT C8",M"
MMY9-M';02[D6^+^]@YU]6"PKZ/QP8,5SXMB#EPBW(#]8,WHZW*J1;%O<5H5!
M=<=NJCXYDAE!I68R!SZ*,+/1AW,B3&Y$1IVJ5!GJ<)0FV,8Q"#/N,%K6%;2Q
M:#'"B?QDBF^R\,(Y?#*92FQ'F*/#_VQX]>=6"1]C8#0YZW7%5Y]XJLA4 L(]
M2M"QES]L6 \.&#?,WI]R&\3I8IZ LBCRZ2)-0ICBC%[&PVJ8\8XWS$RR1#69
M!SV5=B.JL>2V[C 012NTFV[#9]Q,[BVM:]MD=B-B^,*:\'-T AK10847,*O&
M( C*Y-=&4=MM4?,2 2Z-1=56T/O.]&W+3>E\JJ9;JY[LUGBC1.TY<6M#)D1;
MY[MJBKYAO(:YN8QH@T)97J@JSUQ]8)9HQ"0U'\LX/ZFE\YNN&4UI5O,DP_04
MA<M=@KVE"F]ZJ@,+.CFHUDCPIXASY5QYA16RHORZ0D"E$S&ERYCD&94 ,^ :
M$Q1X%=QX;>#% K/H= M9NJ2$\X2*C9G>L@3Z[;;K]^ EPEP^)"F<6Y_$7[)(
MF^L@(:8X9&5X)!>)*09GHO;."5(65*&^1&F8.;&1L2@BHNM83B*D,;\LYJCZ
M%;;7XR-/L8WP5,/VY V9M&)A(;8Q_(&O_@-[5=^BCN.#-42%5IC!,>4L39,4
MM0V!%@[Q*=;""+]0E"=*_"_;28''_1S$S SUIK$((_PB55!2DP&AP7VFBQS3
MC:F&2\K?B5'1 CL^I?[L7&9#'?@JM0O_&@O?>M"DXJ*U 4)4HKJ1YM-_%>*+
MM'D_5]7&L>H%?"<7\/YD/I76*.$SD= 9OOX4N#/ESE 66!N^EZ/F8^$\K%]!
MRPNP[J^1M4Z<EK?>1,#49ZUB-""K(R:%LG<"R"85Y5)IH_(KBFJ6F-F7$$MD
M!:&B#E8@YRELJ@/NY:HL]/:1=%(X4*EC+R'P!&62^ 8V+/C]"N"'O\'FP'L#
M'#!FILIX(B;2[<&9+^8T-,+NY^(+5Q/661MT"]*-JE'CAZE?S!#SZ<O.X-\/
M7B)HZ@^L(\.55UK:L$WP#J!Z+%&48V=9+++&M(CMJN,,9(O&*@"??042^;=6
M>JQB,C>AW9I<X1O*%N]:QC:J$AG#H>R<)_@%,TVQ_IS$8+FOQ96,@X'1_GUN
M\2O4][I]LK]$M)'.PKC"#@&M'NJ+*<KQO8H&:9O[>-<5_ ,TT&'F*[_>,58&
MHZ+!*/OG]=^<!@641P:GPLC40'" 3+:-84GX=F.#.JD$7*:I%-9662D[ Z7;
ME/T2D4!_I\HL#P,"#= 5W4)/VZ/%=FLS\S ;?!^(R-+8O@5-9%'U?;(AFN%$
M5,NF$4_4#/&Y)YJH[6&<NUWN\'$P3([,0AE4%1'WZI'3(TR6(TQ>]PB3YZO&
MOT1P&Y\62Y#6WW4TV"AMKN%8!5_?=5H-&O'-;AJKTG!(WKII??"=%P=_/GB)
M0*D[$W;""H4Y)=TT@6$M,"1+TLC#&55SQ>.07,8)POSQAYF$ S3@:W<K/?4,
MH9)XEY$]4?.R&_#ON[CGO@&*K5(U&SP X-UM/GJ)D+%/XB_88(XS :E0**F]
M;"KCJZYR5D\_4+F\@7>:"P0^N^BK@?>'Q H@\,/57&#A/:)?,>^Z"?H2X556
MGM,/0ATZ%8&:"1B;4WR1ND0W_&-F96=9O7E8\(.()]<[%B'(IB@1_2^@LP^X
MUO? N/1UW7O0]0LN'XFE^]A*&U @B-K68<U4\HOG"56SP> C*B<#U7J"*BJ5
M<50NL0.WQ*Q)R50FX^7M(JP]J"^^LSRM?22:VD?8E0$K=9?*6=QK]%WF^L.7
M"-%JJ,+5%T.[NQB:Q:AW%$.S-,D@+2:Z-X7/OF:Z9)?$I,(*JG,X^81U&_%*
MP[E-%REB"OJZ]ZN^= WSU[TVK%X'.G9;C?)47':T*098.N0&#SB]*RP*(](@
MV]K:\:Z=>L,TQA:43>9QPP N8:S1-.@K!-%#85Z4MI8'S>D\!SJOGUNG  EM
MJS<UJ/)DSXI'J@[^Z;S6_;2IT!W5?99X[G .2)%O)^/M>>*C"E>IRV9*?2N<
M45H!#U4$.HO_!87%)))([)=Q:3P10I_;4P()@E)7?;\F#-ME>:]U-N#FQO&$
M'4^R/'R)H+LZM.V^9\?<QMB1X"74K@;"53O.\ZG2W K47*Q$&KAW=,A=7E+@
M!'EK:8CDMLVG:5),2,*E8K[@DO.13+E@I$;K80-7@4!_8($OB'D!.A)J5"P6
M-50?9+OJ.K%E:NMGA(4+*9BNZQ(([CZC.8?DW@1]&+'J R1,>YJR4($N;65K
MO#;BCB%[IEJ^W]"UM8*RLS9!=1QM67RSVIS@T 3<KIB5Y>*-O?<?A_C*L^-A
M*2/TIY58^@"_X6G7]&8WX<A]M2@7H+QN;\KFI^%PJT%F5KY_\FG(=5BX4*5I
MC <_#\N3[Z.X+=OC<1,KB61I*G"35-75L$T[6,(]B@KVLVVQRZHOJF:F!6Q
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MU  TW.)N4 '2,Y:?AA-"%R]Y6W8"N*+BN]2._33VDYFJ)WY3HA!*-JG7#%,
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M@D&N8@WPJF-[X)(F4 5F0IH=HU&>$-U96!8;S-4(%5N"S=YIL*966"QB)>+
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ML+:NS.I/FU2N=C@4=I!T#ZU:J [U;^M0"@KM:]$Y>-2Y/4??I@6O5FH%UK,
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MX#.4KNS*YX%9$P<V_K+A<W8N>B5(3=FX+KL\$R9_8IQ]EN3(,QBB,*[[,B>
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M'A:!'MBO^[?KHX&5B]N8\1B?IL;,.^:\,6Z)H$;,,*LP9B1<0MT/?H-!,DT
M@=&*JV@9&MLD)@TKKI5#LS0$.1&,V@KRCNJ=T(_-0&?Z8I'.@C*MOL!F%5?&
MQZPNC(1TSM=#K4%H(S7&DL"1H(<->0,JO&(9'#<,!&H!ZQW>H>U+H%P61WW:
M2CL,!,YO'T%U4EVOKQBE<471 #HX*6E7<*E3VD@.7-(^7E!%@U$]SB%_X-5]
M@JO^K(KGQ 6B3HR77:84V3Q(H,U9 Z<J=!-P1'WU$&(])G KHW2'$Y\ 6P>W
M1YD6Q1<0/] FD8_S4+X@#WP1OO[U5?C<Z+B>LRMY'*\Z -6CNW%&1[[R=.2Q
M_1$]Q68405%= -\58OWR(M]1#57G[9;-W)R8^H:HA<IPH4C1S.T*X;V,,@?B
M;(ZC*[[[4J[X$+R5[I]!$B$QI]VRQ^%;/-1L(ZPB#[?ZU([>J"L*=..K(!TA
M"4Z!\B.JS84SH3P0UL(8^1V+M>LOFE/[4/%EQ!/&<KG,SZP:G+EEFC-'1R-H
MJ^B'0/4HVA;;*""="Z0+]Y 2+?PS5<Z'OX=R "JE:<1>X9^T@ZKI-PC\N2S!
M+13"W:GV'J6<B[=:SLE-PHX&23"N9F5QU<9[*"I7Q'*CS80Y.XQ[ R*?"\_I
M":YB [NPFF^.C*V:!;^BO?Z*K-C@T^[I;O VRK\$AQBZ-X=OY%IQ8S(NH<?1
M>7W C%QC%BT[7\LI5T+\OWX-GSU[!O]+@&E[@VV];DMR=4EEV@PKDZ_,.B"3
MOEWOQ*X+U8TJX]+XP-,LK2[\=%UC.L:+6G*:1//.HV&S3$O5'LTK)1<^4Y([
M&#R"?\[-BP O#"V\)(O+X]/#T4O6-2BNK*6GN7)>Z'R:J*5$.$H8T' %%NNG
M^[ 52#!X\1_5:BE'!"VZ692)L$#!41?+9E#$BW%4"R.R,=P+V!OSM+\/@[=0
M9@  _7< H%XLDAB$'43@-._41?_"LI,H\C).P/.B.V*UQU(5(W<L5*..7=U.
M4C)<,6@T"J0\:NLAI@+/<#6V^H*Y5>P_.N)3VGEZ-Q1TF5H2WKV *OSMYJJ]
M%.V+X!+I\"*.!*A7BH4]08&_*3OPX@D*_!- @;>:G5/859_ OS_5MIU*K5W7
M_NG6EV)#W-PQL]46$]K\^H4M4BT,/8C7%7Z%+:N4661PU#)D)ZHL<T3/TU3^
MQ;JJEH#Z;QUY^.#HZ[4QQ1;F]^:T!B-CNA:V^BP,7C_[BZ,?A5&^Y#\(=R58
M,!U//1CM')]]<,\QOA94CS:##-XR84T^6Y=D@\46,J.*\V"]!V2P#6^W?#>L
M6I,EWM:2W["8O[YJK,W>*[TV#RT<[E^@;WE*9E^U\E,,=7>0[X\*O'W+$&PO
MHEOF\?H%SN-&./<=0$N?UU LW9(5;9J80>>V1S5\O_6=5!J4V8L/4F">E@C3
M9E8?5_MG7,YRE<2:;U8XB"TS;Q>=$+F_\@K%]#%'[R@"]ES5J#Z8Y+-B0>*M
MBP9@3?L*R6AT"++FW&&F%'J]Q+A^GIQCN<*P_1N9/__TC<PZ#BD DLZIW *?
MR5!=XV0CL%7I45CN[K&X5J=II3K4,?.,=$&7G[O2<5ILYO!0?&>NI-3V+(#5
M*2'_-$LSA[AVC0AYW^3O(K]EZLTAMQ+JWP2W^9[K=FN8^W=?M2:A&2V5$3K*
M?X<,JSD2*VCAB9AL1;WU<+&K]RDU7SU(HKA9F2!!Z"+'*+(Y#E1  C*@I/[Q
MV*^0P=OVL*2,ON8B87- H; 7YPA=$35WFBXDI_L(4?LB5$Q]:A&['A]"AUSI
MV]AFQ6Y8*0_9-Z+)EG!VH>8NU)/KUXPM+9#:BDNGO71!P5ETMP#>QE(<EHO%
MB]P![7F)S;MLMTY+N,%Y 4W>U#-:&B84A-#7;+%Z>Z#KF "[[P[/6HO0B^(*
MX-4B2U4'3P4<F',-4M6@EFA@L!O-AM>>M 9S5Y,'8.WJ #@.HKP]Y"P6!84B
MO$9YKC?$=J" A)!JZ9S,82E]@B3IY F_Y<$2E2+UE:6_,'HDHFS4-$'N*?R=
MI6N$(.!@[YD?Q=36!(/_>0T T+:JJ/$J]<L1%\2NF!"$V"4I$R-:^)0IV>B4
M3#&?F\TO'5.EO4$ 78:*#VSXBP-W*Z![F+K%0L8KBBRVG\]45EU=4&^[''X'
M5X>O)D90-U'SB7&OF-\_"K(B/S=?8B((\UV^I\ 4Z?$Z"+&86E*[DJW=[SQI
MFY%U>R]W]YZUZ)A0@INK2Z^'\U&LIN8265FL#@&,$BXV.*20&(+_Q@B!W^.Y
M,1O'@^EFKP@QQ]*4O7DQ632<$A>4&<]Y&2W,9BZB<X)W-#XY,3\WX@:[,H@)
ME'4]-,N4S=IM*>(=+F;&4&[0&5?IUV#P>A@LS I>>"9[(\E"X9#=^P/.WY-E
M]7VF58L1I@$-14Q<D9%QRUV]*2^A=+MU/\3O0&H?$/XQ\ZYV?8<;9^B,TV;N
MR:^[>^CN*^*K>6^HAJ:<$+=WE^+J/(565:5SWZ.)NMT9%$%X_OX[*94*B2&(
M8Z3BX'\]&R+Q=H]ND\P;LH6CA>?( ]$[H6"3T30M=R XB< N"-G]X>(4<]K!
MH>O>3:RY:<U#-<P6; 5[0R5=7#2E?+X;?9V$0%BI#\C,D)B17O-EF5*/Q2ON
M S=?87.:YF@J6'D8 Y!^7C-<OM>+(Q:$3EM7LEN@H5$[TP-Q_*!)SR/(S\E&
M5#)'@9%,Q,$$?6+ECYR)8!IEU/-'DP;[>5%B-QVKKDY@!N(RXQ#E$:P=<R.U
MP7/YS3)Y>D>;H",P!.'RU'*MU G0#M'V5-QS<_KNY5-QSUJ=]V,9'S:97?IE
M]^4VQY!/T#S\DB1+Z7,R,F9=[>/\ :&B>/4I463D,)/ 1Q)B:/NC4%L-DHJ5
M*@0RV:<&K<F03$2D0+110#1@**@V8XH=D,)F%FMGOF\TN*(S:V#;)>+3:*5K
M/"DCJ0"Y">$7 'D"-RBV<K!]N:HAUP(3\3,%/$D@!%/Q42Z*58D%\A$L&K>%
MH^)[IP(!6UK9@)^QGAN,A_0:LS@+ZER6^LXKA;=D=V87>->[.Y? -U24QEK+
M/DA%N:LT;(?PL5L,+(ZKTJ46JEFQ-'[NN$%@/S5""*$SQ54N9L9<!4#P\>*+
MR2H9BR"!N!Q48AD#PM+=E81UL5&:' VT"A^)P0Q;<O3*EAR):D<KZ$KS(H+1
M%+J(^BR2]FGF^8U>!3[]:;&J=XKYSK*8?4GJ#I.)W4:/I#&7@V*Q.#A5M!0:
MJZ%FKZ<;-@D#=3<(090BNQ_F^\SC]*]56M*W,_S\9 63RZ2GWCVW"090EQGW
MKYK[L=GP@&!D:0(>-%>SJQNGNZ9L*G#X\GO0#X^TJ^PONZ^V645]=OBSX"SZ
M^GWL=3]16<=C@[5\IIP:BK.%N$0<>552IY!FW'3O'6H]K;0.1MH'M;.JP*N.
MOH8Z-,?!+ C.NCRC$8<G3E^-;:36JFR+=(R ?U]E.2GND\Q6.K1$T5LAY$#=
MGW#B#P**MFX[OC3&"99\SWTZ$R6Z(18'/XR^L@+5!6NUT;+U-6J&_NES'84@
MER-F#\%G1*OZHBA3L+>:XM5VH+7ZB19 M:&M*%YJ+2B=B2BF5$ "\=05Y;+A
M23A,*$1ICC$,- ^M?L ,VM+V]$N@Z<'4MOGR/C;DR<0O1AG9T^HV\""Z8BB!
M#1Z#85QGDD' :^7'4^ 68^V /LNTPQBP0B8B-NB\($IW*UO]>B&$;@1OZ.$N
MX%06QAT!Z\9=$>B\+)<$K5<!8;NWFY]!N:>*RBC692L/\%V[P9G7KMD] >Y:
M)> +;!9P:<Y4[*V%JCJCVB+7[ZHJHR0#C69<+AEMYXVQ)J):'8B"R7M42S!E
M,J/O@.&@4M90DGP8..2XF5^,U3'L;;ZECZUR\K:WU,,*WO:>TH%+[W!5\;QU
M7U1O!)NYJOCV[[BH\GNZIC;6NIF+:KT\>UE;!9K?=5W=_"7>_6]X71]; >"(
MSC[E"-P]<7OE"K:P+!9RIA73,OYS=";M!\0UCF)$AM7-4  >"RT7,I !DJ20
MPVSN@.MKH*DJ%>8WR#'L[AJ!B4SP#W=4>:_37_QGE*V2G1&.%'Z$XFCOMU]>
M/94&?6MNX55G;N&I-.AQE0:]?ERBY[Y;@I%._9@8$1 _%0C]5)OWD9A1P7K:
MAQ!U/KMNT#1A_%T1G0(W71QV],ETMHETC%D'*?23T#JN;FD2%-ZPH=1<&V*E
M1!5&8I5T-]%V/IRU?K'?[Y2;G)5%GLZDNE5(&J :6A7#1I=1FA%AC%3!1KDD
MG[K;_OCC5%$M?Q3F1>@.OR.(QVZPCPPV0LP+7!B5A61A-S*CF;-@1OMFWN/%
M4_2C%-*16G4)9&--C^.TI\<QI[&60":%_8%Z<).=O9"W0B(\MO#,9L3Y.[K>
M50,IO<'TRFL?@\6(&FE22[XE#XHCE(B/,EJG2CR?RKL'DLD4@QF$$]B^201U
MCK8A[\; YMZ,IN:%E-BS8&Z7C\8$L(80V]D2$24WUP6^!,8WU]081$B_B<[%
M3^)Y,/X&2-6E,JVC:6Y+U^WW*@OF/ER98$+<0PP?OF(LD:MGS!((?3L70P#4
MW>,H\NP:L6N4WG-0=PX'- <'?^OJ=M_3#LZ(8TNEP$ $)B.#Z2!C9585ME0G
M$K(<2YQA?*V4B4[2',2I!4M5JZ4DW"4?P'!(KH-HS7CM 9A2OA/C[GD"WC[@
M#C!.0["LQ!9YK&EL)]O0U--4^-!<3-J"M</B+G$VQBCKHPZ)I=I.$4/Q0K!G
MQ=RJ=3Z\&JP@G$1Z53&PXZTE[@(DU[.(B3FBBBHWU-G7 [OQB8).%-7N2D)N
M1O=;8'K4Q/&CAN6Z+U*TVQQ?>6SAT/L5Z,+3#M+N &0;J\E&._K\&I'C7IPQ
M5[(I;%Y"90PJ4 R_++3L+A24A#/J\SB[("\%4R*D+S-G;04(9,9SUE<*/^Q1
M[Z(^8JBMF3'] BCGV7[]#*+@M#8F;1W\4:Q*D'A,.!3K:0*U$4A]%C07Y@##
M6N'CEB"HZL[Q0N-7HY*Q(8.Y@AGP0@Y#JKA<Y53IF&/I/+,2+,CA<*WH<;RZ
ML$E&XO"[\!U?):I2+K"[MP?)\<LVW\!#-.7^18:5?^T<'0/3$<R 4!V);U5Q
M)*I@<X4NJ+MITS>T+A)WOX+35[FF)!P.!=K !4?:EW8X=,^E T7,KIIKI@))
M%<Y/?AS]8WP:'"H>U9/Q\<GX='QX-CJ;'!T&1R?!Y]')R>CP[,\P&$_./HQ/
M@O'_AJ^<PF>3C\<'D_&[,#C[,#H+)F?!Y\G!0?!V'(S>'HR#LZ/@]-/^OOGN
M^T\'!W\&^T<?/XY/]B>C@\G_:[YR^&=P?'+T[M/^F7E4&$S>^U^0I^+W1B=G
MD_U/!Z.3X'1T8(9\,/[G^" X>@\O^& ?8]^^_V%BOO!N>R[3K]M\F4Y@ ZCY
M2;US-)^WFH<#F5>6+M):^#[)CRCA=W2RO9;;C;NDJ:4]I E=,MM''A\7(H$,
M]A6\2!2D+R2J:ACF/.PF9+9I# VF<4_ 2RK"O@94I\TH:@1FUQ2H^ 4L3>!A
MHP*TT*Q(-(7V#%AP!@;6(B<(,EO4CE3;17NP $<L93,585/@ULMM0&AGSG1K
MKM5OVWRML!\V;^.1PZ8^80Y_R-YV%2[B15/6,&3)*X_H:C/(YE]T&,@(B<WC
MIQL@ N*46A\@4%Y+65Q'&82,S!B,S0/L$&!)>;)-PZ^%1304^(>["N1"MQ$/
MQU%- K(,_F',M9T/6.F!I>]&/6!E'9/(: 96M.=*;%JG/UV#-ADQT*.% JD:
M\7<+E9]:AOF>V#8QI4E+-9_% .6\-WNND;58#DWE8E[0KL0H%.F-]0^?<N3?
MFB-__90C?TJUW!.,79O&ME9Y4[F#WWRB&I2Q'CY>16EM1)B[S["E[LG:T I:
M9:A"L E;+Z\PJU<L$WCR?J%;.46!MFQ _-IHM+*[2SV>597,5QGU&XT)DZ<$
M7:C(P!(<C"8!2_H((X51YGT*D/(!2&<.Q8M=C[5FDC%VF"EA([OWRB7>+%V-
M&P3/=_<TET#H)T'^.-VW_,XNBI^N]9%@>GER7F!'5]*!W%2+XMR\V1=&()P#
M1%'FZ_7X464,FE(!X];&*<D8;";J;*B)D0B=;RO4^(60*R'(:*A8.A$0RE
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MX1'].91 <''YC:%U/ZH>=E=AR<%+'K!5THO=YX-DN(4,S[]N>Q,"[.#8ZXO
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M1T/"!A@WPHGU8@-8)C??N8BRN0I$E-(HP1'"@'F'=XG--_I\2K))+;__%$=
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MO&9,D%,F>7)E=-,\2;H#FFMFTYA$7R)$PIR7*AK-)\)#'<?%;.6L-X]HP&(
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M]+[ %9@6Q1>1@80M1X W3;!B/4-850V6B(&\,:-2&?P*'WG^\:HD4\_8.YF
M)%1UGM86W5?#(YSE<LN<2&_=T5&'9HL#"_GC=%Y$GF@AI(0VG9B9K6&^26O[
M7**=-F-43J,\J7:.OF;&[!E1!>[S9\^>.X1Z8IT)%[\',1B(=R(4J_I=G58
M-#1;9><:KJXL@MJEQ>7=JMQ__2!V@S4KZ% U45!=5W"C(40-/P"@@!(\EF:T
M6D%%4IJ0$)#^PNJN1E)22Y5IF'CSPLVX<D(:TD'180X!BUPK:-D$0<0PZ>*9
MVGPF?Z&EY"1:ZXTD;ZAOHQ?%70(==LV&D87^=RIG"J]C<:<0UX(6%GHVMYC
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M&734%)Z4JH;4P<.FMK@&9<)%806"ZPC+5169Q[Q;^(<*D&<,ZU@M"^ 7-VX
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M^71T:!X\_GA\!E]]?W+TD8=R,L*_?#I\-SYIC6;_#)Y*BMW,8O1Q;+[V+AC
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M/=KHQF W9IBMM&C\?8LK+9YO=Z5%'Y?X$]W+#]G<,[]3/(I<) Y1&$!+"[G
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MRA1.45,'>YB9S6JB1!K>][A^V]WD)=M[9M8UVN2ZXANFPZZU[2I2HFHA:'#
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M="8#9ESA61JW22V'+HJ%V!4.E:CMHESC9901TE4OUBY($T\N=FC4$/JHKN9
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M;A_?;W XC(UP+3A-DCWPY9+%A<-KVD=0I52%Q7FS55EB-%YC)U0R9(84]I&
M#"R',!-T)<N(L^^.$31T20)$D38SH-N':,/C_GJ;C_NI40K@8&9I[15Q(A$E
MP+QSU->+HE098TNFTL:OI$S]2V9(FE^:S8D)2<+-TJ@E(D$JRFEJU&E=()?/
ME'K( =TW-9L'6CK,D_]K5:95G)*TQ40\Z?F\@#QB A1V48ZTU,  IB"[QG#)
M0W_05CHC."C&7%254,J,<_S>A&RR#HPKR(TEW*0+)H:4V]3\BQLVJ,5A;-+V
M7(1?MODB'!;!9V3":B71T59&5#L>8 0'-2S=-76=@NMFFBWJ%A,1T_!L!>45
M@D:V%B9CV^RIZZ3KTI9O<QS"]+'R\=M\ :5L3YF?W06I[ JTS,Y<=)_U4!18
MBL='U0_$9>_-EB='K+KJ[TRD"Q+%;,U3/O-;\YF_/N4S?VHA^^LV"]F)D3/+
M!(L+J4,*M8UZ$YQPL51UD2Y]R[MA/T/MB#3&JJBFS#W2=:(*I<+N@O$^/= F
M%*W";XN<X)Y'B98#EF2!N)*> 2C39@AE52$5<'-#J9%)6U$1*9(W=PJ@KC0P
MAL%VCF9F[B)7NY1J=4!"@MC,C6< ACI8\DL&G)LK#'+;C.%?T'%V!_Q]  K*
M][M *,U@%@7<C?V/96$M5=8<CB8$;@-<L#.QO!T&C\5&T5=7>F4!N!S[;Q5M
M-<#-%HJ#\8T=&C-Q$<_2J$R3J@U%VR(3[+=ME@Z0,S>:!\Y+M:8T0_4U)NI[
MY/IT/W4T&&61$TAQBT[ WK.M/@(7!6.3S=5_$_P3LU!KCH)(3D+EH?P@T<^V
M;NS88U"NMI&?Y!YBB3/[MZ<UTWG 0/\LRB\NGELFYU')S!B5K;_ 7T+QJW/^
M2'$U2P=!D!D!EY9E<EG,,#9?K::+U)GLKF3(\WF+.8$^:VZ'5?</-L@*X@TW
M4W43./S3XCGA5Y]V3W>#=ZE9%/,"P*J4M:T#/343Q1R@_=Q;"OF:+I[%BG7A
MHJE6:=THEW><(%4PF!58*FOFF)F]8OZ>S=;WC6AL]N(@+= 0.8,Q,+V.-;C9
M;U'1I-*AHRC!.189\2*@@1 C2[+9"@UFM?#7[I)A*0.GQI4 CMTYAU(=;P49
M*(U[2#WE\9"?E<88AWY<#%1P_B2TAH=\ ^C8RRA+_.<-/2,+ZX28@H587EQ]
M+"VC6$B<5+C-47(KT'6F<.'GWBNHSKS&[($Q^Z&85]ISS>P;] W!)NF0\*+.
M,]]Q3[S5T#>5ZMMLL@QS4NCL5A0HFPI1#%_E++K&PZ7XIC"I+A>&I^K-R\B-
M8^[@)&AVB#C%0J4C<S/'/H="?0MUWQP-H8^([ET=NQ*QJS_C?*1F$#!OH$9+
MQC&,&^M&,3TSR055V=M(.W6-Y=R3WO4P4/TF>$T@,$((=K24:371XH;K+*5L
M\&HRP7FWR'4HKRVW OP1L?)+H.2R72)8E5A*()@"7\*6+O(H,UKU!K[2\<1]
MFNOF>_)X8TS/$6$/H@>D N1OJ:EC, />=CHRVV3K;'5A\B=BL#N,%KW9IC7<
M'[GGM>'9 R(K3.4@"5A6G!<A Q)8,70 "#@ZV4[]#H2)9CHUMSRUQ-I1'"UK
M:17#+!9-8K7E:IIQ"03FDM#!P]X"(7>,E I+J$XK6( OH&UL&F6AI[D6>(WQ
M@2E38G2C)"+NNM?9'1JBMQ'2IX$$F"5$.E(FI(U09Z<+L&>X;^ F<\5[>ZUD
M,78N+ LL,?<C$)B26$1?6&9A#[6LJ+#\KU+%7!3!W1@5K5<5LS&&>/.BEUZE
M%+79GE]+%7Y7:^TUH8,MDH1;79([\?1LERR\PAB0*&JSX$HT\@%0N7GG+*TJ
M:V^=)WA%&B$W5W]G;-UBL8Q05G&;3V(;DI)W#&/S8RI'N<BO0&B+.:>0S'"2
ML/T:HI6@N2RS%=0*#! C A8+-%.)AF^LGW9E;(;*<9SB+T.A-?7_7%F*5?,P
M[R,S*/FL/9RI\"RYCJG+BQ*L"7Z&"-PL-9*&.A[)TP8S-TKW]2R3SRT]E1?7
M)&N.N2J#11+EH@RHJ8-'.-5\/#[2#2 F+DWI?$@F&=892J-69FB*-*\'C$7B
MF211XF)&?^D-R$9\+$JV&7W"H!N>"I8;II;-P4>#$_X_<AF "5>MC-3"QY!M
M9X^Q6XE%$9.=/Q#^"VGGIC68=**U+ F5?GA%>?P8"W>Y\W"#CP%.'M.3NA7D
M)>$7 @<(=]@ SK'K[MBU=\CQ%S9%:7_IFG0Z0)CKZ5N9H<S5)7!KP2>![:#&
M92"+I.,JN(;'^D.Z7V P,-4=& %E'7;/JJ?261K3)D@TPPQ1#,7$)5-)3HM"
MH(&:29X/ PJX6YGC%EQ:PH1")5BA;62Y:%JC])JGV.'>])@.]A*BAM-BL#5G
MVF'LI%;7QK:B,T;4,F9>%\/& W@CXG)U;F45>((74;F(9LD*.['!"E%O=0HA
ME-&2"F7I;5,N;>O[XAN?LLT?P/]M[\IZTP:"\%]9\=1(I(00DH*:2#U(@T0.
M!=0\5'TPMA/<&!QA0$I_?6=F9]>[BYNKMIK#52H!ACUF9V?GVF_(C\$WU]'V
MJHOY,@[Y6O(R]K1%Z4EZ87C65VHO[^B(EX]5W_H] A[^SS8I$PNE@-Z6\N?P
M75V@ZR;V?!UCR7)A_S)*U3U,]]>&X7V#;QGWAWW9L>^(^ZQTCD3@L7,1) !/
MSBGA_JS9[+8[XNQ8]$9:\."O&8KM>D.G7ZJ53^;N,:3MZPP;)RO"D!+$-WJA
MDAE%^]+$C\ACHPWH_-;Q.&TD\PW#D'(PGYW\/5<,ULTL'J[;3"J&,"N2V05Y
M>25E[&\1FF7*>(!T6+CRBI.#C?V@ODW63&@\((]!=!TJG'!C1.YAI%..YYE5
ME"$C^$(6"S= '=R\:- $M%F5-1N'"[J*PF,+X/"6EMPTFA$RNU4T#DL=9^GD
MZ9WT)K<W^67"3;PMP2.D[&_H)4V]*WB(5:YA0X4K!NWCZE!4])%X= J&+DU:
M.^+@0TH"RT_-,:T'JUJYT$W)7Z/S!Z_[6YA&%B!"G7%<>$B*P]T1J=9DQB6H
ML68;!N(E;Z=;7?[4:AU!890*PO!/:&9[4T8:S$EA([P"0E6\H4T\"3WI38:M
MK,X'VVFOS@J&KT7/76B510$N6X6S*.3\STQCH%-\'MK0"5Z:(3@204 ZH;#1
M@]+YA*SCJPL/;@1:F?=ZU(FN(I#^!XN/\W^*O@%F9?> X@UF+0SKQQ#Z]"BF
MCQD\XI 8)OU9I4D]-DVJ4Z5)E;8]UIMQ6.>NRY46_GBK_;[3+N4J>=FPI_T3
M<=$?G?2&0W%QU#OOG1XJIY:-**PA&=$JUAD-4NI-67*".#T'.X]T'_OJ#3X:
M<#$4JRZ!A",+EJ@X9;AU)MC?2J;GY$(POG\:LSQBE0N_+YO#D>9KB7WDAW&<
MWGB8PKM?VZK1^QN\O\7OY=:DEU&P7_L]#BZW@Z;7;C4[G9W.3OCA<OM#:V^[
MTVPU6[N=W=W: ^78W9+>VM\FM?""L=[D\ZOQNZVZP+\-@]*&T%F8)9SQ?:"&
MQSVTL8,5XC&! :4ZF49!$(>6^"II!9\"[B !3?JG@]-O_2]#,1A]7:N6C2N]
M")[WU!]PU#L3[YV,>N>?<.HXZ8)EE:M6Y*E-N:2%MU:=\']BN7O.EG]:T\>T
M7>BD_C<SU0X^WW9YFLLBW?2-M"&&8(8MQ!GH],GF8807YQ7?+._GG9=-R4:!
MI 1*NF@CCR'D*^-7C']WUUDK?H4,):>ZOO9O:\%'6*JD*[YCP.L,]%$*\@I8
M= S,O\)5Y_G^#4ZH.G-?/DO#22&*/VX'WG+NB>,D]2=^LHK\29G'[1M>/2F6
M<ZA=D;A@&:C0$8^]F7?U -GW8BA<R=52V.;0KM)5AEVC0@>R[3U=^P"%;+V,
M#IM;NMY.F7V8\Y!=@-)94E\[:WUAR+9;;>]G/:GG[/([ZGT:C([JHG_RI7B'
M7\5&KXN-#$]-:9ZO10@FV_ER',TJ);RD161'D$GIBKS%D9=5\,P!83M@G@^Q
M5?B.8G9&X/% 9."J5G!O@O51H)O]FLPR<$+M&/:?P7@X\*YR&C"^GB:(3C6.
M/?]:/Y=9$.Y#O19;9N#]DO[E!M[5H[Q<$0M V%MBOB1_-)>]T&=9S/YC8YP$
MM_1BLIC&\.(/4$L#!!0    ( !% 1%PHV7>4=Q<  #=7   0    97AH:6)I
M=%\Y.2TQ+FAT;>U<:W,;-[+]?JON?\ JM8E415(/RTHLR:JE+2O1M64KMN+=
MO=\P,R ):SB88&8H,[_^GFX \R)E*XEE7V_%Y3CD/#! H_OTZ<?P>%;.TY/_
M_B\ACF=*)OP)GTM=INKD>-O]WQ_\VW H7NA8985*1&D.Q?\^_]&=XC^G)J[F
M*BM%;)4L<4E5Z&PJGE@C$ZN3J1*7KU]-=*K$WL/1[LYH=_3PP8,'K0&>FGQI
M]716BMU'CQZ*H=C;V3MHWS\<NIEN^ZD>1R99BF@:F]38QQO?3/C/ABC*9:H>
M;TQ,5@XG<J[3Y:'X[DK/52%>JAOQVLQE]MU \)&!*)35DR/!5Q?Z-W4H=G?R
M\DB4ZGTYE*F>9H<B51,<X><<BF]V^,_1AIM-HA=!0O@8'I[J3 UGBI:# 4=[
M#_WEO^<ZVA0K> J/-R#W4MEZ<9&QB<)D,I.I(^&^#2-3EF:.<?+WHC"I3D24
MROBZ/E^:_%#L]T_63]_)WS>+=,+$K;AF:DV5)</^J;:$W/2.Q%S:J<Z&)+!#
M(:O2U(>L>PH?VSC!+C:"^YA(.D_B<3#"<75R3)O6V>X;?UMDT@37/'L_TY$N
MQ:-'H]WC;;H"2HW[(GNG??H=4]RXGT%;JE#*"+83JS0M<AG#M!YO[&SP]UPF
M2?CN=IH_?AHSZ"F]N-%).:.3.W\_VA Z>;SQV][>_N2'@X-DYZ&4^_N[WS]Z
ML+L?/]I_( \F!U$R2=K+$*+]F99E3[I'Z%@2)N^?]G!GQ,];N;1C?ZLGPC!M
M_7E7%:6>+(_$VDW4\ZE;XN.-W9T'&]XX'F\<D$!M_'A#S^54[8[>Y5-<O;W^
MX>N/ TZ3/[_6=4L*)O'M-[L'.T>_1QCNSH^+8G^_$<7>05L4.Y](%#AD;]$3
MG"+=_WQVV?E\B^2<2UB#51^Q-V=N:ZQMCZQM%<36 +"=1IM[#Q\.1/AGJS93
M.K4S$/1W*PQ/<R='8><R]<<6TFJ9E<U17EEI959,<,2[E8V35Y?/7P4!_:1D
M6LZ$S!+QC+!>BB?:B&?O<SIR*6V9*5O,= YJ(,;)0F:Q$F?:%N40X/\TE44A
M7EF9BA<&K& <ET0.+J]^$E>TMR7F93%*J>%'"J@=GO33,C>YM+*<+:W1B2[F
MM^W+RBX$4[C/C?P8<+:%KTL\+(9 KV:Z$/A;SA3^TS81N353*^?X)N'*JCA6
M13&ITG2)+9U'F%7AQ?WM-S_L[7Y_5 A#4LQ57NI$B9=#R.^XJ/*PM(6RI8YE
M&I;G=M;D_25V9EQ "5*X;Y;;]_N0&T8\$7DJ2]('MQ^D#&$202FDVVA>1JET
M)N*9FNNBM)B^S&6D4XTM+;[^C5N'-E]0BQ1I!RP/LA4SN5!"0G&P@TR\2U*R
MH%=DG5+/R2J9?,M,Z&RAX .GL#:309<R3">QU51LGK\\W1(RS_$8/HE+!71
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MY.<2<Y)N.D#_W*J%-E61MCW%P<[?M_<Q.ONV;;?DK=:JH(Y57%;6N2%ZS+"
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M%>8&P-MN&B/JVE:DFNP/F( _$)M=EHT':<J?LDNKPP]9]*@$^!MB# -*[IC
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M$'BC:?;J/?<&^GXE;O8OF\8URA_+F[OW57S*--L]O=/^27.]ZQ-VW@\"D4M
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M?B14-_3^%-";A4'H2_$,#3TN2M !RER74;OM,-?QG';':GLMV_,=%IB<MM;
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MZOR 9%3T.8H+7&+H''$NZ C=#@B20+_P#$0JTL& 9I.(9[D?N8#HZNCSS3L
M*.(J8YO&-)IDZ.95YEKQ_6K,.Q[KHSLJBBW*I%**,$RY2*6WQ"& 5F696E%@
MI#>ET6+ZU]P'R8I2!YW&GP]^(X%(AN1@W =Q@.QA:OE\S4>9HFC\WOA*<.C<
MQK687#D([=2?H97SS[WS=V6W=XDZ$%5#F=DECU]S)AUQZ $*@0XG!+N3= GO
MH)JFE^8\B>NG,3P$]BXF?Y;$(4"HLN=3F%Z: W)QTSL\[)Z?GOTBX<B'47WF
M8.FN>S3%<Q:'8*RQHH/S_[T^[EYI"M3@RX(P.?1JHP'<#</QD'CX,LPB%&&6
M@_PQ9+>P>_,J3!\_GWZ2L0*MHBH$1TBL-3(>I0 FX)KZ823SG&K$E^XHI?$"
M:WF)B)%:1#+N#PI,!( 6]6$%V-:)/P@C)KCR"</:A8)(X8^T+YV*>,(/U_@.
M?8%"):,'9<\;2D14832S3,=-JD/E<_U\>$H^4Q\D++Q1I@72.^OBT\\Y/0SQ
M4VDT NT5V!9Y>U01  M)!L:_S[2HSJWS6SV: J! Q!$(GF%E%<G9QYLN.;KZ
M64*0YU5&,J;+^\J[DJ)(3+7[/*?20FI6R>6:!AQVV@PT@#-%5GJTD4#F13<U
MO(/Y-WF(Y0;39&2$+[Q7;:?RIH9? _]T<842'Z7<['-@^CX0^9PP_G"C*)-F
M5&UEN2PJ,)$C4DD@R;=1,F9UCV+RC2[^6O<QG0[Q7A9?<O9<R!NXKTSYM1!L
M%3T-"0& .6P<-&#=T)134N@&&#GFY)<82$:D8:9<<I3\C-6*\4/I2/VR9:D)
MK.U)!$S-Z+-8:,^3>/-4J3<;EWRS"=KG#?H[">[7<4)HQ:DFE&]#9HT!?:9%
M$&!*G8H[)CJ2 F2=8ARDE%.FO+4EDPNWO\+8J%A=2XRY!ID:A@,98<#0@4R+
MS08T*_4M2Y4Q/L)H'HP^#0+3HM0Y$>.(3P/"TXQ7G$B1ZE:JWYS'S73ZM$SB
MU\G3#1 ;1;2H5C)\ED.8VW:IG/DT!JF]5K.FT32)3^K<61YIWJZF!DMOK .:
MO?H>RSA2@N:Z_O'=FQM[>M98&CG2:N# V;&VUV?->EDU, A152"X$5>CR0/M
M9RLIQGA;YFI27Q%"HDK;36T6K+:7I*606*5Y&,\QR8 R[$6Z)Z23(%<8\2Z&
M*^7O(I06RLAVFBEJNTO&$<:(_QR'2@F'G2E%!WV9+37).#K1LTHU;T0S;YNK
MQ9"A5:PEFW%<MT5NH3S'%K\^6N>J?#B?RK:*XZ0L;O,X_YT4QUBA\;8(Z58B
M()7!RLXF .CG<331&51A4<=4^H01*40F/DB'E4_3 <QFHB3];*2XY+^92LZI
M6$)#)M015QKG72+!@8;1EY_Y+0G?>;^9V2''JC'H71@O! J_!&7FC>Y6QMS:
MF#59XM:3(W)4</@K=KI7$WF<18D\(5918=+?A(6=!8_0NX#4!YJ6GQ/ZJD!V
MOI_3JC\?^+Q@,L7O.@0B6:%!#HKPLTYY*4& H>BQB,-T4 U'NV[#E-%DR79?
M%7+>_.5#':ULY>A]IY2+!V@J2+@LG@#7%8S1+*,^HE*AKH;XU?I1@>92RIW<
MCO/GF!&0/T/3&K8\W'E+D:M@>LJAL^;!IYI4UG2.V 8$&<LP+HXUUHIOU]R%
M0*#IV/M7*0<H"JFG'2 * Z TI HI#7(]]J>.CXK7388L$-D>?X"4I4*DK %=
M#WA)%9UD875/?8RMC/(:GNG'["(-OG1$9QA,&9#*0*GZ^&#N?R@@3%7;\F3*
M(#_A*BZ4VZ\_97/Y=N3B=G126"G%D>?<GI)L_5 P^*^UKV_MXY=YUT#+(RGB
M=98=*A4>6E1K8^D1[G:C]4#MH9G#VAO#+WK5YPY6;Q"(ZA,("R"</5N_O!2<
MU;#=U[<V1].$R#5F/W/X_6FH=Q@R%O'U,?1LY^CW*!D(/$',%<'^;AIULS'(
MAEO[F%_YC[T=NO\<)/(:$+#HT-8,N/AOC6-<-0PN0$_S9Q<\[<<?8IK\S$>A
M:_,G<9:=BUESF?YBM.RZ^5*BJ?'7(^7I_"_+)JRFQ@6D/&N2OY'5+LI!Y[LF
MFUX"H!&,H(&(00&D4K".,!PJOV>YC;D.#"4A>@ZU(_0T1E#(;X=7GPA+_#&*
MN2+^\"ABT3^J!65>E\FTM?\/<CGK;V\9YC9]M]U<X'*'CM#G(8-3,MDAA(&I
MT,X095+E)QLT,Y?2!Q/IF 5+G/M4UY&8P!H4"$6K'8N#8'Y\V0R>'L9!#Q4\
MNH5-3;G$!+E-,G58Q ^+2-B<(1VJ<,C4US#U^\!8LKD&5X7Q<F>>RKP<CT81
M5QD141Y+YZ6C'C*RJ.>6XX?(?+59[.3.@5\:UU-'WAKA/8RG9-)I'P1D/(([
M&#@!++R%QU]/>/S9"F\M-!:N3S^<']S\<G5\_?)"9E/<&F51IXX@R.AC<3AG
M+2_K@AHY#.-94J8Q)?M4T0 <!H\HPKS@02(/GA5D[/$!C8+\,*3*8% -44CQ
M,1[_E?W2<39(!)X7_]:>&,5<WY53IFFL5P'^I2O#52!95V.SG\"EL<'3<]H;
M[;*153"/KP[(X>D%^71S]$4ZY=<3\\:HYV_T_"WH^>7G]PPTO$E,#>8D7,P[
M&%Z6K)]SQH>3[G.1]6R=]J(^>_73]1N!AIUTAYR%F--/R4T2<4;CY'6PP\O+
MA#>1OJ&\C1\AZ*Y#UB^4GH-%_+ND-PAY4#H_J(LE;)R3[L$2BW->BB[F6O(Y
M&>@4,M"+J/]'\5QY7&8?%J,999]%(/\M]%GDCQ9Y(K0G!QFJBW9F4MP2:A1Y
M;VMGOUI_L_B=_])_]W:\A$WP[R ;1OO_#U!+ 0(4 Q0    ( !% 1%Q00BNS
M_@,  &@2   1              "  0    !E;G1X+3(P,C8P,3(Y+GAS9%!+
M 0(4 Q0    ( !% 1%S4_FB3)0<  $]&   5              "  2T$  !E
M;G1X+3(P,C8P,3(Y7V1E9BYX;6Q02P$"% ,4    "  10$1<?4(N()8*   >
M:P  %0              @ &%"P  96YT>"TR,#(V,#$R.5]L86(N>&UL4$L!
M A0#%     @ $4!$7'Y0=] O!P  VDX  !4              ( !3A8  &5N
M='@M,C R-C Q,CE?<')E+GAM;%!+ 0(4 Q0    ( !% 1%R4RO$!ENX  (I4
M!P 0              "  ; =  !E>&AI8FET7S$P+3$N:'1M4$L! A0#%
M  @ $4!$7"C9=Y1W%P  -U<  !               ( != P! &5X:&EB:71?
M.3DM,2YH=&U02P$"% ,4    "  10$1<EU2*(I$>  #?LP  #0
L    @ $9) $ >FLR-C,T,C<Y+FAT;5!+!08     !P ' +\!  #50@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>zk2634279_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:entx="http://enterabio.com/20260129"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="entx-20260129.xsd" xlink:type="simple"/>
    <context id="c20260129to20260129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-29</endDate>
        </period>
    </context>
    <context id="c20260129to20260129_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">entx:OrdinarySharesParValueOfNIS00000769Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-29</endDate>
        </period>
    </context>
    <context id="c20260129to20260129_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">entx:WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20260129to20260129"
      id="Fact_e3793fd0246149fc909fd1fcfc95fa89">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20260129to20260129"
      id="Fact_2783e5c0c3ef4b5c98066465eeb39ec2">0001638097</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20260129to20260129"
      id="Fact_1fc99da374d94b47827b63bc4df1ea69">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode
      contextRef="c20260129to20260129"
      id="Fact_845dc47bf7764f37ae6b3ec21fdb1f1c">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20260129to20260129"
      id="Fact_5b00f5ad8e2a42019f08b2e5b15a63bf">2-532-7151</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20260129to20260129_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember"
      id="Fact_33337dadb56448e6803d820203d94d6e">Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20260129to20260129_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember"
      id="Fact_a700b67d61a142d989acfd1e03ccdf9c">ENTXW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20260129to20260129_StatementClassOfStockAxis_WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember"
      id="Fact_19ac239564e543ae8bdeb253ce77e391">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="c20260129to20260129_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member"
      id="Fact_90e9abc973f6425ea56ebe4d147111d6">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20260129to20260129"
      id="Fact_854b9d1282cb4016850c835312cb7428">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20260129to20260129"
      id="Fact_24f7136a7a434d1c8823a066ae74f5f0">2026-01-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20260129to20260129"
      id="Fact_dc6cd0bdce1a4d91ac30bf2333ad64ce">Entera Bio Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20260129to20260129"
      id="Fact_5ccef13b5de64531b55131310f990d6d">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20260129to20260129"
      id="Fact_8531f7f8deb54d378365f039779ae88e">001-38556</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20260129to20260129"
      id="Fact_53e7134a8dee464d8f80218269c94f83">Kiryat Hadassah, Minrav Building</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20260129to20260129"
      id="Fact_2921a3eff99c4dd5bff84c01cafc4be3">Fifth Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20260129to20260129"
      id="Fact_c317e05c204f4a59a1e4dc8b1f3613c8">Jerusalem</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="c20260129to20260129"
      id="Fact_5dfe71dfd21e4ab8aee3d679ab8f226a">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="c20260129to20260129"
      id="Fact_70b738c460a04d3c9513ff7984b36624">9112002</dei:EntityAddressPostalZipCode>
    <dei:WrittenCommunications
      contextRef="c20260129to20260129"
      id="Fact_aedbad8e66824d61914f676dc82e5ccb">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20260129to20260129"
      id="Fact_76572359dc7d4cb7bad6d925fd113c86">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20260129to20260129"
      id="Fact_25c510ae2a4d49a890418808323caadb">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20260129to20260129"
      id="Fact_095cdde2305a4992902e14b13d9e8daf">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20260129to20260129_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member"
      id="Fact_ed98f41c93304b78938876a12e4df08c">Ordinary Shares, par value of NIS 0.0000769</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20260129to20260129_StatementClassOfStockAxis_OrdinarySharesParValueOfNIS00000769Member"
      id="Fact_8f25ca98f88f4f82bc488b6b84f08e53">ENTX</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20260129to20260129"
      id="Fact_93ab7cbcbd0b4c55bd07e713e802587e">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
